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In 2007, we and another group in the US showed for the first time that human 
pancreatic cancers contain so-called cancer stem cells (CSCs), which express the stem 
cell marker CD133, which are exclusively responsible for tumourigenicity, and which are 
highly resistant to standard chemotherapy (Hermann et al., 2007, Li et al., 2007). 
Specifically, we have provided conclusive evidence that these highly tumourigenic 
cancer stem cells represent the “root” of the tumour due to their ability to generate all the 
different lineages of cells that comprise a tumour. Most importantly, we have shown for 
the first time that cancer stem cells are heterogeneous, and that a specific subset of 
CSCs expressing the chemokine receptor CXCR4 is exclusively responsible for 
metastatic spread of pancreatic cancer. Furthermore, the CD133+ cancer stem cells are 
also highly resistant to chemotherapy and irradiation, they represent an intriguing new 
target for therapeutic intervention. 
 
Therefore, after comprehensively studying their molecular characteristics and 
defining distinct cancer stem cell-related features (such as developmental pathway 
activity, DNA damage response etc.), we subsequently designed several projects 
investigating the role of cancer stem cells in pancreatic and colorectal cancer with 
respect to their contribution to tumour growth and therapy resistance. More importantly, 
however, we were interested in elucidating the potential of cancer stem cells as potential 
targets for therapy. Therefore, these studies were directed towards the development of 
novel targeted therapies against cancer stem cells, and to investigate the influence of 
CSC elimination on clinical outcomes such as long-term survival in mouse models of 
primary pancreatic or colon cancer. With the presented studies, we are now proposing 
three novel targeted therapies for pancreatic and colorectal cancers to get one step 
closer to finally overcoming these devastating diseases. 
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En 2007, ha sido mostrado por primera vez, tanto por nuestro equipo como por 
otro en los Estados Unidos, que los cánceres pancreáticos humanos contienen  células 
troncales cancerígenas (CSC, en inglés), las cuales expresan el marcador CD133. Las 
células troncales cancerígenas han sido descritas por ser exclusivamente tumorigénicas, 
así como también altamente quimioresistentes. De manera extensiva, hemos 
proporcionado evidencias conclusivas que estas  células troncales cancerígenas son 
altamente tumorigénicas y representan la raíz del tumour debido a su habilidad de 
generar todos los diferentes linajes celulares que conforman un tumor. Lo más 
importante es que hemos mostrado por  primera vez que las células troncales 
cancerígenas son heterogéneas, y que una población distinta que expresa el receptor 
CXCR4 es exclusivamente responsable para la metástasis de canceres del 
páncreas. Siendo, las células troncales cancerígenas son altamente resistentes a la 
quimioterapia y radioterapia,  por tanto, representan una nueva diana terapéutica. 
 
Por lo tanto, después estudiar comprensivamente sus características 
moleculares y definir sus propiedades (respuesta daño AND etc.) posteriormente 
diseñamos distintos proyectos investigando el rol de las células troncales en páncreas y 
cáncer colorectal respecto a su contribución en el crecimiento tumoral y resistencia a la 
quimioterapia. Sin embargo, aun mas importante, estábamos interesados en mostrar el 
potencial de las células troncales cancerígenas como una posible diana terapéutica.  
Por tanto, el objetivo de estos estudios fueron el desarrollo de nuevas dianas 
terapéuticas contra las células troncales cancerígenas, así como el resultado de su 
eliminación, midiendo la supervivencia en modelos animales de cáncer primario de 
páncreas o cáncer colorectal. Con estos estudios, estamos proponiendo tres nuevas 
dianas terapéuticas para cáncer pancreático y colorectal y así acercarnos un paso hacia 
adelante para finamente poder avanzar contra estos tipos de canceres tan devastadores. 
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Solid tumours  !
Despite intense research efforts, the death toll of oncological diseases is steadily on 
the rise in Western countries, second only to deaths caused by cardiovascular diseases. 
Among all cancers, solid tumours represent the major cancer burden, and cancers 
arising in epithelial tissues such as breast, lung, colon, prostate and ovary constitute 
approximately 80% of all solid cancers. Whereas other tumour entities such as 
glioblastoma multiforme and pancreatic ductal adenocarcinoma are considerably less 
frequent, they constitute a major health risk due to their extraordinarily high mortality 
rates (Jemal, 2008). Tumours are generally assessed clinically at the gross level by 
histology and by expression of specific markers. In combination with gene expression 
analysis, this has lead to the definition of distinct tumour subtypes. The cellular origins of 
most solid tumours still remains unknown in most cases, but it is hypothesized that 
different subtypes correspond to distinct cells of origin at the time of tumour initiation. In 
addition to different tumour subtypes, cells within the tumour population frequently also 
exhibit functional diversity termed tumour heterogeneity (Heppner and Miller, 1983), with 
some cells exhibiting high proliferative and differentiating capacities.  
!
Colorectal Cancer !
Colorectal cancers are the third most frequent cancers in men as well as in women  
with an expected 101,340 cases of colon and 39,870 cases of rectal cancer to occur in 
2011, and therefore represent a major challenge for the healthcare systems in Western 
countries. Colorectal cancer accounts for approximately 9% of cancer related deaths 
(Cancer Facts & Figures 2011). Risk factors associated with colorectal cancers are 
genetic pre-dispositions such as familial adenomatous polyposis (FAP) and Lynch-
Syndrome (hereditary non-polypous colon cancer syndrome, HNPCC), but also age 
(over 40 years of age, the incidence of colorectal cancer doubles every 10 years), fat- 
and meat-rich diets, smoking, and alcohol intake. !
These cancers arise from dysplastic epithelium, usually from colon adenomas after a 
sequence of genetic alteration events that were first described by Vogelstein and 
colleagues in 1990 (Fearon and Vogelstein, 1990). During this progression from 
dysplastic adenomas to full-fledged colon cancer, the loss of the APC tumour 
suppressor gene in normal epithelium constitutes the initiating event. Familial 
adenomatous polyposis (FAP) is a hereditary, autosomal dominant colorectal cancer 
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syndrome, which results from a mutation of APC, which can be found in 50% of the 
patients. Physiologically, APC is part of a protein complex binding to ß-catenin in the 
cytoplasm, resulting in the inhibition of its nuclear translocation. Mutation or loss of APC 
therefore results in ß-catenin translocation and the subsequent activation of transcription 
factors such as c-myc and Cyclin D1, which have been shown to be crucial players in 
proliferation, differentiation, migration, and apoptosis. Interestingly, another 
consequence of APC loss is an increased activity of the Wnt (wingless in drosophila) 
pathway, a signaling pathway strongly associated with stemness and self-renewal in the 
colon. Recent evidence even suggests that FAP may be a stem cell disease, showing an 
increase in the stem cell population at the bottom of intestinal crypts (Boman et al., 
2008), pointing to a potentially essential role of the stem cell population during  the 
progression process. 
As the next step during progression, a mutation in the K-Ras gene leads to a 
constitutively active K-Ras protein, and to subsequent increase in proliferation and 
increased cell survival. These changes result in type II adenomas in patients, which are 
1-2 cm large, and display medium-grade dysplasias. After the additional mutation or loss 
of the DCC tumour suppressor gene, type III Adenomas (> 2cm in size with high-grade 
dysplasia) can be observed in patients. The final step for the progression from high-
grade adenomas to malignant carcinoma is the mutation or loss of the tumour 
suppressor p53. The progression to cancer is thought to take approximately 10 years, 
and while it is not obligatory, once a critical number of genetic changes have occurred, 
malignant progression is very likely to take place (Figure 1).  
 
! 15!
Figure1: Genetic progression model of colorectal cancer, modified after Fearon and Vogelstein. 
From: (Walther et al., 2009) 
 
There has been great progress in the treatment of colon cancer over the last 
decades (Table 1). Fortunately, the mortality rates for colorectal cancer have declined 
significantly throughout the last 20 years. Since 1998, the rate has declined by 2.8% per 
year in men and by 2.7% per year in women (Cancer Facts & Figures 2011). This 
positive development is mainly attributed significant improvements in early detection and 
treatment. In clinical practice a marked shift can be observed with regards to screening 
methods for colorectal cancers. Fecal occult blood testing (FOBT) is an easy-to-use and 
low-priced diagnostic tool, which detects blood in human stool samples as a 
consequence of tumour bleeding. However, if the amount of blood in the stool sample is 
low (usually <20ml/d), tumours may remain undetected by this test. Even more 
importantly, however, this test is not useful for detection of early lesions such as 
colorectal adenomas, since they rarely bleed. Thus, while this test is easy & cheap to 
perform, it may not be the best option for the early detection of colorectal tumours.  
In order to detect early and late neoplastic lesions in the colon and rectum, screening 
by endoscopy remains the gold standard. While this is an invasive and complex 
screening tool, it yields the best results by far, with the additional advantage of being 
able to take biopsies in situ during the colonoscopy. This will allow for detailed 
histological analysis of suspicious tissue in the very early stages of malignant 
transformation. Therefore, only repeated routine colonoscopy will lead to early diagnosis 
with high curative potential.  
Surgery is the most common treatment for colorectal cancer, and may be curative for 
localized tumours. In advanced disease, different approaches have been tested, 
involving neoadjuvant or adjuvant chemotherapy (most frequently combination therapies 
with 5FU and/or platin-containing chemotherapies like oxaliplatin) and/or radiation. 
Furthermore, several targeted therapies are emerging as promising additions to the 
therapeutic regimen: the monoclonal antibody bevacizumab (Avastin), which binds to 
vascular endothelial growth factor (VEGF-A) and thus blocks the angiogenic properties 
of the tumour. Furthermore, two antibodies against the Epidermal Growth Factor 
Receptor (EGFR) have been approved by the FDA for the treatment of metastatic 
colorectal cancer. 
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However, while the prognosis of patients suffering from colorectal cancer keeps 
increasing, a large percentage of patients, especially with advanced metastatic cancer 
will still succumb to the disease. Therefore new the further development of new 
therapies, and the identification of new therapeutic targets is of great importance to this 
day.   
 
 
Table 1: 5-year survival rates of colorectal cancer.  
 
Pancreatic Cancer !
Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive and deadly 
diseases, making it the fourth most frequent cause for death due to cancer. Full-blown 
pancreatic cancers have a ductal morphology, and it has been shown that tumours stem 
from neoplastic lesions (pancreatic intraepithelial neoplasias (PanIN)) (Feldmann et al., 
2007a). Pancreatic cancers are thought to follow a progression model from low-grade 
(PanIN 1A and PanIN 1B) to high-grade (PanIN 2 and PanIN 3) lesions, before 
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becoming fully malignant PDAC (Figure 2A and B). This progression to invasive 
pancreatic cancer occurs due to the accumulation of key genetic alterations such as 
telomere shortening, activating mutations of the KRAS oncogene, inactivation of tumour-
suppressor genes such as CDKN2A, TP53, and SMAD4 (Figure 2C). The importance 
and sequence of these genetic alterations in pancreatic tumour development is 
supported by studies in genetically engineered mouse models (GEMMs), in which 
activating mutations of KRAS with concomitant inactivation of Trp53 or Cdkn2A/Ink4A 
results in the development of pancreatic cancer that closely mirrors the human disease 
(Hingorani et al., 2005, Guerra et al., 2007, Bardeesy et al., 2006). 
Altogether, while genetic inter-patient diversity in fully developed pancreatic cancers 
is extremely high, the key initiating mutations are extremely frequent: ~90% of the 
tumours have activating KRAS mutations, resulting in aberrant activation of proliferative 
and survival signaling pathways. 90-95% of PDACs have inactivating mutations of 
CDKN2A, and up to 75% of pancreatic cancers present with mutated TP53 (Maitra and 
Hruban, 2008).  
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Figure 2: Key mutations and histological changes in pancreatic adenocarcinoma. From:  
(Mihaljevic et al., 2010) 
 
Pancreatic adenocarcinoma is the fourth most frequent cause of cancer-related 
deaths. Despite its moderate incidence compared with other solid cancers, it has an 
exceptionally high mortality rate (Jemal et al., 2010). This is due to a combination of late 
diagnosis, lacking early symptoms, frequent impossibility of resecting the primary tumour, 
early and extensive metastasis, and high resistance to current treatments. Despite 
intense research and significant advances that have been achieved in the understanding 
of the mechanisms underlying pancreatic cancer, these advances have had only modest 
relevance for clinical treatment. In this respect only very little progress has been made 
since the introduction of the nucleoside-analogue gemcitabine in the late 1990s, which 
improved clinical response mainly in terms of pain reduction and loss of weight (Burris et 
al., 1997). Gemcitabine still remains the first-line chemotherapy for patients suffering 
from pancreatic cancer. However, the overall prognosis of pancreatic cancer patients 
remains extremely poor with the 5-year survival rate being only 1–4% (Table 2), and a 
median survival time of 4–6 months. Virtually all targeted therapies so far have failed to 
improve the miserable prognosis of patients with PDAC. Also the recent approval of 
Erlotinib, an inhibitor of the EGF-Receptor, into the therapeutic regimen resulted only in 
a minor prolongation of patients’ survival (Moore et al., 2007). New and more promising 
combination therapies are currently being evaluated, as in the case of a quadruple 
combination of different chemotherapies (FOLFIRINOX) (Conroy et al., 2011). While the 
results of this study are very promising, it has to be kept in mind that the patients 
enrolled were a very well-selected group of patients with a high performance status. 
Additional trials using conventional cytotoxic approaches in combination with advanced 
delivery techniques such as Paclitaxel (Von Hoff et al., 2011) or in combination with 
stroma-targeting agents (i.e. the Infinity trial using the smoothened inhibitor IPI-926) are 
currently underway and bear the potential to significantly enhance response rates in 
patients with PDAC. 
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Table 2: 5-year survival rates of pancreatic cancer.  
!
Cancer Stem Cells and tumour heterogeneity  !
The fundamental cellular mechanisms underlying tumour heterogeneity are 
subject of intense research activities. As early as 1961, rather extraordinary studies by 
Southam and Brunschwig provided first evidence for heterogeneity also in 
tumourigenicity by autologous transplantation of malignant cells from patients with 
different carcinomas into subcutaneous tissue (Southam and Brunschwig, 1961). 
Intriguingly, the smallest inoculation resulting in transplant growth was 106 cells 
suggesting that a large number of viable cells is necessary to promote tumour growth. 
While it is possible that there are growth-inhibiting factors that may need to be overcome 
by larger populations of cells or that the provision of a peculiar local milieu suitable to the 
growth of the transplanted cells is mandatory for engraftment, these data are also 
consistent with a hierarchical organization of the tumour cells. This would implicate that 
only subpopulations of cells are capable of engrafting consistently.  
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Despite these intriguing early data, it was not before 1997 when pioneering 
studies from John Dick’s laboratory identified for the first time leukemia-initiating stem 
cells (Bonnet and Dick, 1997, Reya et al., 2001) followed by landmark studies in breast 
cancer (Al-Hajj et al., 2003) and then rapidly emerging investigations on tumour-initiating 
stem cells, also termed cancer stem cells (CSC), in numerous other solid tumours.  
According to the cancer stem cell hypothesis, cells with certain stem cell 
properties are at the bottom of the tumour hierarchy, and are the only cells that can give 
rise to tumours in secondary recipients. These cells have the ability so self-renew, giving 
rise to more cancer stem cells as well as more differentiated daughter cells (Figure 3).  
Consequently, since CSCs are the only cells that can give rise to tumours. 
Interestingly, we were able to show that only a subpopulation of cancer stem cells that 
express the chemokine receptor CXCR4 can generate liver metastasis in a mouse 
model of pancreatic cancer (Hermann et al., 2007). Interestingly CXCR4 is the key 
receptor for stromal derived factor 1 (SDF-1), a chemokine that is detectable in high 
levels at typical sites for metastasis such as liver, lung, brain, and lymph nodes. 
The source, or cell-of-origin of these cancer stem cells is currently unknown for 
solid tumours, but may vary between tissue-resident stem cells, progenitor cells, and 
differentiated cells, depending on the tumour type. In most solid tumours, the 
dysregulation of the tumour microenvironment such as chronic inflammation plays an 
important role during carcinogenesis, as well as secreted factors from immune cells or a 
tumour cell niche.  
While this thesis will focus on those solid tumour entities where cancer stem cells 
were first identified (colon, breast, brain, and pancreas), evidence for cancer stem cells 
using several different (surface) markers have been found and functionally investigated 
in most other tumours such as prostate cancer (Collins et al., 2005, Miki et al., 2007), 
melanoma (Fang et al., 2005) (Schatton et al., 2008), lung cancer (Kim et al., 2005) 
(Bertolini et al., 2009), head and neck squamous cell carcinoma (Prince et al., 2007), 
and liver cancer (Yang et al., 2008) (Ma et al., 2007).  
The frequency of CSC in solid tumours appears to vary considerably between 
tumours of the same entity from almost undetectable in some tumours to highly 
abundant in other tumours. Currently it is not clear whether this increase in CSC 
numbers is indeed related to tumour progression or related to limitations of the available 
set of markers for their identification, emphasizing the urgent need for more definitive 
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CSC markers. This must be resolved by clonality studies and more extensive studies in 
genetically engineered mouse models covering the full spectrum of tumour progression.  
 
Figure 3: The cancer stem cell hypothesis in solid tumours. 
Image courtesy of C. Heeschen 
 
 
Colon cancer stem cells !
Colon cancer is one of the few solid tumours for which the progression from a 
normal cell to a cancer cell is reasonably well understood. If applied to a (cancer) stem 
cell setting, one would hypothesize that the disease starts from one of the few stem cells 
at the base of the crypt. These have recently been identified by Barker et al. to express 
Lgr5, a leucine-rich repeat with G-protein-coupled receptor 5 (Barker et al., 2007). This 
landmark study seems to provide us with the most specific stem cell marker for normal 
intestine to date, but its role in tumourigenesis still remains to be determined. 
Unfortunately, it has been particularly difficult to develop high-affinity antibodies against 
! 22!
Lgr5 so that studies for the prospective isolation of Lgr5 positive cells from human 
tumour samples are still lacking. 
Colon CSC were first prospectively identified in 2007 by two different research 
groups published back-to-back in Nature using CD133 (Ricci-Vitiani et al., 2007, O'Brien 
et al., 2007). In contrast, a third later study by Dalerba et al. used a combination of CD44 
and EpCAM, and then identified CD166 as an additional putative CSC marker 
generating more consistent data as compared to CD133 (Dalerba et al., 2007). In all 
three studies, xenotransplantation of the isolated cells into immunocompromised mice 
not only led to engraftment of the investigated cells in far lower numbers than the 
negative cells in serial transplantation studies, but the implanted cells were also able to 
recapitulate the original tumour on histological levels. However, Shmelkov et al. later 
demonstrated that CD133 expression in colon cancer may not be restricted to CSC at all 
(Shmelkov et al., 2008). They claimed CD133 to be expressed on colon cancer cells 
regardless of their differentiation state, and demonstrated that isolated CD133– cells 
were at least as capable of giving rise to tumours in NOD/SCID mice as their CD133 
positive counterparts.  
Only recently, CD133 was finally shown to actually change its conformation upon 
differentiation, which could explain the opposing results seen with different antibodies 
and diverse staining protocols (Kemper et al.). Importantly, the AC133 epitope 
decreases upon differentiation, which was not linked to a change in CD133 promoter 
activity, mRNA, splice variant, protein expression, or even cell surface expression of 
CD133. In contrast, the only observed change concerned CD133 glycosylation 
suggesting that CD133 is expressed on both CSC and differentiated progenies. Since 
this change in glycosylation alone did not affect binding of AC133, its lack of binding to 
differentiated cells is more likely related to differences in protein folding as a 
consequence of this glycosylation. Therefore, though CD133 is certainly not a perfect 
marker and data need to be interpreted with great caution, it has been one of the most 
successful markers for the identification of CSC in various tumour entities to date.  
 
Pancreatic cancer stem cells  !
First evidence for a distinct CSC population in pancreatic cancer, one of the most 
lethal cancers, was provided by Li and colleagues (Li et al., 2007). The authors identified 
a highly tumourigenic CD44+CD24+EpCAM+ subpopulation using a xenograft model of 
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immuno-compromised mice for primary human pancreatic adenocarcinoma. Only these 
cells were able to form tumours at low numbers and only these cells displayed typical 
stem cell features like self-renewal, activation of developmental signaling pathways, 
generation of differentiated progeny and the ability to recapitulate the phenotype of the 
parental tumour from which they were derived (Li et al., 2007). Apparently, the finding 
that tumourigenicity in pancreatic cancer is confined to CD24+ cells is in stark contrast to 
the original findings in breast cancer, where only CD24–/low cells were tumourigenic. 
However, these different findings have now been extended to other tumour entities such 
as ovarian cancer (Cao et al.). In a second study, Hermann et al. showed that CD133 in 
pancreatic cancer cell lines and primary pancreatic cancers also reproducibly 
discriminates for cells with capacity for self-renewal, sphere formation, and, most 
importantly, in vivo tumourigenicity in secondary and tertiary recipients (Hermann et al., 
2007). Not surprisingly, CD133+ cells show some overlap with the CD44+CD24+EpCAM+ 
subpopulation. More recently, additional markers have also been associated with 
pancreatic CSC. ALDH-1 has been shown to label tumourigenic cells in pancreatic 
(Feldmann et al., 2007b, Jimeno et al., 2009, Rasheed et al.) and breast cancer (Table 
3). Since cell surface markers merely enrich for CSC populations, and therefore their 
use is controversial, functional assays like sphere-formation capacity in vitro, and 
tumourigenicity in vivo, are becoming even more important for the identification of CSC.  
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Tumour Entity  Markers Citation 
   
Breast cancer CD44+ CD24-/low (Al-Hajj et al., 2003) 
 CD133+ (Wright et al., 2008) 
 CD133+ CXCR4+ (Hwang-Verslues et al., 2009) 
 ALDH-1+ (Ginestier et al., 2007) 
 CD49F+ DLL1high DNERhigh (Pece et al.) 
   
Colon cancer CD133+ (O'Brien et al., 2007; Ricci-Vitiani et 
al., 2007) 
 EpCAM+ CD44+ CD166+ (Dalerba et al., 2007) 
   
Glioblastoma CD133+ (Singh et al., 2004) 
 SSEA-1+ (Son et al., 2009) 
   
Pancreatic 
cancer 
EpCAM+ CD44+ CD24+ (Li et al., 2007) 
 CD133+ (Hermann et al., 2007) 
 CD133+ CXCR4+ (Hermann et al., 2007) 
 ALDH-1+ (Feldmann et al., 2007; Jimeno et 
al., 2009; Rasheed et al.) 
   
Prostate cancer CD44+ alpha2beta1 high CD133+ (Collins et al., 2005) 
 CD133+ CXCR4+ (Miki et al., 2007) 
   
Melanoma CD20+ (Fang et al., 2005) 
 ABCB5+ (Schatton et al., 2008) 
   
Lung cancer Sca-1+, CD45-, PECAM-, CD34+ (Kim et al., 2005) 
 CD133+ CXCR4+ (Bertolini et al., 2009) 
   
Head & Neck 
cancer 
CD44+ BMI-1 (Prince et al., 2007) 
   
Liver cancer CD90+ (Yang et al., 2008) 
 CD133+ (Ma et al., 2007) !
Table 3: Several surface markers and marker combinations have been used for the identification 
of cancer stem cells in solid tumours  
From: (Hermann et al., 2010) 
 
 
Metastasis is the major cause of death in pancreatic cancer patients and 
currently there is no effective treatment available for this deadly disease. However, not 
all cells within a tumour possess the same metastatic potential, and only a rather small 
subset of cells is directed through lymphatic or blood vessels toward specific secondary 
sites to form metastases. In order to be able to establish secondary lesions, the 
migrating cells would require similar features to the cells initiating the primary tumour. 
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For this reason CSC were proposed to represent the only cell population capable of 
spreading and giving rise to metastases. Indeed, Hermann et al. for the first time 
identified two distinct subsets of CSC based on the expression of the chemokine 
receptor CXCR4 in pancreatic cancer. CXCR4 is a chemokine receptor responding to 
chemotactic gradients of its specific ligand SDF-1 that was originally found to be 
responsible for leukocyte and hematopoietic progenitor cell homing. Emerging evidence 
suggests that CXCR4 plays a pivotal role in the metastatic process of different tumour 
entities towards a gradient of SDF-1, which is highly expressed in secondary sites 
usually associated with metastasis.  
In 2007, we identified a “stationary” population expressing CD133, but not 
CXCR4, which is responsible for the initiation and maintenance of the primary tumour, 
and a “migrating” and highly metastatic population characterized by co-expression of 
CD133 and CXCR4. Only CD133+CXCR4+ cells had metastatic potential, while depletion 
of the CSC population for CD133+CXCR4+ cells completely abrogated the usually strong 
metastatic phenotype of the implanted tumours (Figure 4) (Hermann et al., 2007).  
 
 
Figure 4: Identification of a metastatic subpopulation of cancer stem cells generating liver 
metastasis (top panel), and giving rise to circulating tumour cells (bottom panel).  
From: (Hermann et al., 2007) 
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Consequently, pharmacological inhibition of the CXCR4 receptor by AMD3100 
also prevented the metastatic activity of purified CSC. These data provide convincing 
evidence for a crucial role of the SDF-1/CXCR4 axis in metastasis. Since most cancers 
initially spread to local lymph nodes long before solid organ colonization, the lymphatic 
system and lymph node metastases also need to be investigated for the presence and 
contribution of migrating CSC. Indeed, we also found significantly higher numbers of 
CD133+CXCR4+ migrating CSC in patients with lymph node metastasis (pN1+), 
demonstrating a close clinical correlation between migrating CSC and advanced disease 
(Hermann et al., 2007). A different study by Nakata et al. suggested that CCR7, another 
chemokine receptor (also know as BLR2 or CD197), is also associated with lymph node 
metastasis in pancreatic cancer and, based on multivariate survival analysis, could serve 
as an independent prognostic factor (Nakata et al., 2008). 
CSC may acquire a migrating phenotype through Epithelial-Mesenchymal-
Transition (EMT) in primary tumours, because the mesenchymal phenotype is usually 
associated with strong migration capacity while maintaining stemness, thus allowing the 
production of progenies during metastasis. Recently, Weller et al. showed in pancreatic 
and colon cancer that the EMT-activator ZEB1 represents an important promoter of 
metastasis by suppressing E-cadherin. Furthermore, the stem cell phenotype was 
maintained by suppression of miR-200 family members that usually target stem cell 
factors such as Sox2 and Klf4 (Wellner et al., 2009). Together, these results suggest 
that in cancer the metastatic process is not random, but rather regulated by specific 
mechanisms related to the expression of adhesion molecules, chemokine receptors and 
their respective ligands.  
Several studies have shown that standard therapy has limited or no significant 
effect on CSC, but only enriches for these population due to the elimination of more 
differentiated cells (Bao et al., 2006, Hermann et al., 2007, Mueller et al., 2009). For this 
reason it is important to identify new therapeutic approaches that can (selectively) 
eliminate this population and thus improve cancer treatment. It has been demonstrated 
consistently that the treatment with the first-line chemotherapeutic agent gemcitabine of 
fresh and in vivo expanded patient-derived pancreatic cancer cells preferentially targets 
the more differentiated tumour cells with a resulting enrichment of CD133+ cells in which 
the tumourigenic population is contained. Gemcitabine treatment of nude mice bearing 
orthotopic human tumour xenografts is only effective to control the tumour growth and 
prolong survival, but does not affect CSC as the root of the tumour. The basis of 
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resistance to chemotherapy in this population is provided by anti-apoptotic mechanisms 
(Visvader and Lindeman, 2008), increased repair of DNA after damage, and by the 
presence of membrane transporters that pump drugs out of these cells (Goodell et al., 
1996); this way the CSC population is protected from damage caused by external agents. 
This population shows the ability to efflux the fluorescent dye Hoechst 33342, producing 
a characteristic profile in flow cytometry analyses. This ability has been attributed to the 
expression of the transporters ABCG2 and MDR1 and has been related to tumour-
initiating cells (Hirschmann-Jax et al., 2004, Ho et al., 2007), and may well be 
responsible for the resistance to chemotherapeutic agents and thus for the exceptional 
malignancy of pancreatic cancer (Zhou et al., 2008). Thus, withdrawal of gemcitabine 
treatment usually results in a rapid relapse of tumour growth and increased 
aggressiveness of the tumour.  
 
However, these latter approaches are unlikely to eliminate the root of PDAC as 
they primarily target proliferative and more differentiated cells. Since the identification of 
exclusively tumourigenic cells in the hematopoietic system several decades ago, stem 
cells have changed the way we study biology and medicine. More recently it has been 
shown that stem cells play a decisive role not only in the generation of complex 
multicellular organisms but also in the initiation and propagation of solid tumours (Clarke 
et al., 2006), (Jordan et al., 2006). These cells with stem cell properties (therefore 
termed cancer stem cells; CSC) are an integral part for the perpetuation and progression 
of various human cancers (Al-Hajj et al., 2003) (Kim et al., 2005) (O'Brien et al., 2007) 
(Ricci-Vitiani et al., 2007) (Singh et al., 2004), and, according to the current consensus 
definition, are able to self-renew and to produce all the heterogeneous lineages of 
cancer cells that comprise the tumour (Clarke et al., 2006).  
Increasing evidence now suggests that among several other solid malignancies, 
the CSC model can also be applied colon cancer. A CD133+ subpopulation of colon 
cancer cells derived from primary tumours was shown to be highly enriched for 
tumourigenic colon CSCs, capable of self-renewal and the recapitulation of the bulk 
tumour population (O'Brien et al., 2007, Ricci-Vitiani et al., 2007), thus demonstrating the 
three defining properties of cancer stem cells. Based on this demonstrated principle of 
CSCs as the root of the tumour and their resistance toward conventional chemotherapy 
(Hermann et al., 2007, Bao et al., 2006, Todaro et al., 2007), the development of 
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approaches aiming at the specific eradication of CSCs in colorectal tumours represents 
an innovative goal for improved colorectal cancer treatment. 
The cancer stem cell hypothesis has also been shown to hold true for pancreatic 
cancer (Li et al., 2007, Hermann et al., 2007). Furthermore, it has been shown that 
CSCs may not only be associated with tumour growth, but also contain a subpopulation 
of migrating cancer stem cells that is exclusively responsible for metastatic spread to 
secondary tumour sites (Hermann et al., 2007). Furthermore it has been demonstrated 
that CSCs are highly resistant to chemotherapy (Hermann et al., 2007) as well as 
radiation (Bao et al., 2006), standard therapeutic approaches that preferentially target 
differentiated tumour cell populations, but sparing cancer stem cells.  
 
Because these cells cannot be targeted by standard cytotoxic therapy, and at the 
same time possess the potential to repopulate the entire tumour (thus explaining the 
surprising clinical finding of relapsed disease after previous regression, CSCs offer a 
very challenging, but at the same time promising novel entity for the development of new 
therapies. 
 
 
 
 !  
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 AIMS OF THE PROJECT 
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1. Identification of putative new targets and signaling pathways that may serve to 
eliminate cancer stem cells 
 
2. Functional and molecular validation of the previously identified pathways and their 
significance in cancer stem cells 
 
3. In vitro inhibition of the previously identified targets and evaluation of its effects  
on cancer stem cells 
 
4. In vivo inhibition of the previously identified targets and evaluation of its effects  
on tumour growth, survival, and cancer stem cell populations in a clinically most relevant 
model of primary human pancreatic and colon cancer 
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A very typical characteristic of cancer stem cells is a highly efficient response to 
DNA-damage, which is partly dependent on their more robust activation of DNA-damage 
checkpoint proteins, and which leads to their widely described chemo-resistance 
towards DNA-damaging drugs. In this part of the thesis project we established the 
abrogation of DNA-damage checkpoints through inhibition of the PIK kinase ATR as a 
therapeutic approach for the elimination of cancer stem cells in colon cancer: Using 
three independent model systems (chemical ATR inhibition, genetic inactivation of the 
ATR gene, and siRNA-mediated ATR protein depletion), we demonstrated that ATR 
inhibition depleted the cancer stem cell fraction of established human colon cancer cell 
lines as well as xenograft-derived primary colon cancer cells. This effect was attributable 
at least in part to apoptosis, accelerated on combined treatment with DNA-damaging 
chemotherapeutics, and accompanied by a drastically decreased in vitro and in vivo 
tumourigenicity of the remaining cells. This specific depletion of cancer stem cells was 
mechanistically due to the preferential activation of the ATR-dependent DNA-damage 
response in cancer stem cells. Our study thus illustrates a novel therapeutic approach to 
overcome the chemoresistance of cancer stem cells and specifically eliminate the very 
subpopulation of tumour cells that is exclusively responsible for tumour development, 
growth, and metastasis in colon cancer. Furthermore, in a second line of investigation, 
we have shown that the combination of ATR / CHK1 inhibition and conventional 
chemotherapy successfully eliminates CSCs in human colon cancer cell lines, providing 
a rationale for a new combination chemotherapeutic approach against colorectal cancers. 
Since currently no specific ATR inhibitors are available, we are collaborating with the 
Experimental Therapeutics Programme of the CNIO to identify and develop such 
compounds, which are ready to be tested in (pre-) clinical studies within the Clinical 
Research Programme of the CNIO and collaborating hospitals.  
 
 
I contributed to the design of this study, performed the experiments together with 
the other authors, analyzed and interpreted the results. I also participated in the writing 
of the manuscript, with input from the rest of the authors and under the supervision of 
the thesis director Prof. Christopher Heeschen. 
  
! 38!
  
CANCER STEM CELLS
Inhibition of Ataxia Telangiectasia- and Rad3-Related Function
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Cancer Cells Through Depletion of the CD1331 Tumor-Initiating
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ABSTRACT
The identification of novel approaches to specifically target
the DNA-damage checkpoint response in chemotherapy-re-
sistant cancer stem cells (CSC) of solid tumors has
recently attracted great interest. We show here in colon
cancer cell lines and primary colon cancer cells that inhibi-
tion of checkpoint-modulating phosphoinositide 3-kinase-
related (PIK) kinases preferentially depletes the chemore-
sistant and exclusively tumorigenic CD1331 cell fraction.
We observed a time- and dose-dependent disproportionally
pronounced loss of CD1331 cells and the consecutive lack
of in vitro and in vivo tumorigenicity of the remaining cells.
Depletion of CD1331 cells was initiated through apoptosis
of cycling CD1331 cells and further substantiated through
subsequent recruitment of quiescent CD1331 cells into the
cell cycle followed by their elimination. Models using spe-
cific PIK kinase inhibitors, somatic cell gene targeting, and
RNA interference demonstrated that the observed detri-
mental effects of caffeine on CSC were attributable specifi-
cally to the inhibition of the PIK kinase ataxia
telangiectasia- and Rad3-related (ATR). Mechanistically,
phosphorylation of CHK1 checkpoint homolog (S. pombe;
CHK1) was significantly enhanced in CD1331 as compared
with CD1332 cells on treatment with DNA interstrand-
crosslinking (ICL) agents, indicating a preferential activa-
tion of the ATR/CHK1-dependent DNA-damage response in
tumorigenic CD1331 cells. Consistently, the chemoresist-
ance of CD1331 cells toward DNA ICL agents was over-
come through inhibition of ATR/CHK1-signaling. In
conclusion, our study illustrates a novel target to eliminate
the tumorigenic CD1331 cell population in colon cancer
and provides another rationale for the development of spe-
cific ATR-inhibitors. STEM CELLS 2011;29:418–429
Disclosure of potential conflicts of interest is found at the end of this article.
INTRODUCTION
According to the cancer stem cell (CSC) model, solid tumors
may not be viewed as simple monoclonal expansions of func-
tionally equal cancer cells. Instead, despite their clonal origin,
only a fraction of tumor cells, termed CSC, ‘‘tumorigenic
cells’’ or ‘‘tumor-initiating cells,’’ appears to bear exclusive
tumorigenicity based on functional assays of self-renewal and
tumor initiation [1–3]. Increasing evidence suggests that
among several other solid malignancies, the CSC model can
also be applied to colon cancer. A CD133þ subpopulation of
colon cancer cells derived from primary lesions was shown to
be highly enriched for tumorigenic colon CSC capable of
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self-renewal and recapitulation of the bulk tumor population
[4, 5]. Based on the demonstrated principle of CSC as the
root of the tumor and their resistance toward conventional
chemotherapy [3, 6–8], the development of approaches aiming
at the specific eradication of CSC in solid tumors represents
an innovative goal for improved cancer treatment.
Recently, cell cycle modulation through checkpoint abro-
gation emerged as a promising approach in cancer therapy. In
contrast to normal cells, cancer cells appear to be selectively
sensitive toward treatment with inhibitors of checkpoint ki-
nases, especially when these agents were combined with
DNA interstrand-crosslinking (ICL) agents [9, 10]. Impor-
tantly, a preferential activation of the DNA-damage response
(DDR), comprising both amplified DNA-damage checkpoint
activation and increased repair of DNA-damage, has been
described as likely mechanism of CSC drug- and irradiation-
resistance in several tumor entities [11, 12]. However, the
impact of checkpoint abrogation through inhibition of check-
point kinases specifically on the CSC population in colon can-
cer has not yet been systematically explored. Therefore, we
investigated the effects of checkpoint-modulation through in-
hibition of phosphoinositide 3-kinase-related (PIK) kinases
specifically on the exclusively tumorigenic CD133þ colon
cancer cell population in multiple model systems using pri-
mary colon cancer cells and human colon cancer cell lines for
a comprehensive mechanistic investigation.
MATERIALS AND METHODS
Cell Lines, Primary Colon Cancer Samples,
and Cell Culture
The human colon cancer cell lines DLD1, Colo320, and RKO
were purchased from the American Type Culture Collection
(ATCC, Wesel, Germany, www.atcc.org). COGA-12 was
kindly provided by M. Ogris (Department of Pharmacy, Lud-
wig-Maximilian-University Munich, Germany). RKO cells
harboring an inactivating deletion of FANCC and FANCG,
respectively, and DLD1 cells harboring the Seckel mutation of
the ataxia telangiectasia- and Rad3-related (ATR) gene have
been described previously [13, 14]. Primary colon cancer cells
for ex vivo experiments were established through subcutaneous
xenografting in nude mice according to a protocol described
earlier [15]. Importantly, all in vivo-expanded cell lines used in
our study were transplanted as tissue, using their natural envi-
ronment for expansion according to a previously established
protocol [16] and analyzed during early passages: CCR004 (pas-
sage 5), CCR005 (passage 5), CCR010 (passage 2), CCR14
(passage 8–10), and CCR19 (passage 3). All cell lines were
maintained in Dulbecco’s modified Eagle’s medium (DMEM)
medium supplemented with 10% fetal calf serum and penicillin-
streptomycin (1%) and incubated at 37"C and 5% CO2. Cells
were treated with caffeine (Sigma-Aldrich, Munich, Germany,
www.sigmaaldrich.com), UCN-01 (Sigma), SB-218078 (Merck
KG, Darmstadt, Germany, www.merck.de), RAD001 (Novartis
GmbH, Nuremberg, Germany, www.novartis.de), KU-55399
(Sigma), cisplatin (cis-diammineplatinum(II)-dichloride; Sigma).
Sphere Formation Assays
CSC spheres were cultured in DMEM-F12 (Invitrogen, Karls-
ruhe, Germany, www.invitrogen.com) supplemented with B-
27 (Invitrogen) and basic fibroblast growth factor (bFGF)
(PeproTech EC, London, U.K., www.peprotech.de). A total of
10,000 cells per milliliter were seeded in ultra-low attachment
plates (Corning B.V., Schiphol-Rijk, The Netherlands,
www.corning.com) to avoid cell adhesion and subsequent dif-
ferentiation. Three to five days after treatment, four visual
fields of at least two wells were counted. Three or more inde-
pendent experiments were performed for each group. When
no sphere formation occurred, the remaining single cells were
kept under sphere culture conditions for up to 12 days to
ensure a sufficient observation time. For primary cancer cell
experiments, in vivo-expanded primary colon cancer samples
from five different patients were digested with collagenase
(Stem Cell Technologies, Vancouver, Canada, www.stemcell.
com) for 20 minutes at 37"C. Dead cells were removed using
a kit according to the manufacturer’s instructions (Miltenyi,
Bergisch-Gladbach, Germany, www.miltenyibiotec.com). Sphere
formation capacity was assessed 3–11 days after treatment. For
sphere reformation, single-cell suspensions were plated in nor-
mal sphere medium after 11 days of treatment. Spheres were
defined as morphologically characteristic three-dimensional
structures of approximately >35 lm, containing an average of
50 cells. According to this definition, all sphere formation
experiments were evaluated by two-blinded observers (P.C.H./
C.H. or M.T.M./C.H., respectively).
Animals and Transplantation of Human Colon
Cancer Cells
Female Naval Medical Research Institute nude mice (NMRI-
nu/nu, Janvier, Le Genest-Saint-Isle, France, www. janvier-
europe.com) at 8–12 weeks were used. All animal protocols
were approved by the Institutional Animal Care and Use Com-
mittee of the CNIO or by the Administrative Panel on
Laboratory Animal Care (Government of Upper Bavaria,
Germany). Colon cancer cells were injected under the renal cap-
sule of anesthetized mice as described previously [4]. One day
prior to cell transplantation, mice were sublethally irradiated
(350 cGy). Then, single-cell suspensions were suspended in a
1:1 mixture of media and Matrigel (BD Biosciences, Heidelberg,
Germany, www.bdbiosciences.com) and 5 # 105 cancer cells
were injected using a PB600 repeating dispenser (Hamilton AG,
Bonaduz, Switzerland, www.hamilton-ag.ch). Tumorigenicity of
DLD1 ATRþ/þ cells was validated in two independent experi-
ments (n ¼ 10 mice, 100% take rate) and served as a control for
all animal experiments involving DLD1 cells. Additionally, all
experiments were microscopically evaluated to confirm sufficient
cell grafting (through confirmation of single tumor cells or small
aggregates, respectively, under the renal capsule) and to exclude
macroscopically invisible small tumor formation in macroscopi-
cally tumor-negative animals. For s.c. transplantation models,
single-cell suspensions containing 2# 104 xenograft-derived pri-
mary cells were suspended as described above and implanted s.c.
into both flanks of nude mice.
Flow Cytometry
For the identification and FACSorting of colon CSC, cells
were stained with allophycocyanin- or phycoerythrin-labeled
CD133/1 (Miltenyi) or epithelial cell adhesion molecule
(EpCAM) (BD) antibodies or appropriate isotype-matched
control antibodies. Dead cells were excluded using 7-amino-
actinomycin D (7-AAD) (BD Biosciences) or 4’,6-diamidino-
2-phenylindole (Sigma). Cell cycle analysis was performed
using a 5-bromo-2-deoxyuridine (BrdU) flow cytometry kit
(BD) according to the manufacturer’s instructions. For detec-
tion of apoptotic cells, costaining with 7AAD and Annexin
V-fluorescein isothiocyanate (FITC) (BD) was performed.
Caspase inhibitors Z-VAD-FMK (R&D Systems, Minneapolis,
MN, www.rndsystems.com), Z-IETD-FMK (BD), and
Z-LEHD-FMK (BD) were applied at 20 lM for 3 hours,
followed by caffeine treatment. Flow cytometry was per-
formed on a FACSCanto II, FACSorting on a FACSAria II
www.StemCells.com
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(both BD), and data were analyzed using FlowJo 9.0.2
(Ashland, OR, www.flowjo.com).
siRNA-Mediated ATR Protein-Depletion
DLD1 cells at 30%–50% confluence were transfected using
oligofectamine (Invitrogen) and siRNA directed against either
ATR (Hs ATR 12 HP, Qiagen, Hilden, Germany, www.
qiagen.com) or CHK1 checkpoint homolog (S. pompe)
(CHK1) (Hs CHEK1 7, HP, Qiagen) or non-coding sequences
of the b-galactosidase (b-gal) gene (sense, UUAUGCCGAUC
GCGUCACAUU; antisense, UGUGACGCGAUCGGCAUA
AUU; Fisher, Schwerte, Germany, www.de.fishersci.com). siR-
NAs were used at final concentrations of 5 nM (ATR siRNA)
or 50 nM (CHK1 and b-gal siRNA). After transfection for 4
hours, serum-containing medium was added. To ensure effi-
cient long-term downregulation, siRNAs were applied repeti-
tively (according to a previously established protocol at 48, 96,
168, 216, 264, 336, and 384 hours for ATR and at 48, 96, 168,
and 216 hours for CHK1). Efficiency of ATR and CHK1 pro-
tein-depletion was evaluated using Western blotting.
Western Blotting
Western blotting was performed using standard protocols.
Briefly, equal amounts of protein were separated by SDS-poly-
acrylamide gel electrophoresis and transferred to polyvinylidene
fluoride membranes. After blocking, the membranes were incu-
bated overnight with the primary antibody either against ATR
(Santa Cruz Biotechnology, Santa Cruz, CA, www.scbt.com),
pChk1 (Cell Signaling, Danvers, MA, www.cellsignal.com), b-
actin or glyceraldehyde 3-phosphate dehydrogenase (Sigma),
washed three times, and probed with the corresponding second-
ary antibodies (1:10,000; Santa Cruz) for 2 hours. Enhanced
chemiluminescence detection was performed according to the
manufacturer’s instructions (Little Chalfont, U.K.,
www.gelifesciences.com).
Immunohistochemistry
For histological evaluation, tumor tissue was fixed in formalin
and embedded in paraffin. Histological staining for cytokera-
tin 5, 6, 8, 17, 19 (Dako, Hamburg, Germany, www.dako.
com), and hemalaun (Sigma) confirmed the nature of the
tumors. For immunostaining, slides were incubated for 1 hour
with a Ki67 antibody (Abcam, Cambridge, U.K., www.
abcam.com) followed by a biotin-labeled secondary antibody
(Cytomed, Baden-Baden, Germany, www.cytomed.de) and
streptavidin-FITC for detection. CSC were identified by Texas
Red-labeled antibodies for CD133 (Abcam). Cell nuclei were
counterstained with Sytox Blue (Invitrogen). Sections were
analyzed with a Leica SP5 confocal microscope.
Statistical Analyses
Results for continuous variables are presented as means 6
SEM. Treatment groups were compared with the independent
sample’s t test. Pairwise multiple comparisons were performed
with the one-way analysis of variance (two-sided) with Bonfer-
roni adjustment. p values <.05 were considered statistically
significant. All analyses were performed using SPSS 17.0
(SPSS Inc., Chicago, IL, www.spss.com).
RESULTS
Tumorigenicity Is Restricted to the CD1331 Cell
Fraction in DLD1 Colon Cancer Cells
We first evaluated whether CD133 represents a suitable
marker for the identification of tumor-initiating cells in the
colon cancer cell line DLD1 as a versatile model system.
Consistent with previous findings for primary human colon
cancer cells [4, 5], we detected a small fraction of CD133þ
cells in DLD1 cells (Fig. 1A). Separation of DLD1 subsets on
the basis of CD133 expression resulted in the significant
enrichment of CD133þ cells and the efficient negative selec-
tion of CD133" cells (Fig. 1B, second and third panel).
CD133" cells, subsequently kept under adherent culture con-
ditions for 14 days, were not capable of producing CD133þ
cells, whereas CD133þ cells readily generated a heterogene-
ous population of CD133þ and CD133" cells compositionally
comparable with that of unsorted cells (Fig. 1B, first and
fourth panel). Sphere formation capacity as a surrogate for
CSC activity and in vitro tumorigenicity [5, 7] was signifi-
cantly lower for CD133" cells as compared with CD133þ
cells (Fig. 1C). The depletion of the tumor-initiating fraction
in a cancer cell population is expected to decrease the in vivo
tumorigenicity of the remaining cells. Therefore, we assessed
the ability of sorted CD133þ and CD133" DLD1 cells to
engraft and give rise to tumors when implanted under the re-
nal capsule of sublethally irradiated athymic nude mice [4].
Although 104 CD133" cells did not form tumors in any of the
mice, the injection of 104 CD133þ cells resulted in macro-
scopic tumor lesions in all animals within 30 days (Fig. 1D).
Therefore, CD133 can serve as a suitable marker for the iden-
tification of the tumorigenic cell fraction in DLD1.
Depletion of the CD1331 Cell Fraction By
Caffeine Treatment Abrogates In Vitro and In Vivo
Tumorigenicity of Colon Cancer Cells
Treatment with caffeine, an unspecific inhibitor of check-
point-modulating PIK kinases, at 0.2–5 mM over a time
period of 21 days every 2 days dose-dependently depleted
the CD133þ cell fraction of DLD1 cells (Fig. 2A). This effect
became statistically significant at 5 mM (Fig. 2B). Caffeine
treatment of another colon cancer cell line, COGA12, had a
similar effect, ruling out cell line-specific artifacts (Fig. 2C).
As sphere formation capacity serves as a surrogate marker
for CSC activity and in vitro tumorigenicity of cancer cells in
solid tumors [5, 8], DLD1 cells were next treated over a time
period of 21 days every 2 days with caffeine at 5 mM and
consecutively, sphere formation was evaluated. Although
untreated control cells readily formed spheres within 3–5
days, caffeine-treated cell populations exhibited a strongly
diminished sphere formation capacity (Fig. 2D).
As the depletion of the tumor-initiating CD133þ cell frac-
tion is expected to decrease the in vivo tumorigenicity of the
remaining subpopulation, DLD1 cells were next treated over a
time period of 21 days every 2 days with caffeine at 1 and 5
mM and then implanted under the renal capsule of nude mice.
Thirty days after cell implantation, tumor take rate and tumor
size were assessed (see Fig. 2E for experimental setup). We
observed a dose-dependent decrease of the in vivo tumorige-
nicity of the cell populations pretreated with caffeine as
shown by a decreased to completely absent tumor take rate
(Fig. 2F). In contrast, large tumor formation was observed in
all animals of the control group (Fig. 2G).
Depletion of the CD1331 Cell Fraction by Caffeine
Treatment Abrogates In Vitro and In Vivo
Tumorigenicity of Primary Colon Cancer Cells
To generalize our findings beyond the setting of established
cell lines, we expanded primary colon cancer cells from surgi-
cal tumor specimens using an in vivo xenograft model modi-
fied from Jimeno et al. [15]. Xenograft-derived tumor
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specimens of five patients were dissociated and single-cell
suspensions investigated for surface expression of CD133
prior to and 11 days after caffeine treatment. Coexpression of
EpCAM was used to discriminate tumor cells from potential
contaminating endothelial or hematopoietic stem and progeni-
tor cells. We found a significant decrease of the EpCAMþ
CD133þ cell fraction in primary tumor cells after caffeine
treatment (Fig. 3A, left panel). Importantly, we observed sin-
gle viable cells, which were not clonally expanding under
these conditions by the end of the treatment period (Fig. 3A,
right panel), although apparently lower in numbers as com-
pared with control cells, thus confirming a preferential target-
ing of the clonally expanding cells. Consistently, caffeine-
treated primary colon cancer cells, although viable, demon-
strated a strongly diminished sphere formation capacity as
compared with control cells (Fig. 3B).
Figure 1. CD133þ as a marker for the tumorigenic fraction of DLD1 colon cancer cells. CD133 expression in DLD1 colon cancer cells (A) before
and (B) after FACS according to CD133 expression (second panel CD133" cells, third panel CD133þ cells). Subsequent adherence culture of sorted
CD133þ (fourth panel) and CD133" cells (first panel). (C): Sphere formation capacity of CD133" and CD133þ cells. (D): Tumor take rate after injection
of 104 CD133þ or CD133" cells, respectively, under the renal capsule of nude mice (n ¼ 5 per group): Statistical evaluation (upper panel) and representa-
tive macroscopic images (lower panel). Note that the connective tissue adhering to the kidneys on the left picture represents adipose tissue. Abbreviations:
7AAD, 7-aminoactinomycin D; FSC-A, forward scatter - area; SSC-H, side scatter - height.
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As we detected a small proportion of viable CD133þ cells
after caffeine treatment, representing either CD133þ nontu-
morigenic cells or surviving tumorigenic cells, we performed
sphere reformation assays after caffeine treatment. Although
control cells reproducibly generated second generation
spheres, no sphere formation was observed in the caffeine-
pretreated cells, when cultured in caffeine-free medium
(Fig. 3C). Finally, dissociated control or caffeine pretreated
single-cell suspensions, derived from xenograft-derived tumor
specimens from three patients, were implanted s.c. in the re-
spective flanks of the same mice to allow direct comparisons
and to exclude interindividual take rate variability. During an
observation period of 100 days, we observed a reduced tumor
take rate, a decreased average size of engrafted tumors, and a
significantly higher event-free long-term survival in the caf-
feine-treated group (Fig. 3D).
Caffeine Treatment Increases Proliferation and
Apoptosis of CD1331 Colon Cancer Cells
To elucidate the mechanism underlying the caffeine-mediated
depletion of the tumorigenic CD133þ cell fraction, we com-
pared the effects of caffeine on proliferation of and apoptosis
in CD133þ cells versus CD133" cells. For technical reasons,
we used colon cancer cell lines as a model system for these
experiments. DLD1 cells were treated over a time period of
up to 7 days with caffeine at 5 mM. Consecutively, BrdU or
Annexin V staining along with concomitant CD133 staining
was performed to separately analyze CD133þ and CD133"
cells with regard to proliferation and apoptosis. In the control
group, 10% of CD133" cells and 17% of CD133þ cells
showed an early BrdU incorporation by 2 hours, while up to
96% of CD133" cells, but only 56% of CD133þ cells had
incorporated BrdU by 96 hours, indicative of a quiescent sub-
set in the CD133þ fraction. Caffeine treatment caused an ear-
lier increase of BrdU-incorporating cells in both the CD133"
and the CD133þ fraction. Of note, the amount of BrdU-incor-
porating CD133þ cells increased to 87% at 96 hours, suggest-
ing a caffeine-induced activation of a formerly quiescent
CD133þ subset (Fig. 4A, 4B).
In a time-lapse analysis using AnnexinV as marker of
early apoptosis, we observed an initial rapid decline of
CD133þ cell content after caffeine treatment, followed by a
subsequent slower decline (Fig. 4C). Consistently, the fraction
of CD133þ AnnexinVþ cells was rather high (up to 8%)
during the initial 72 hours, although a smaller yet sustained
fraction of CD133þ AnnexinVþ cells was observed up to 168
hours, presumably representing the quiescent CSC fraction
progressively recruited to enter an active cell cycle. As
apoptosis can be initiated via either the intrinsic (involving
activation of caspase 9) or the extrinsic pathway (cleavage of
caspase 8) [17], DLD1 cells were next preincubated using
either pancaspase-, caspase 8-, or caspase 9-inhibitors before
caffeine treatment. Incubation with the pan-caspase inhibitor
strongly decreased the fraction of CD133þ AnnexinVþ cells
after subsequent caffeine treatment. However, inhibition of
either caspase 8 or caspase 9 alone was also sufficient to
decrease apoptosis (Fig. 4D), suggesting that caffeine initiated
apoptosis through cleavage of caspase 8, but that the recruit-
ment of caspase 9 by a mitochondrial amplification loop was
Figure 2. Dose-dependent depletion of CD133þ cells after caffeine treatment and reduced in vitro and in vivo tumorigenicity of the remaining cell
population: CD133þ fraction of DLD1 cells treated with caffeine at the indicated concentrations for 21 days. (A): Representative results and (B) sta-
tistical evaluation (n ¼ 5). (C): CD133þ fraction of COGA12 cells treated with caffeine for 21 days (n ¼ 3). (D): Representative images (left two
panels) and statistical evaluation (n ¼ 3; right panel) of sphere formation capacity of DLD1 cells treated with caffeine or control for 21 days. (E): Ex-
perimental setup for the in vivo experiments. (F): In vivo tumorigenicity, evaluated 30 days after injection of DLD1 cells under the renal capsule of
nude mice: tumor take rate (left panel) and volume (right panel) after implantation of cells treated with control (n ¼ 10) or caffeine at 1 mM (n ¼ 5)
or 5 mM (n ¼ 7), respectively. (G): Representative macroscopic and microscopic pictures of tumor formation after injection of untreated control cells
(upper panel) or cells treated with caffeine for 21 days (lower panel). Abbreviations: CSC, cancer stem cell; SSC-H, side scatter - height.
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additionally required for the activation of effector caspases in
the CSC fraction.
Caffeine-Induced Depletion of CD1331 Colon
Cancer Cells Is Mediated by ATR
Caffeine acts as an unspecific inhibitor of the checkpoint-
modulating PIK kinases ataxia telangiectasia mutated (ATM),
ATR, and mammalian target of rapamycin (MTOR), without
being a global inhibitor of protein kinase activities [18]. To
identify the signaling cascade mediating the caffeine-induced
depletion of tumorigenic CD133þ cells, we used KU-55399
for ATM inhibition [19] and RAD001 for MTOR inhibition
[20]. Because of the lack of ATR-inhibitors and as CHK1
represents the major effector kinase of ATR, we additionally
applied the potent, but in comparison with the highly specific
ATM inhibitors, less-specific CHK1 inhibitor UCN-01 and its
analog SB218078 [21–25]. UCN-01 was chosen as it currently
represents the most clinically advanced CHK1 inhibitor,
which has already undergone clinical trials, whereas
SB218078 was chosen due to its better specificity as it exerts
much less inhibitory activity against protein kinase C as com-
pared with UCN-01 [26]. Although treatment with either
RAD001 or KU-55399 had no significant effects, UCN-01
and SB218078 both caused a significant decrease of CD133þ
cells, suggesting that inhibition of either CHK1 or the
upstream PIK kinase ATR mediated the caffeine-induced
effects (Fig. 4E).
DLD1 Cells Harboring an Inactivating
ATR Mutation Lack the Tumorigenic
CD1331 Cell Fraction
To further support that disruption of ATR function was
responsible for the caffeine-induced effects, we applied a
genetic knock-in model. The hypomorphic ATR splice-site
‘‘Seckel’’ mutation 2101A!G leads to a subtotal depletion of
ATR protein but has no gross effects on cancer cell growth or
viability [14, 27]. Therefore, parental DLD1 (ATRþ/þ) cells,
constitutively expressing ATR protein, were compared with
cells homozygously harboring the Seckel mutation (ATRs/s
cells) [14], which express no detectable ATR protein (Fig.
5A). ATRþ/þ and ATRs/s cells were long-term passaged for at
least 3 months before analysis of CD133 expression status.
Although ATRþ/þ cells displayed a CD133þ cell population
ranging from 3% to 8% (Fig. 5B) when assessed at different
time points during cell culture, ATRs/s cells exhibited a near
absent CD133þ cell fraction. Consistently, ATRs/s cells were
severely impaired in sphere formation capability (Fig. 5C)
and completely unable to form tumors in nude mice (take rate
0%; n ¼ 10; Fig. 5D, 5E).
Depletion of the Tumorigenic CD1331 Cell Fraction
on Continuous siRNA-Mediated ATR-Knockdown
To exclude potential artifacts that might occur due to clonal
variability in the ATR knock-in experiments, we additionally
assessed the effects of continuous ATR protein-depletion on
Figure 3. Effects of caffeine on the CD133þ fraction of xenograft-derived primary colon cancer cells. Dissociated single cancer cells, derived
from xenograft-expanded surgical colon cancer specimens from five patients, treated for 11 days with either control or caffeine at the indicated
concentrations. (A): Quantification of the EpCAMþ CD133þ cell fraction (left panel) and viability of the gated cells (right panel; n ¼ 4). (B):
Representative pictures of sphere formation assays (upper left four panels) and assessment of cell viability after caffeine treatment (upper right
two panels) for CCR-014 and CCR-019 primary tumor cells. Statistical evaluation is provided for all five tumors (n ¼ 3 experiments for 1 mM
caffeine, n ¼ 10 experiments for 5 mM caffeine; lower panel). (C): Caffeine pretreated primary cells, seeded into medium without caffeine. Rep-
resentative pictures of sphere reformation after 9 days. (D): Caffeine- or control-treated primary tumor cells, implanted s.c. into nude mice (n ¼
7 for CCR-010, n ¼ 5 for CCR-014, n ¼ 4 for CCR-005). Representative pictures of tumor-bearing mice (upper left two panels); Kaplan-Meier
curve depicting cumulative event-free long-term survival (event ¼ tumor growth exceeding 1 cm3; upper right panel). Statistical evaluation is
provided for tumorigenicity (lower left panel) and tumor size (lower right panel). Abbreviations: DAPI, 4’,6-diamidino-2-phenylindole; EpCAM,
epithelial cell adhesion molecule; FSC-A, forward scatter - area.
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unselected cancer cells, using repetitive applications of
ATR-siRNA over a time period of 384 hours. ATR protein-
depletion efficiency of >80% was confirmed for all time
points starting from 96 hours up to 384 hours (Fig. 6A).
ATR siRNA-treated cells displayed a time-
dependent reduction of the CD133þ cell fraction when com-
pared with mock-transfected or control siRNA-transfected
cells, starting at 96 hours after transfection (Fig. 6B). After
384 hours of repetitive ATR-siRNA treatment, the cells
were implanted under the renal capsule of nude mice, and
tumor take rate was assessed 30 days later (Fig. 6C). The
ATR siRNA-treated cells displayed a reduced but not com-
pletely absent capability to form tumors (take rate 33%;
n ¼ 6) as compared with control cells (Fig. 6D). Two mice
bore clearly diminutive tumors, approximating 2 mm3 in
both cases, as compared with 970 mm3 on average observed
in control mice. In these diminutive tumors, we detected
only sparse proliferation activity and rare presence of
CD133þ cells (<1 cell per high-power field for ATR-
siRNA-treated cells vs. 6.1 6 2.7 for control cells;
Fig. 6E).
No Significant Depletion of the Tumorigenic
CD1331 Cell Fraction on Continuous
siRNA-Mediated CHK1-Knockdown
Analogous to the above experiments using ATR siRNA, a
similar set of experiments was performed for ATR’s major
effector kinase CHK1, using repetitive applications of CHK1
siRNA. In contrast to ATR siRNA-treated cells, which dis-
played a strong reduction of the CD133þ cell fraction as soon
as 96 hours after transfection, CHK1 siRNA-treated cells,
even though efficiently depleted of CHK1 protein, did not dis-
play a significant reduction of the CD133þ cell fraction over
a time period of 264 hours when compared with control cells
(data not shown).
Depletion of CD1331 Colon Cancer Cells on
ATR-Inhibition Is Fanconi Anemia
Pathway-Independent
As ATR-inhibition causes disruption of the Fanconi anemia
(FA) DNA-repair pathway [28], we tested whether this path-
way contributed to the ATR inhibition-mediated effects on
CD133þ cells. The CD133þ cell fraction of RKO colon can-
cer cells was compared with the CD133þ fraction of RKO
cells engineered to harbor inactivating deletions of either the
FANCC or FANCG gene [13]. No significant differences were
observed in this FA model, excluding the FA pathway as a
major contributing factor to the ATR inhibition-induced
depletion of CD133þ cells (data not shown).
Induction of Stalled Replication Forks Increases
the Effects of ATR/CHK1-Inhibition on the
CD1331 Cell Fraction
ATR acts as a central regulator of the replication checkpoint
and participates in the detection and repair of endogenous and
exogenously induced stalled replication forks (SRF) via
Figure 4. Mechanism of the caffeine-induced depletion of the CD133þ cell fraction. (A): BrdU-incorporating fraction of CD133þ DLD1 cells
after treatment for 7 days with control (upper panel) or caffeine (lower panel) at 2–96 hours after treatment. (B): Representative flow cytometric
assessments of cell cycle profiles of CD133þ DLD1 cells after treatment for 7 days with control or caffeine at 2–96 hours after treatment. (C):
CD133þ fraction and CD133þ Annexin Vþ subset of DLD1 cells, either treated with control (upper panel) or caffeine (lower panel), assessed at
the indicated time points. (D): CD133þ Annexin Vþ fraction of caffeine-treated DLD1 cells pretreated with the indicated caspase inhibitors for 2
hours. (E): Statistical evaluation (n ¼ 3) of the CD133þ fraction of DLD1 cells treated with the indicated PIK kinase or checkpoint inhibitors,
respectively, at the indicated concentrations for 21 days. Abbreviations: 7AAD, 7-aminoactinomycin D; BrdU, 5-bromo-2-deoxyuridine; FITC,
fluorescein isothiocyanate.
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phosphorylation of the checkpoint kinase CHK1 [29]. Consist-
ent with previous reports describing amplified checkpoint acti-
vation in some CSC [11, 12], upregulation of CHK1 phospho-
rylation was significantly more pronounced in the CD133þ
than in the CD133" cell fraction on treatment with the SRF-
inducing ICL-agent mitomycin C, when compared with the
respective untreated cell fractions. Importantly, the increased
CHK1 phosphorylation levels in the CD133þ cell fraction
were not merely ascribable to increased levels of total CHK1
protein (Fig. 7A, left panel). As ICL-inducing platinum com-
pounds are more commonly used than mitomycin C for the
treatment of colorectal cancer in the clinical setting, the above
results were additionally validated using cisplatin, a classic
platinum ICL-agent, yielding similar results (Fig. 7A, right
panel).
To test whether consequently, ICL-agents would synergis-
tically add to the preferential depletion of CD133þ cells
through inhibition of the ATR/CHK1 axis, DLD1 cells were
treated with caffeine, the CHK1-inhibitor SB218078 or the
ICL-agent cisplatin alone, or using different combinations of
Figure 5. Reduced tumorigenicity of colon cancer cells harboring an inactivating ATR mutation. (A): ATR protein content of ATRþ/þ and
ATRs/s cells, as assessed by Western blotting. (B): CD133þ cell fraction of ATRþ/þ and ATRs/s cells: representative results (left two panels) and
statistical analysis (n ¼ 5, assessed at five time points during culture, right panel). (C): Sphere formation capacity of ATRþ/þ cells and ATRs/s
cells: representative results (left two panels) and statistical evaluation (n ¼ 3, right panel). (D): Experimental setup for the in vivo experiments.
(E): In vivo tumorigenicity, evaluated 30 days after injection of ATRþ/þ (n ¼ 10) or ATRs/s (n ¼ 10) cells under the renal capsule of nude mice:
statistical evaluation (left panel) and representative macroscopic and microscopic pictures (right panel). Abbreviations: ATR, ataxia telangiectasia
and Rad3 related; SSC-H, side scatter - height.
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these agents. Caffeine caused a significant decrease of
CD133þ cells as early as 5 days after initiation of treatment
and a nearly complete elimination on longer treatment (21
days). Treatment with the CHK1-inhibitor SB218078 at 10 or
20 nM resulted in a significant decrease of CD133þ cells only
after 21 days (Fig. 7B). Consistent results were obtained
when using Colo320 cells (Fig. 7C, left panel) and further
supported by the observation that the CD133þ AnnexinVþ
cell fraction inversely correlated with the total CD133þ cell
fraction (Fig. 7C, right panel). In contrast, we observed no
decrease of CD133þ cells on treatment with cisplatin alone at
6.6 lM for 2 days (Fig. 7D) in either DLD1 or Colo320,
whereas pretreatment with either caffeine or SB218078 fol-
lowed by treatment with cisplatin strongly reduced the
CD133þ fraction of both cell lines already after short-term
treatment (Fig. 7E).
DISCUSSION
We demonstrate here that inhibition of ATR function depletes
the tumorigenic CD133þ fraction of established colon cancer
cell lines as well as xenograft-derived primary colon cancer
cells. This effect translated into a markedly reduced tumorige-
nicity of the remaining cells, as shown by an impaired sphere
formation capacity in vitro [5, 7] as well as a strongly reduced
capability to form tumors in vivo. Consistent with previous
reports describing amplified checkpoint activation and
increased DNA repair to be distinct features of some CSC [11,
12], CD133þ cells displayed a stronger activation of the ATR-
dependent DDR on treatment with ICL-agents than did
CD133" cells, as evidenced by a more pronounced increase in
phosphorylation of ATR’s major effector kinase CHK1. Impor-
tantly, the depletion of CD133þ cells was enhanced on subse-
quent treatment with ICL-agents, suggesting that inhibition of
ATR might reverse the chemoresistance of CSC toward ICL-
agents in the clinical setting and could thus serve as a novel
therapeutic strategy for patients suffering from colon cancer.
As the PIK kinases ATM, ATR, MTOR, and DNA-PK all
play pivotal roles in cell cycle checkpoint functions and all
except DNA-PK are effectively inhibited by caffeine [18],
caffeine was used as a screening approach to modulate check-
point function in colon cancer cells. Caffeine treatment virtu-
ally abolished the CD133þ cell fraction and was accompanied
by a decreased in vitro and in vivo tumorigenicity of the
remaining cell population, providing functional evidence for a
successful targeting of the tumor-initiating CSC fraction.
Depletion of CD133þ cells was observable as early as 5 days
after caffeine administration and further enhanced after longer
exposure, indicating that prolonged treatment was required for
the complete exhaustion of the CD133þ subpopulation, first
through the elimination of the rapid cycling cell fraction and
consecutively through activation of a slow cycling or even
Figure 6. Decreased CD133þ fraction and reduced tumorigenicity of colon cancer cells on ATR protein-depletion: (A): Representative results
from one of two experiments, showing ATR protein content of mock-, ATR siRNA-, and control siRNA-transfected DLD1 cells at the indicated
time points, as assessed by Western blotting (upper panel), and corresponding densitometric quantification (lower panel). (B): Flow cytometric
assessment of the relative CD133þ content of mock-, ATR siRNA-, and control siRNA-transfected DLD1 cells, compared with each other at the
indicated time points (left panel). CD133þ fraction of mock- or ATR siRNA-transfected cells after 384 hours of repetitive siRNA application
(right two panels). (C): Experimental setup for the in vivo experiments. (D): In vivo tumorigenicity, evaluated 30 days after injection of ATR
siRNA-transfected cells: statistical evaluation (n ¼ 6, left panel) and representative microscopic pictures showing no or diminutive tumor growth,
respectively (right two panels). (E): Histological analysis for the presence of CD133þcells (red) in tumors from control- or ATR siRNA-trans-
fected cells. Cell proliferation was assessed by Ki67 staining (green). Nuclei were identified by Sytox Blue staining (blue). Abbreviations: ATR,
ataxia telangiectasia and Rad3 related; FITC, fluorescein isothiocyanate; SSC-H, side scatter - height.
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quiescent fraction. Consistently, caffeine increased the prolif-
erating fraction of CD133þ cells in our experiments.
A panel of small molecule inhibitors was applied to dis-
sect the contributions of the different PIK kinases on the caf-
feine-induced preferential depletion of CD133þ cells. As no
specific ATR-inhibitors are currently available, several potent,
but in comparison with the highly specific ATM inhibitors,
less-specific inhibitors of CHK1 as the major effector kinase
of ATR were used as surrogates for ATR inhibition. In con-
trast to the ATM inhibitor KU-55399 and the MTOR inhibitor
RAD001, only CHK1 inhibitors mimicked the effects of caf-
feine. As CHK1 activity itself is only marginally suppressed
by caffeine [18], whereas the upstream PIK kinase ATR is
potently inhibited, these data suggested that the caffeine-
induced depletion of CD133þ cells was mediated through
direct inhibition of ATR followed by indirect inhibition of its
main effector kinase CHK1. Importantly, caffeine exerted its
detrimental effects on CD133þ cells already after short-term
treatment, whereas the effects of CHK1 inhibitors were
observable only after long-term treatment. To exclude differ-
ent pharmacokinetic properties of the used agents as the
underlying reason for the observed differences, our findings
were corroborated by a set of siRNA experiments. Consis-
tently, knockdown of CHK1 protein expression over 264
hours did not lead to comparable detrimental effects on the
CD133þ cell population as did ATR protein depletion. Fur-
thermore, we analyzed an isogenic FA knockout model [13,
30], as ATR had been linked to the FA DNA-repair pathway
[28], but found no evidence for an impact of FA pathway
abrogation on the depletion of CD133þ colon cancer cells.
Together, these data suggest that besides CHK1 as the major
effector kinase of ATR, other ATR-dependent, but FA-inde-
pendent pathways are operative in this setting.
The complete disruption of the ATR gene is a lethal event
in human somatic cells [31] and no applicable cellular model
presently exists to investigate the null state of the ATR gene.
However, the hypomorphic ATR-inactivating splicing mutation
2101A!G, naturally found in Seckel syndrome patients [32],
causes subtotal depletion of ATR protein without gross effects
on cancer cell growth or viability [14, 30]. Therefore, cancer
cells homozygously harboring this mutation (ATRs/s cells) were
used as a highly specific tool to model ATR inhibition in
tumors. ATRs/s cells were virtually depleted of CD133þ cells
as compared with parental ATRþ/þ cells. Consistently, ATRs/s
cells were impaired in sphere formation capacity and unable to
form tumors in vivo. ATRs/s cells did not show significant dif-
ferences in proliferation rates as compared with their ATRþ/þ
counterparts, excluding that their loss of tumorigenicity was at-
tributable to a hypothetical cell cycle arrest. It should be noted
that a limitation of our genetic ATR model is that confounding
artifacts due to clonal variability cannot definitively be
excluded [30]. Therefore, our data require cautious interpreta-
tion, especially when considering the CD133 expression status
of the originally derived ATRs/s cell clones. As can be derived
from our initial experiments, tumorigenicity was mainly re-
stricted to the CD133þ cell fraction of DLD1 colon cancer
cells, which constituted only about 5% of the unselected DLD1
cell population. Thus, the engineered ATRs/s cells were more
likely originally derived from a CD133" cell clone, which
according to our data, would be expected not to be capable of
regenerating tumorigenic CD133þ cells, at least in our short-
term experimental setting (14 days). On the other hand, it
remains a controversial issue whether non-CSC or a subpopu-
lation of them might be able to regenerate CSC in the long
run, or correspondingly, whether CD133" ATRþ/þ cells might
at some point regenerate CD133þ cells [33]. Taken together,
Figure 7. Additive effects of interstrand-crosslinking (ICL)-agents on the depletion of CD133þ cells after inhibition of the ataxia telangiectasia
and Rad3 related (ATR)/checkpoint homolog (CHK1) axis. (A): Western blotting showing increased Chk1 phosphorylation in CD133þ as com-
pared with CD133" DLD1 cells on treatment with ICL-agents: Comparison of pCHK1 and CHK1 protein levels in CD133þ and CD133" cells ei-
ther left untreated or treated with mitomycin C (left panel), representative results from n ¼ 2 experiments are shown. Comparison of pCHK1
protein levels in CD133þ and CD133" cells treated with either mitomycin C or cisplatin (right panel), representative results from n ¼ 3 experi-
ments are shown. (B): CD133þ fraction of DLD1 cells after treatment with SB218078 or caffeine for 5 or 21 days, respectively. For illustrative
purposes, data for long-term SB218078 treatment were taken from Figure 4E, for caffeine treatment at 5 mM from Figure 2B. (C): Total
CD133þ cell fraction (left panel) and CD133þ Annexin Vþ subset (right panel) of Colo320 cells after treatment with SB218078 for 5 or 21 days
(left panel). (D): CD133þ fraction of DLD1 and Colo320 cells after treatment with cisplatin at 6.6 lM for 5 days. (E): CD133þ fraction of
DLD1 and Colo320 cells after pretreatment with SB218078 or caffeine for 5 days, followed by cisplatin for 2 days. Abbreviation: GAPDH, glyc-
eraldehyde 3-phosphate dehydrogenase.
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our data demonstrate that ATR-deficient CD133! cancer cells
retain a nontumorigenic phenotype for at least several months
during cell culture.
To exclude potential artifacts due to clonal variability, we
employed a third model of ATR function, using RNA-interfer-
ence through repetitive application of ATR siRNA, which
facilitated the continuous depletion of ATR protein in unse-
lected colon cancer cell populations. Similar to the results
obtained in the genetic model, we observed a time-dependent
decrease of the CD133þ cell fraction in ATR siRNA-treated
cells along with a concomitant reduction of the in vivo tumori-
genicity of the remaining cell population, strongly indicative of
a successful targeting of the tumor-initiating stem cell fraction.
In contrast to ATRs/s or caffeine-treated cells, however, ATR
siRNA-treated cells did not exhibit a complete abrogation of in
vivo tumor formation in all animals. This could most likely be
ascribed to an inevitable methodological shortcoming of experi-
ments applying siRNA technology, that is, the incomplete tar-
geting on the cellular level, generally leaving a remaining sub-
population of not efficiently siRNA-transfectable cells
(including CD133þ cells), unaffected. Accordingly, traceable
amounts of ATR protein were still detectable in the ATR
siRNA-treated cell population after 384 hours of repetitive
siRNA-application. As a consequence, the decreased, but
maybe not absent, tumorigenic cell fraction on ATR siRNA
treatment would be expected to lead to a significantly
decreased, but not absent, tumor take rate, as observed in our
experiments. Interestingly, in those rare instances, in which
tumors were generated by ATR siRNA-treated cell populations,
these tumors were clearly diminutive as compared with those
observed in control mice. This could be explained by the
decreased fraction of tumorigenic CD133þ cells in the ATR
siRNA-treated population, as a smaller fraction of tumor-initiat-
ing cells could perceivably also account for a decreased tumor
size in those rare instances of successful tumor formation.
Indeed, a very rare occurrence of CD133þ cells was observable
in tumors that originated from ATR siRNA-treated cells.
Another explanation, consistent with the observed sparse prolif-
eration activity of the diminutive tumors in vivo, would be that
these tumors did not arise from the successfully eliminated tu-
mor-initiating cell fraction but rather from an untargeted subset
of short-lived transient amplifying cells, which only divide a fi-
nite number of times until they become terminally differenti-
ated and finally undergo senescence [34].
A preferential activation of the DDR, comprising both
amplified checkpoint activation and increased DNA-repair, has
previously been proposed as a likely mechanism of CSC drug-
resistance [11, 12] and could also explain the increased sensi-
tivity of CD133þ colon cancer cells toward ATR inhibition;
ATR is a central regulator of the replication checkpoint, which
blocks cell cycle progression on detection of endogenous or ex-
ogenously induced SRF. In this process, ATR stabilizes SRF
via its main effector kinase CHK1 and prevents the inappropri-
ate processing of DNA [29]. Accordingly, cells harboring a
complete disruption of the ATR gene display increased chromo-
some breaks even in the absence of exogenous replication
stress, most likely induced through SRF occurring during nor-
mal cellular proliferation, and are not viable over extended peri-
ods of time [31]. The significantly stronger upregulation of
CHK1 phosphorylation in the CD133þ as compared with the
CD133! cell fraction on treatment with SRF-inducing ICL-
agents in our experiments thus supports a preferential activation
of the ATR-dependent DDR also in colon CSC.
Consistently, treatment with SRF-inducing ICL-agents
accelerated the depletion of CD133þ cells on ATR inhibition,
further supporting that the detrimental effects of caffeine spe-
cifically on CD133þ cells were attributable to the particularly
reduced capability of these cells to repair, endogenously or
exogenously inflicted, SRF when ATR function was impaired.
It is tempting to speculate that the impaired DNA repair capa-
bility of CD133þ cells in response to ATR inhibition could
be ascribed structurally to differences in chromatin compac-
tion between CD133þ and CD133! cells. Overall, chromatin
accessibility, a dynamic process largely mediated by chroma-
tin compaction, represents an innate property of stem cells,
which is lost during differentiation [35]. The degree of chro-
matin compaction, on the other hand, determines at least in
part the extent of DNA damage, the feasibility of DNA repair
[36], and the strength of the DDR [37] and could thus explain
a particularly strong dependence of CSC on an intact DDR.
On confrontation with DNA damage, the DDR mediates
whether cells undergo a replication arrest to allow DNA
repair, bypass the DNA damage and continue to replicate
DNA, or eventually, undergo apoptosis [38]. We found that
after caffeine treatment, apoptotic cell death did not occur im-
mediately in CD133þ cells, but progressively increased with
cumulative BrdU incorporation, excluding cytotoxicity as the
sole source of the caffeine-induced effects. Notably, a small
fraction of AnnexinVþ CD133þ cells was detectable up to
168 hours after treatment initiation, likely representing the
CSC fraction progressively recruited to enter an active cell
cycle. Consistently, after an initial caffeine-induced increase
of CD133þ AnnexinVþ cells, their amount subsequently
declined, paralleling the decline of total CD133þ cell num-
bers. Thus, the caffeine-induced depletion of CD133þ cells
was at least in part attributable to proliferation-dependent
induction of apoptosis. As apoptosis was triggered by caspase
8 and reinforced by a mitochondrial amplification loop
involving the recruitment of caspase 9, sensitization to extrin-
sic receptor-mediated apoptosis might provide another tool for
the specific depletion of the CSC fraction in colon cancer.
CONCLUSION
Using three independent model systems, that is, pharmacologi-
cal ATR inhibition, genetic inactivation of the ATR gene, and
RNA interference-mediated ATR protein depletion, we found
that inhibition of ATR function depleted the tumorigenic
CD133þ cell fraction of established human colon cancer cell
lines as well as xenograft-derived primary colon cancer cells.
This effect was attributable at least in part to apoptosis, acceler-
ated on cotreatment with common chemotherapeutics that gen-
erate SRF, and accompanied by a drastically decreased in vitro
and in vivo tumorigenicity of the remaining cells. Mechanisti-
cally, the preferential depletion of tumorigenic CD133þ cells
was attributable to the preferential activation of the ATR-de-
pendent DDR in these cells. Our study thus illustrates a novel
approach to selectively eliminate the tumorigenic cell popula-
tion in colon cancer. As the caffeine blood levels required for
inhibiting ATR function cannot be achieved in vivo due to the
narrow therapeutic window and the pronounced cardiovascular
side effects of caffeine and its derivatives, our study provides a
strong rationale for the pharmaceutical development of specific
ATR inhibitors as a potentially powerful approach to eliminate
CSC in colorectal cancer [39–41].
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We have provided conclusive evidence for the re-activation of the developmental 
Nodal/Activin pathway in pancreatic cancer stem cells, which strongly increases their 
plasticity and aggressiveness. Intriguingly, this pathway is not only active in pancreatic 
cancer stem cells, but also in pancreatic stellate cells (representing a putative CSC 
niche). Furthermore, we demonstrated that the Nodal/Activin pathway is essential for the 
self-renewal capacity and the stemness properties of pancreatic CSC, and therefore 
represents a novel therapeutic target. In this context we have shown that targeting of the 
Nodal/Activin pathway but not of TGF-β by small molecule inhibitors or genetic 
knockdown, respectively, eliminates cancer stem cells and thus the tumourigenic 
potential of pancreatic cancer cells. Embarking on further preclinical studies we have 
shown that the cancer stem cell compartment can be severely altered by inhibition of this 
pathway, resulting in chemo-sensitization of the cancer stem cells, which then can be 
eliminated by standard chemotherapy resulting in disease stabilization. However, a 
major challenge in pancreatic cancer remains drug delivery, since poor vascularization 
and massive stroma content are hallmarks of the disease. Intriguingly, we were able to 
overcome this hurdle by simultaneous targeting of the sonic hedgehog pathway as a 
crucial signaling component for pancreatic stellate cells and other stromal cells, an 
observation that confirms the results of a study that we published previously.(Mueller et 
al., 2009) The resulting triple therapy containing a Nodal/Activin inhibitor, a hedgehog 
pathway inhibitor, and a chemotherapeutic agent resulted in long-term survival of all 
mice in a clinically most relevant primary pancreatic cancer model, while mice receiving 
only the chemotherapeutic agent had to be sacrificed within a few weeks due to rapid 
tumour progression. 
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SUMMARY
Nodal and Activin belong to the TGF-b superfamily
and are important regulators of embryonic stem cell
fate. Here we investigated whether Nodal and Activin
regulate self-renewal of pancreatic cancer stemcells.
Nodal and Activin were hardly detectable in more
differentiated pancreatic cancer cells, while cancer
stem cells and stroma-derived pancreatic stellate
cells markedly overexpressed Nodal and Activin,
but not TGF-b. Knockdown or pharmacological inhi-
bition of the Nodal/Activin receptor Alk4/7 in cancer
stem cells virtually abrogated their self-renewal
capacity and in vivo tumorigenicity, and reversed
the resistance of orthotopically engrafted cancer
stem cells to gemcitabine. However, engrafted
primary human pancreatic cancer tissue with
a substantial stroma showed no response due to
limited drugdelivery. The addition of a stroma-target-
ing hedgehog pathway inhibitor enhanced delivery of
the Nodal/Activin inhibitor and translated into long-
term, progression-free survival. Therefore, inhibition
of the Alk4/7 pathway, if combined with hedgehog
pathway inhibitionandgemcitabine,providesa thera-
peutic strategy for targeting cancer stem cells.
INTRODUCTION
Although pancreatic ductal adenocarcinoma has become the
subject of increasing research efforts over the past decades,
poor response to therapy with subsequent dismal survival has
remained the hallmark of this disease. Recent evidence from
our and other laboratories suggests that pancreatic carcinomas
harbor a distinct subpopulation of putative cancer stem cells
(CSCs) defined by their self-renewal capacity, differentiation
ability, exclusive in vivo tumorigenicity (Hermann et al., 2007;
Li et al., 2007), and ability to drive metastasis (Hermann et al.,
2008). Most importantly, CSCs have also been proposed as
the major source of resistance toward conventional chemo-
therapy and radiotherapy (Bar et al., 2007; Hermann et al.,
2007; Mueller et al., 2009). Therefore, novel therapies capable
of eliminating CSCs while leaving normal stem cells unaffected
are urgently needed.
Members of the TGF-b family, namely Bone Morphogenic
Proteins (BMPs), TGF-b, and Nodal/Activin, exert multiple, and
sometimes opposing, effects on a variety of cell types depending
on the cellular context, including the stage of the disease, the
local environment, and the identity and the dosage of the ligand
(Massague´, 2008; Watabe and Miyazono, 2009). Nodal and Ac-
tivin as secreted proteins are expressed during embryonic devel-
opment and are implicated in developmental events such as
mesoderm formation and left-right axis specification. Moreover,
they were shown to be essential for human embryonic stem cell
(ESC)maintenance (Vallier et al., 2005; Xiao et al., 2006), but their
role in cancer still remains poorly defined. Nodal and Activin bind
to their common receptors, the Activin-like (Alk) type I receptors
Alk4 and 7, while Cripto-1 constitutes an important coreceptor
for Nodal signaling only (Strizzi et al., 2005). Recently, Nodal
signaling was linked to a more aggressive phenotype in mela-
noma and breast cancer cells (Topczewska et al., 2006). Further-
more, inhibition of Nodal signaling has been shown to reduce
tumorigenicity in melanoma cell lines, suggesting a potential
role in tumor-initiating cells (Postovit et al., 2008). Encouraged
by these reports, we investigated the role of the Nodal/Activin
signaling cascade in the tumorigenic stem cell compartment of
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pancreatic cancer, and its potential as a therapeutic target for
the successful elimination of pancreatic CSCs as the root of
this deadly disease.
RESULTS
Pancreatic CSCs Express Pluripotency-Associated
Markers
We have shown that primary pancreatic CSCs can be enriched
in vitro as anchorage-independent spherical colonies termed
spheres (Hermann et al., 2007). These spheres are composed
of a small number of cells with stem cell-like properties including
the ability to form secondary spheres as well as more differenti-
ated progenies. Recently, we also reported the enrichment of
pancreatic CSCs within the CD133+-expressing cell population
as assessed by flow cytometry (Hermann et al., 2007). Therefore,
for the present studies, we used these two supplementary
methods for studying pancreatic CSCs.
A total number of eight human pancreatic adenocarcinoma
xenografts were used, with A6L, 185, JH051, 247, and 198 being
described earlier as primary tumors or tumor-derived primary
cell lines (Jones et al., 2008; Rubio-Viqueira et al., 2006), and
with 265, 286, and 354 produced by the same technique. Impor-
tantly, all cells for in vitro experiments were freshly isolated from
early passage xenografts. Isolated cells from these xenografts
were cultured as adherent cells (monolayer) or anchorage-inde-
pendent spheres at low passages (Figure 1A). Moreover, three
established pancreatic cancer cell lines (L3.6pl, MiaPaCa2,
and Panc1) were used. Cells were phenotyped by flow cytometry
for the expression of CD133, CD44, CXCR4, SSEA-4, and SSEA-
1. As previously reported, spheres are enriched in CD133+ cells,
as well as several other markers that have been associated with
a CSC phenotype such as CXCR4, SSEA-4, and SSEA-1, as
A
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Figure 1. Sphere-Derived Pancreatic CSCs Express Pluripotency Markers
(A) Morphology of pancreatic cancer cells derived from xenografts and freshly isolated human tissue grown as monolayers or spheres.
(B) Flow cytometry analysis for CD44, CD133, CXCR4, SSEA-4, and SSEA-1 as cancer stem cell markers in spheres as compared with adherent cells from A6L or
185 tumors.
(C) qPCR analysis of pluripotency-associated genes in adherent cells versus spheres. Data are normalized to GAPDH expression and are presented as fold
change in gene expression relative to adherent cells.
(D) Western blot analysis of Nanog, Oct4a, and GAPDH in spheres as compared with adherent cells. Nanog promoter RFP reporter construct illustrates the
presence of single Nanog promoter+ cells in spheres.
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compared with adherent cells (Hermann et al., 2007; Scaffidi and
Misteli, 2011). In contrast, cells expressing adhesion molecules
such as CD44 (Figure 1B) and EpCAM (data not shown) were
not consistently enriched in sphere culture, mostly likely reflect-
ing anchorage-independent culture conditions, and were there-
fore not linked to a CSC phenotype in cultured cells (Figure S1A
available online).
Next, the expression of pluripotency-associated genes
(Nanog, Oct3/4, Stat3, Klf4, and Sox2) was determined by real-
time PCR. Expression of pluripotency-associated genes was
significantly higher in first generation sphere culture (d7) versus
70% confluent monolayer culture (Figure 1C). Intriguingly, the
expression levels observed for pancreatic spheres were compa-
rable to those of human ESCs (data not shown). Expression of
protein levels was validated for Oct4a and Nanog by western
blotting and using a Nanog promoter reporter construct
(Figure 1D).
Components of the Nodal/Activin Signaling Cascade
Are Overexpressed in Primary Pancreatic CSCs
Because theNodal/Activin pathway is reportedly inactive in adult
tissue (Hendrix et al., 2007; Topczewska et al., 2006), we deter-
mined whether this pathway is reactivated in pancreatic cancer
(stem) cells by assessing mRNA expression for its components,
namely Nodal, Cripto-1, FoxH1, Smad2, Smad4, Gdf1, Activin,
and Alk4. Real-time PCR demonstrated that Nodal/Activin
signaling-related genes are significantly overexpressed in first-
passage spheres as compared with those in adherent cells,
although marked differences in mRNA expression between the
various tumorscanbenoted (Figure2A). Interestingly, theexpres-
sion further and strongly increased in second-passage spheres
(Figure 2B). Western blot analysis demonstrated that Nodal is
consistently and strongly overexpressed in spheres as compared
with adherent cells on the protein level (Figure 2C), and that Alk4+
as well as Cripto+ cells are also enriched in sphere culture as
determined by flow cytometry (Figure S1B). In contrast, mRNA
levels for TGF-b1, TGF-b type I receptor/Alk5, and TGF-b type II
receptor did not differ between sphere-derived cells and
adherent cells, while flow cytometry revealed even decreased
numbers of Alk5+ cells in spheres (Figures S1B and S1C).
Most importantly, spheres showed enhanced expression of all
essential components of the Nodal pathway including phosphor-
ylation of Smad2. This allows its association with Smad4 fol-
lowed by subsequent translocation to the nucleus to regulate
target gene expression, suggesting that the Nodal signaling
pathway is operational (Figure 2C). Nodal was hardly detectable
in adherent cells by immunohistochemistry, while sphere-
derived cells displayed strong cytoplasmic and membranous
Nodal protein expression (Figure 2D). Data in established
pancreatic cancer cell lines also showed increased expression
of Nodal and some of its pathway components in sphere-derived
cells, although differences were less pronounced as compared
with primary cells, with no difference for the TGF-b signaling
pathway (Figures S1D and S1E). We next validated our sphere-
based in vitro data using magnetic activated cell sorting
(MACS) of CD133+ cells from freshly digested human pancreatic
tumor xenografts (185, 198, and 354). Flow cytometry showed
good depletion for CD133+ cells in the CD133! population and
revealed enrichment to "75% in the CD133+ population (Fig-
ure 2E). Real-time PCR analysis showed increased expression
of Nodal-signaling-associated genes. Specifically, Nodal,
Cripto-1, Cripto-3, Activin, and Alk4 were overexpressed in
CD133+ cells as compared with CD133! cells (Figure 2F). Impor-
tantly, Nodal expression at the mRNA and protein level was not
detectable in normal pancreatic tissue (Figure 2G), but Nodal
was highly expressed in pancreatic cancer tissue with strong
upregulation during development and progression of primary
pancreatic ductal adenocarcinoma as shown in representative
tissue microarray samples (Figures 2G and 2H). Because Nodal
expression has recently been shown to be reactivated in breast
cancer tissue (Topczewska et al., 2006), we also investigated the
modulation of Nodal and its pathway components in putative
MCF7 breast cancer stem cells (Engelmann et al., 2008). Consis-
tent with the data obtained for pancreatic cancer cells, Nodal, its
cofactor Cripto-1, and several pluripotency-associated markers
were overexpressed in MCF7-derived spheres as compared
with adherent cultures (Figures S1F and S1G). These results indi-
cate that enhanced Nodal expression in the CSC fraction is not
restricted to pancreatic cancer.
Nodal/Activin Signaling Is Functionally Active
in Pancreatic CSCs
Nodal andActivin aresecretedproteins that exert their functionby
binding to and joining the cell surface receptors Alk4 and Alk7 to
form a tertiary ligand-receptor complex that leads to the phos-
phorylation of Smad2 or Smad3 as intracellular effectors and
the subsequent regulation of cell functions. Todeterminewhether
rNodal and rActivin, respectively, are capable of activating this
signaling cascade, we starved human primary sphere-derived
CSCs as illustrated in Figure 3A. Cells were then treated with
recombinant protein in the presence or absence of the Alk4/7
inhibitor SB431542 or LY2157299 (specific inhibitor of Alk5). After
30 min of stimulation, phosphorylation of Smad2 and expression
of Nanog, Oct3/4, Klf4, Sox2, and Stat3 were determined. Puta-
tive cytotoxicity of the utilized inhibitors was excluded by expo-
sure of the cells to the inhibitors for 24 hr followed by DAPI/
Annexin V staining (Figure 3B). rNodal/rActivin strongly induced
phosphorylation of Smad2, while pretreatment with SB431542
partially abrogated Smad2 phosphorylation after stimulation
with rNodal (Figures 3C and 3D). In contrast, TGF-b1 did not
induce phosphorylation of Smad2 in sphere-derived cells; nor
did theAlk5 inhibitor LY2157299 result in a reducedSmad2phos-
phorylation. These results suggest that only Nodal andActivin are
capable of activating the Alk4/7 signaling cascade by Smad2
phosphorylation in pancreatic CSCs.
Nodal and Activin Drive Self-Renewal
of Pancreatic CSCs
To characterize the biological effects of Nodal and Activin on
human pancreatic CSCs, we first examined whether Nodal is
capable of enhancing colony formation and self-renewal
capacity of pancreatic CSCs. In the sphere formation assay,
single cells in suspension were treated with rNodal, rActivin,
rTGF-b1, rLefty (endogenous direct inhibitor of Nodal), the
Alk4/7 inhibitor SB431542, the specific Alk5 inhibitor
LY2157299, and TGF-b receptor II neutralizing antibodies.
After 7 days, treatment with rNodal increased the number of
spheres as compared with control cells (Figure 4A). In contrast,
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stimulation with rActivin did not result in a profound increase in
sphere formation for all tested cells, but in long-term experi-
ments, it did enhance the number of cells with active Nanog
promoters in sphere cultures to the same extent as Nodal (Fig-
ure 4B). The diverse stimulatory effects of rNodal are most likely
related to varying levels of endogenous Nodal expression in
sphere-forming cells, because pretreatment with the Nodal-
specific inhibitor rLefty or the less specific Alk4/7 inhibitor
SB431542 dose-dependently (10, 20, and 40 mM) blocked
sphere formation, whereas this was not the case in untreated
cells (Figure 4A). Consistently, rNodal treatment resulted in the
formation of more and larger colonies as compared with control,
as determined by a soft agar assay (Figure S2). These data
further corroborate the crucial importance of this pathway in
the self-renewal capacity of pancreatic CSCs. In contrast,
neither the Alk5 inhibitor LY2157299 nor TGF-b receptor II
neutralizing antibodies resulted in significant changes in
sphere-forming capacity (Figure 4A), suggesting that TGF-b
signaling is not relevant for the self-renewal capacity of CSCs.
Next, we investigated the role of the TGF-b family members in
the invasive capacity of pancreatic CSCs. A Matrigel-coated,
modified Boyden chamber was used to quantitatively evaluate
cell invasion. As shown in Figure 4C, the percentage of migrated
cells increased significantly after stimulation with rNodal,
rActivin, and TGF-b1. Inhibition of Alk4/7 by SB431542 as well
as inhibition of Alk5 by SB505124 or the more specific
Figure 2. Components of the Nodal/Activin Signaling Pathway Are Overexpressed in Pancreatic CSCs
qPCR analysis of Nodal-signaling-associated genes in adherent cells versus spheres (s) in first (A) and second passage (B). Data are normalized to GAPDH
expression andpresentedas fold change in geneexpression relative to adherent cells. (C)Western blot analysis forNodal, Smad4, pSmad2, andSmad2proteins in
adherent cells versus spheres. Parallel GAPDH immunoblotting was performed and signal quantificationwas performed by densitometry. (D) Confocal images for
EpCAM (green), Nodal (red), and nuclei (blue) of adherent cells and spheres. (E) CD133 MACS of fresh tumor-derived cancer cells. Purity was validated by flow
cytometry usingCD133/2. (F) qPCRanalysis forNodal-signaling-associated genes inCD133+ cells versusCD133!cells. Data are normalized toGAPDH. (G) qPCR
analysis for Nodal and Activin in normal pancreatic tissue from healthy donors (M722 and M723) and pancreatic ductal adenocarcinoma (PDAC). (H) Immuno-
histochemistry for Nodal (brown) in tissue sections from patients with PanIN-I to PanIN-III lesions and three different patients with PDAC. See also Figure S1.
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Figure 3. Nodal Signaling Is Functionally Active in Pancreatic CSCs
(A) Schematic illustration of Smad2 phosphorylation assay: cells were kept in basic sphere medium for 3 hr and stimulated for another 30 min with rNodal or
rActivin alone or in combination with SB431542. After stimulation molecular and histological analyses were performed.
(B) Cell viability was determined by flow cytometry using DAPI/Annexin V.
(C) Western blotting for pSmad2 and Smad2 after stimulation with rNodal or rActivin alone or in combination with SB431542.
(D) Immunocytochemistry for pSmad2 and Nodal in A6L cells after stimulation with rNodal.
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Figure 4. Pharmacological Inhibition of the Nodal/Activin or TGF-b Pathway
(A) Sphere formation capacity of 185 (top panel) and A6L (bottom panel) cells after treatment with the depicted combinations and concentrations of agonists and
antagonists of the Nodal/Activin and TGF-b pathways.
(B) A Nanog reporter construct expressing RFP was used to detect Nanog promoter+ cells (red). Cells were treated with vehicle, rNodal, or rActivin.
(C) Invasion of sphere-derived 185 (top panel) and A6L (bottom panel) cells after treatment as depicted.
See also Figure S2.
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compound LY2157299 completely blocked the enhanced
invasiveness of pretreated CSCs. These data indicate that
pancreatic CSCs are capable of responding to TGF-b1 by
enhanced invasiveness, most likely via Smad2-independent
mechanisms (Zhang, 2009).
Finally, the above findings were validated using specific
genetic targeting of Alk4, Alk5,Nodal, and Smad4 using lentiviral
delivery of specific shRNA (Table S2 available online). Cells were
either selected by FACS for GFP (Alk4, Alk5, Nodal) (Figures
S3A–S3C) or by using puromycin resistance (Smad4) (Fig-
ure S3D). Knockdown of Alk4, which was validated by reduced
surface expression of Alk4 as assessed by flow cytometry (Fig-
ure S3A), resulted in a significant reduction of sphere formation
capacity and, most importantly, drastically reduced in vivo
tumorigenicity (Figure 5A). In those few and diminutive tumors
that actually formed, CD133+ cells were undetectable. In
contrast, knockdown of Alk5, also validated by reduced surface
expression of Alk5 (Figure S3B), neither affected sphere forma-
tion capacity nor resulted in reduced in vivo tumorigenicity (Fig-
ure 5B). Consistently, the content of CD133+ cells was not
changed as compared with that of scrambled control. Impor-
tantly, population doubling of adherent cells was not significantly
altered by either knockdown, indicating that these differences
were not related to changes in proliferation rate (Figures S3A
and S3B). Knockdown of Nodal also resulted in significantly
lower sphere formation capacity (Figure 5C, Figure S3C). The
strong knockdown of Nodal translated into significantly reduced
in vivo tumorigenicity. Finally, knockdown of Smad4, a crucial
component of the canonical Alk4/7 signaling cascade, led to
a significant reduction in sphere formation capacity (Figure 5D,
Figure S3D). Intriguingly, the Smad4 knockdown translated
into reduced in vivo tumorigenicity to a level that was compa-
rable to inhibition of sphere formation and can be rationalized
by downstream inhibition of the Nodal/Activin pathway. Indeed,
while cells with scrambled shRNA strongly responded to
SB431542, cells with knockdown for Smad4 virtually lost
A B
C D
Figure 5. Genetic Targeting of the Nodal/Activin or TGF-b Pathway
(A) Lentivirally transduced cell cultures were sorted by FACS to highest purity based on GFP expression. Comparison of sphere formation capacity (upper
panel), in vivo tumorigenicity (lower panel, left), and CD133 content of harvested tumors (lower panel, right) after lentiviral delivery of scrambled or Alk4 shRNA
is shown.
(B) As in (A), but with Alk5 knockdown.
(C) Lentivirally transduced cell cultures were sorted by FACS to highest purity based on GFP expression. Comparison of sphere formation capacity (upper panel)
and in vivo tumorigenicity (lower panel) after lentiviral delivery of scrambled or Nodal shRNA is shown.
(D) Lentivirally transduced cell cultures were selected using puromycin resistance. Comparison of sphere formation capacity (upper panel, left), response to
SB431542 (upper panel, right), and in vivo tumorigenicity (lower panel) after lentiviral delivery of scrambled or Smad4 shRNA is shown.
See also Figure S3.
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responsiveness to SB431542 with respect to sphere formation
capacity (Figure 5D).
The observation that knockdown of Nodal resulted in a less
pronounced reduction of in vivo tumorigenicity despite virtually
complete knockdown of Nodal and strong inhibition of in vitro
sphere formation suggests alternative sources for Nodal and/or
Activin that may partially overcome the knockdown of Nodal in
pancreatic CSCs in vivo. Indeed, we found robust expression
of Nodal and Activin in human pancreatic stellate cells (PSCs)
as an important stromal component of the pancreas (Jesnowski
et al., 2005; Ohnishi et al., 2003) (Figure S4A). Sphere formation
and invasion of pancreatic CSCs were significantly enhanced by
PSC-conditioned medium, an effect that was abrogated by
pretreatment with the Alk4/7 inhibitor SB431542 (Figures S4B
and S4C). Together with the findings that knockdown of Nodal
did translate into reduced sphere formation in vitro, but only
moderately reduced tumorigenicity in vivo, while knockdown of
Alk4 resulted in strong reduction of both endpoints, we conclude
that in vivo CSCs are most likely stimulated in both an autocrine
and a paracrine fashion by the stromal compartment.
Nodal Inhibition Chemosensitizes Pancreatic CSCs
to Chemotherapy
Pancreatic CSCs are inherently resistant to chemotherapy,
resulting in relative enrichment for CSCs in adherent culture as
evidenced by flow cytometry (Figure 6A) and an increase in
Nodal expression (Figure 6B). Effects were more pronounced
in CSC-enriched sphere cultures (Figure 6C). Intriguingly, using
CD133 expression as readout for CSC content, we observed
a virtually complete elimination of CSCs by inhibiting the
Nodal/Activin pathway (Figure 6D), while population doubling
was not affected (data not shown). This effect was most
consistent in the presence of gemcitabine. These data were
validated in freshly isolated patient-derived pancreatic cancer
cells (Figure 6E).
For the subsequent investigation of in vivo tumorigenicity of
pretreated cells as the most important endpoint, identical
numbers of L3.6pl pancreatic cancer cells were exposed to
gemcitabine alone, SB431542 alone, or both agents. All
surviving cells were orthotopically implanted into the pancreas
of immunocompromised mice. No further in vivo treatment was
administered. Tumorigenicity was determined by noninvasive
PET scan imaging on day 32 and macroscopic and microscopic
evaluation on day 35. Importantly, only combination therapy was
capable of eliminating in vivo tumorigenicity (Figures S5A–S5C).
Mechanistically, we could show that despite a marked decrease
in CD133 content following 4 days of treatment with SB431542
alone, the CD133+ population replenished within 48 hr after with-
drawal of treatment.When cells were treatedwith SB431542 and
gemcitabine, however, the CD133+ population was irreversibly
eliminated (Figure S5D). To further elucidate the mechanism of
this finding, we performed cell cycle analyses using BrdU. Treat-
ment with SB431542 alone did not affect the percentage of
CD133+ cells in S phase, nor did it increase the percentage
of apoptotic CD133+ cells, while the addition of gemcitabine
resulted in a 3-fold increase in apoptotic CD133+ cells and virtu-
ally complete elimination of cells in S phase (Figure S5E). These
findings indicate that SB431542 is capable of reversing the
chemoresistance of the tumorigenic CSC population, most likely
by (reversibly) driving them into amore differentiated state as evi-
denced by temporary loss of CD133.
Nodal/Activin Inhibition in Established Pancreatic
Cancers
Based on these promising findings, we then investigatedwhether
inhibition of Nodal/Activin by SB431542 translates into increased
progression-free survival in pre-established pancreatic cancers.
Because only the combination pretreatment with gemcitabine re-
sulted in loss of tumorigenicity in vivo, we focused on this treat-
ment regimen.Xenograftswereestablishedbyorthotopic implan-
tation of L3.6pl cells into athymicmice and treatment was started
1 week after injection. The detailed experimental setup is de-
picted inFigure 7A.Harvestingof some tumorsafter the last round
of SB431542 administration revealed efficient in vivo targeting of
the Nodal/Activin pathway with subsequent downregulation of
Nodal (Figures S6A–S6D). Tumor growth was assessed on day
42 by palpation and confirmed by magnetic resonance imaging
(MRI) (Figure 7B). No tumors were detectable in mice receiving
combination therapy, so the study was continued until day 100
to monitor progression/putative relapse of disease. Over time,
control animals bore large, life-limiting tumors and succumbed
within 40 days after tumor implantation (median survival time:
32 days). Gemcitabine alone significantly prolonged survival
due to inhibition of tumor growth, but all animals showedprogres-
sive disease with median survival still severely limited with
54 days. For the combination of SB431542 and gemcitabine,
long-term survival was significantly better compared with gemci-
tabine alone, with 100% survival at day 100 (Figure 7C).
Next, we investigated the effects of SB431542 in primary
human pancreatic cancer tissue xenografts as the ultimate
preclinical setting (see study design in Figure 7D). In contrast to
the above findings for implantation of cancer cells, the addition
of SB431542 to gemcitabine treatment did not result in a deceler-
ation of growth of primary tumor tissue (Figure 7E). During long-
term follow-up, it was only when gemcitabine was already with-
drawn that tumor growth eventually started to slow down, as
compared with tumors treated with gemcitabine alone, while the
latter actually reaccelerated ingrowth. Thisdifference in response
to gemcitabine withdrawal resulted in a modest, but significantly
reduced, tumor burden at the 100 day follow-up point.
Based on this rather disappointing outcome and stimulated by
data from Olive et al. (2009), we hypothesized that this modest
treatment effect could be attributed to poor drug delivery in
stroma-rich primary pancreatic cancer tissue. Indeed, mass
spectrometry analysis revealed that SB431542 was hardly
detectable in tumor-bearing mice after 2 weeks of treatment
(Figure S6E). Intriguingly, the addition of the Smoothened inhib-
itor CUR199691 (CUR) for targeting the hedgehog pathway in
stromal cells drastically improved drug delivery by 10-fold.
Therefore, we next tested a triple combination therapy (gemcita-
bine, SB431542, and CUR), which translated into immediate
inhibition of tumor progression and eventually translated into
long-term stable disease at 100-day follow-up (Figures 7E and
7F and Figure S7A). Histological evaluation of the tumors ex-
planted by the end of the study confirmed a marked depletion
of tumor stroma in the triple therapy group, as well as a higher
grade of differentiation, although the later changes were of
a more subtle nature (Figure 7F). Cells isolated from harvested
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tumors treated only with gemcitabine demonstrated strong
sphere-forming capacity as opposed to cells isolated from
tumors treated with gemcitabine plus SB431542, which already
showed a significant reduction in sphere-forming capacity (Fig-
ure 7G, left panel). Most intriguingly, however, cells derived
from tumors treated with triple therapy had virtually lost their
sphere-forming capacity. Consistent patterns were observed
for phenotyping of the cells using flow cytometry. CD133+ or
CD133+/CD44+ cells were significantly reduced in the group
receiving triple combination therapy (Figure 7G, right panel).
Consistently, administration of triple therapy to another tumor
(JH051) resulted in similar treatment response. Taken together,
these data demonstrate that triple therapy is capable of elimi-
nating tumor-promoting pancreatic CSCs in vivo, leading to
long-term progression-free survival.
DISCUSSION
Patients with pancreatic ductal adenocarcinoma are still
suffering from a devastating prognosis, which can be at least
partially rationalized by the observation that the standard
chemotherapeutic agent gemcitabine is not capable of elimi-
nating CSCs. Indeed, gemcitabine rather leads to a relative
increase in the number of CSCs, indicating a preferential target-
ing of more differentiated and rapidly proliferating cancer cells.
The restricted elimination of the more differentiated cancer cells,
even if associated with significant tumor size reduction, will
not lead to the eradication of the tumorigenic potential of the
tumor, as that is restricted to the CSC population. Here we
demonstrate that the Nodal/Activin pathway is essential for the
self-renewal capacity and stemness properties of pancreatic
CSCs. Nodal/Activin is strongly expressed in pancreatic CSCs,
but is also expressed by PSCs, which are abundantly present
in the stroma surrounding pancreatic cancer cells andmay serve
as a CSC niche.
In a large set of primary cells and (fresh) primary patient
tissues, we then showed that the CSC compartment is severely
affected by inhibition of this pathway by making use of three
different approaches: first, by using a small molecule inhibitor
(SB431542) targeting the Nodal/Activin receptor Alk4; second,
A
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C
Figure 6. Nodal Inhibition Targets CD133+ CSCs
(A) Flow cytometry for CD44 and CD133 in A6L and 185 adherent cells untreated or treated with gemcitabine (GEM). qPCR analysis forNodal,Nanog, andOct3/4
genes in A6L and 185 adherent cells (B) or spheres (C) untreated or treatedwith GEM is shown. Data are normalized for GAPDH expression. (D) Flow cytometry for
CD133 expression in L3.6pl cells untreated or treated as indicated (left panel). Quantification of CD133 expression in respective groups, with n = 3 (right panel), is
shown; data are mean ± SEM, nR 3. (E) Flow cytometry for CD133 in freshly isolated primary human pancreatic cancer cells treated with GEM in the presence or
absence of SB431542. See also Figure S4.
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by using recombinant Lefty as the specific endogenous Nodal
inhibitor; and third, by genetic knockdown of Nodal, Alk4, and
Smad4 using shRNA technology. Our findings are in line with
earlier observations that have identified other developmental
pathways such asmTOR, hedgehog, Notch, and BMP for target-
ing CSCs (Bar et al., 2007; Li et al., 2007; Mueller et al., 2009;
A B
C
D
E
F
G
Figure 7. In Vivo Effects of Nodal/Activin Inhibition on Established Pancreatic Cancers
(A) Experimental setup for in vivo experiments using L3.6pl cells.
(B) Tumor take-rate (upper left panel), tumor size (lower panel), and representative MRI pictures (right panel) of treated pancreatic cancers.
(C) Kaplan-Meier analysis depicting cumulative survival of respective treatment groups; data are mean ± SEM, nR 3.
(D) Experimental setup for in vivo experiments using primary human pancreatic cancer tissue.
(E) Tumor growth is depicted for the respective treatment groups. Data are mean ± SEM, nR 3.
(F) Histological evaluation on day 100 using cytokeratin 19 staining for gemcitabine alone (GEM) and triple-treated tumors as indicated.
(G) On day 100, tumors from the different groups were digested and analyzed for their respective sphere formation capacity (left panel) and cell surface marker
expression (right panel); data are mean ± SEM, nR 3.
See also Figures S5–S7.
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Piccirillo and Vescovi, 2006), although their targeting may be of
limited clinical use for at least some of them due to normal
stem-cell-related side effects. Intriguingly, an important feature
of the herein described Nodal/Activin pathway is its complete
lack of activity in normal pancreas and other adult tissue (Top-
czewska et al., 2006), spurring the hope for little to no side effects
because normal stem cells will most likely be spared.
Nodal and Activin are involved in developmental biology by
perpetuating the undifferentiated state of ESCs (Vallier et al.,
2005; Xiao et al., 2006). While the expression of Activin and
the Nodal coreceptor Cripto-1 have previously been demon-
strated in pancreatic cancers (Friess et al., 1994; Kleeff et al.,
1998), we here provide evidence that Nodal, the second ligand
of the Alk4/7 receptor, is expressed in this malignancy, but not
in normal pancreas. Most importantly, Nodal is capable of
strongly propagating the tumorigenic CSC subpopulation as
demonstrated by its pharmacological inhibition using the extra-
cellular Nodal antagonist Lefty and shRNA technology, whereas
Activin was less drastically enriched in pancreatic CSCs and
showed limited effects on their self-renewal capacity in some
tumors. These data are in line with previous reports showing
that Nodal is crucial for tumorigenicity in melanoma and breast
cancer cells, with an embryonic microenvironment reducing
tumorigenic activity and inducing the expression of epithelial
markers by the secretion of Lefty (Postovit et al., 2008; Top-
czewska et al., 2006).
On the other hand, Activin reportedly contributes to an invasive
phenotype in esophageal carcinoma, another epithelial malig-
nancy (Yoshinaga et al., 2004, 2008). In a previous report on the
dynamic regulation of the invasive phenotype of breast cancer
cell lines, the interconversion from noninvasive epithelial-like
CD44+CD24+ cells to invasive mesenchymal CD44+CD24!
progeny was also found to be Nodal/Activin dependent (Meyer
et al., 2009). Consistently, we now provide evidence that Activin
alsopromotes invasionof pancreaticCSCsasdoesNodal. These
data have important implications because they indicate that ther-
apeutic strategies should not focus on either Nodal or Activin, but
rather focus on Alk4/7 as their common receptor. Indeed,
a comprehensive set of experiments proves that targeting this
pathwaybyblocking theAlk4/7 receptor using the smallmolecule
inhibitor SB431542 and shRNA technology has a strong impact
on both theCD133+ fraction that is enriched for CSCs and sphere
formation capacity.
Next, we identified human PSCs as an important component
of the stroma that also strongly expresses Nodal/Activin. Condi-
tioned medium from PSCs promoted self-renewal and invasive-
ness of pancreatic CSCs. PSCs, which reside in exocrine areas
of the pancreas, are myofibroblast-like cells known to be acti-
vated upon insult. These cells are analogous to hepatic stellate
cells, with which they share 99% identity at the transcriptome
level (Omary et al., 2007). PSCs are important mediators in the
pancreatic response to injury because they migrate to the
damaged location and promote cell proliferation, migration,
and assembly (Shimizu, 2008). Therefore, because our data
suggest that PSCs may represent an in vivo niche for CSCs,
targeting these interactions could be of pivotal importance for
the development of more effective therapies for pancreatic
cancer. While targeting Alk4/7 as the common receptor for
Nodal/Activin should abrogate autocrine and paracrine
signaling, directly eliminating this paracrine source for Nodal/Ac-
tivin may provide additional therapeutic benefits. Intriguingly,
this can be achieved by targeting the hedgehog pathway as
a crucial signaling component for PSCs (Bailey et al., 2008;
Shinozaki et al., 2008), and may account, at least in part, for
the striking therapeutic effects generated by the addition of a
smoothened inhibitor to our armamentarium for treating primary
pancreatic cancer tissue in our studies.
However, translating our findings into the in vivo setting was
not only challenged by alternative sources for Nodal/Activin,
but also by the fact that the Nodal/Activin small molecule inhib-
itor SB431542 as a single therapy was not sufficient to irrevers-
ibly eliminate the cells’ ability to form tumors in vivo. This lack of
in vivo translation of the apparently encouraging in vitro effects
could be explained by the enhanced plasticity of pancreatic
cancer cells. Indeed, after withdrawal of SB431542 and
continued culture of the cells, a drastic rebound of the CD133+
population was also observed in vitro, which retrospectively
rationalizes the still-preserved in vivo tumorigenicity of the cells.
However, the rebound of CD133+ CSCs upon withdrawal was
prevented by addition of gemcitabine to the treatment regimen.
Further mechanistic studies revealed that SB431542 alone
(reversibly) drives CSCs into a more differentiated state, as
evidenced by loss of CD133, but cells still retain the ability to
revert to the CSC phenotype. Intriguingly, although gemcitabine
alone led to a relative enrichment of CSCs, the combination of
SB431542 and gemcitabine resulted in their irreversible and
complete elimination. Indeed, in vitro combination therapy
resulted in complete abrogation of the in vivo tumorigenic poten-
tial of the remaining cells.
This chemosensitizing effect of SB431542 should be of great
therapeutic value for patients with pancreatic cancer and was
therefore further evaluated in vivo. However, testing this treat-
ment regimen in mouse models of pancreatic cancer came
with another caveat. Our first in vivo experiments in established
pancreatic cancer, which were based on the orthotopic implan-
tation of isolated pancreatic cancer cells, confirmed the in vitro
data by illustrating robust therapeutic efficacy and 100%survival
at 100 day follow-up for SB431542 plus gemcitabine. Surpris-
ingly, however, when we thenmoved to a preclinical model using
xenografted primary human pancreatic cancer tissue, tumor
development remained virtually unaffected by this combination.
It is important to note that xenografted pancreatic cancer tissues
contain large amounts of stroma whereas implantation of cancer
cells regularly lacks this important feature. Tumor-associated
stroma does not only provide an additional source for Nodal/Ac-
tivin as described above, but is also capable ofmodulating tumor
vascularization, which could interfere with drug delivery to
cancer (stem) cells. Indeed, impaired drug delivery has already
been demonstrated for pancreatic cancer in a recent landmark
study using a genetically engineered mouse model (Olive et al.,
2009).
Therefore, breaching the ‘‘stroma fortress’’ of pancreatic
cancer represents an important challenge for drug delivery in
general (Neesse et al., 2010) and CSC-targeted therapies in
particular because these cells have been proposed to preferably
reside in hypoxic niches (Borovski et al., 2011; Heddleston et al.,
2009). Intriguingly, when we coadministered the hedgehog
pathway inhibitor CUR199691 (Mueller et al., 2009) to deplete
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the stromal compartment together with SB431542, we observed
a 10-fold increase in drug delivery into the tumor tissue. The
addition of gemcitabine then translated into rapid disease stabi-
lization, and none of the mice required sacrificing during the
100 day study period. Failure to completely eradicate the re-
maining small tumors can be rationalized by the lack of response
of nonproliferating tumor cells to gemcitabine. Most importantly,
however, these small lesions no longer contain CSCs; cells iso-
lated from these remnant tumors did not form spheres anymore.
In contrast, all mice treated with gemcitabine alone had to be
sacrificed within 100 days due to excessive tumor growth. Cells
isolated from these tumors bear strong sphere forming capacity.
Therefore, our data demonstrate the successful combination of
stroma- and CSC-targeting strategies for effectively treating
pancreatic cancer in most relevant preclinical models.
Canonical downstream signaling of Alk4/7 is mediated by
Smad2/3 as well as the Co-Smad Smad4, which is shared by
all TGF-b family members. Importantly, about 50% of patients
with pancreatic cancer bear inactivating mutations or deletions
of the Smad4 gene, which could result in dysfunction of the
pathway (Schneider and Schmid, 2003). While noncanonical
TGF-b family signaling pathways have been described and may
account for the enhanced TGF-b1-induced invasiveness of
pancreatic CSCs (Zhang, 2009), we found that Smad4 knock-
down in previously Smad4-competent cells resulted in reduced
in vivo tumorigenicity, most likely via inhibition of Nodal/Activin
signaling, because these cells no longer responded to the Alk4/7
inhibitor SB431542. Therefore, becauseSmad4seems indispens-
able for the Nodal/Activin signaling cascade, tumors carrying
functionally relevant Smad4 mutations or deletions may not
respond to a Nodal/Activin-targeting therapy. Importantly,
however, not all Smad4mutations actually result in dysfunctional
Smad4; we have identified several tumors bearing Smad4muta-
tions that still demonstrate a functional Smad2/3 cascade,
including asubsequent translocationof pSmad2 into thenucleus,
and that respond to this triple therapy. Future studies will have to
address the question of which patients will most likely respond to
this treatment modality and how best to identify them.
EXPERIMENTAL PROCEDURES
Primary Human Pancreatic Cancer Cells
Human pancreatic tumors were obtained with written informed consent from
all patients. For in vitro studies, tissue fragments were minced, enzymatically
digested with collagenase (Stem Cell Technologies, Vancouver, BC) for
60 min at 37!C (Mueller et al., 2009), and, after centrifugation for 5 min at
1200 rpm, resuspended as pellets and cultured in RPMI, 10% FBS, and 50
units/ml penicillin/streptomycin.
Pancreatic cancer spheres were generated and expanded in DMEM:F12
(Invitrogen, Karlsruhe, Germany) supplemented with B-27 (GIBCO, Karlsruhe,
Germany) and bFGF (PeproTech EC, London, UK). Ten thousand cells per milli-
liter were seeded in ultra-low attachment plates (Corning B.V., Schiphol-Rijk,
Netherlands) as described previously (Gallmeier et al., 2011). After 7 days of
incubation, sphereswere typically>75mmlargewith"97%CD133high. For serial
passaging, 7-day-old spheres were harvested using 40 mmcell strainers, disso-
ciated to single cells with trypsin, and then regrown for 7 days. Cultures were
kept no longer than 4 weeks after recovery from frozen stocks (passage 3–4).
Human Pancreatic Cancer Cell Lines
The human pancreatic cancer cell lines L3.6pl, Panc1, and MiaPaCa2 were
maintained as previously described (Hermann et al., 2007).
In Vivo Treatment of Established Pancreatic Cancers
Single-cell suspensions were either orthotopically implanted into the pancreas
of female nude mice (Harlan Europe), or 2 mm3 pieces of primary, in vivo
expanded pancreatic cancer tissue were subcutaneously implanted and
mice were randomized to the respective treatment groups. Size and weight
of the pancreatic tumors were monitored. Gemcitabine was administered
twice a week (125 mg/kg i.p.). SB431542 was used at 25 mg/kg, and
CUR199691, at 100 mg/kg, both by oral gavages twice daily for 3 weeks.
Cytometry
To identify pancreatic CSCs, the following antibodies were used: anti-CD133/
1-APC or PE (Miltenyi, Bergisch-Gladbach, Germany); anti-CXCR4-APC, anti-
SSEA-4-FITC, SSEA-1-APC, EpCAM-FITC, and CD44-PE (all from Beckton
Dickinson, Heidelberg, Germany); and anti-Alk4, anti-Alk5, and anti-Cripto-
1-PE (all fromCell Signaling Technology, Inc.); or appropriate isotype-matched
control antibodies. CD133/2-APC (Miltenyi) was used for purity testing after
MACS. Propidium iodide, 7-AAD, or DAPI was used for exclusion of dead cells
(eBiosciences, San Diego, CA). Samples were analyzed by flow cytometry
using a FACS Canto II (BD) and data were analyzed with FlowJo 9.2 software
(Ashland, OR).
Immunofluorescence
Primary pancreatic cancer cells and spheres were seeded in 96-well dishes
(Corning, NY) and incubated at 37!C for 3 hr. Cells were washed with cold
PBS and then fixed with prechilled 4% PFA for 20 min at room temperature.
After blocking with 1% bovine serum albumin in PBS-Triton 0.1%, cells
were incubated with primary antibodies: Nodal (ab556676; Abcam, Inc.),
pSmad2 (3108; Cell Signaling), and EpCAM (BD) overnight at 4!C in the
dark. Then cells were washed three timeswith PBS-Triton 0.1%and incubated
with Alexa-Fluor-conjugated secondary antibodies against mouse or rabbit
(Invitrogen) at room temperature for 1 hr in the dark. Cells were mounted in
Vectashield containing DAPI (Vector Laboratories, Burlingame, CA) and
analyzed using an SP5 confocal microscope (Leica, Heidelberg, Germany).
Western Blot Analysis
PVDF membranes containing electrophoretically separated proteins from
human primary pancreatic cancer cells and spheres were probed with mouse
antibodies against Oct4a (2890), Smad2 (3103; both Cell Signaling Tech-
nology), Nanog (ab21624), Nodal (ab556676), GAPDH (ab8245-100; all Ab-
cam), Smad4 (sc-7966; Santa Cruz Biotech), or rabbit antibody against
pSmad2 (3108; Cell Signaling), treated with peroxidase-conjugated goat
anti-mouse or anti-rabbit Ig secondary antibody (Sigma), and then visualized
by enhanced chemiluminescence (Amersham).
Smad2 Phosphorylation Assay
Human primary sphere-derived single cells were grown for 3 hr in DMEM:F12
(GIBCO) without bFGF and B27. Following starvation, cells were incubated for
30min at 37!Cwith recombinant human rNodal, Activin, or TGFb1 (R&D) either
alone or in the presence of SB431542 (Sigma) or LY2157299 (AxonMedChem,
Groningen, Netherlands. Anti-Smad2 and anti-phospho-Smad2 (Ser465/467,
Cell Signaling) antibodies were used following themanufacturer’s instructions.
RNA Preparation and Real-Time PCR
Total RNAs from human primary pancreatic cancer cells and spheres were ex-
tracted with TRIzol kit (Life Technologies Inc.) according to the manufacturer’s
instructions. One microgram of total RNA was used for cDNA synthesis with
SuperScript II reverse transcriptase (Life Technologies Inc.) and random
hexamers. Quantitative real-time PCR was performed using SYBR Green
PCR master mix (QIAGEN), according to the manufacturer’s instructions.
The list of utilized primers is depicted in Table S1.
Invasion and Migration Assays
Invasion assays were performed using modified Boyden chambers filled with
Matrigel (BioCoat, BD Biosciences, Heidelberg, Germany). Cells were pre-
treated with SB431542, SB505124, LY2157299, TGF-b receptor II neutralizing
antibodies, or recombinant human Lefty for 1 hr. Five hundred microliters of
cell suspensions containing 53 104 pretreated or untreated cells were added
to the Matrigel-coated inserts, and seven hundred and fifty microliters of
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serum-free medium with or without recombinant human Nodal, recombinant
human Activin, or recombinant human TGF-b1 were added to the lower
chamber. The assay chambers were incubated for 22 hr at 37!C. Invaded cells
were fixed in 4% PFA and stained with DAPI. The ratio of cells in the lower
chamber versus total seeded cells was calculated.
Lentiviral shRNA Delivery
As lentiviral shuttle backbone we used a pLVX shRNA2 plasmid (Clontech).
shRNA constructs were generated by hybridization in solution of HPLC-puri-
fied paired oligonucleotides with the recessed restriction sites (BamHI and
EcoRI) added to the sequence for cloning purposes. As control we used
pLVX-shRNA expression vectors encoding a scrambled shRNA sequence
with no target (in silico prediction). The shRNA sequences were selected
from the RNAi Consortium website (www.broadinstitute.org/rnai/public). The
inserts of shRNA were annealed from sense and antisense oligonucleotides
with the sequences as provided in Table S2. Lentivirus production and titration
were carried out as previously described (Torres et al., 2011) and regularly con-
tained 13 107 T.U./ml with a 1:100 T.U./physical particles ratio as quantitated
by qPCR. Cells were then transduced with lentiviral stocks diluted to an M.O.I.
of 50 in the presence of polybrene (8 mg/ml, Sigma). A6L and 185 cells were
seeded at a density of 5 3 104 cells per 24 multiwell plate and allowed to
adhere overnight. The next day, cells were infected with the lentivirus for
6 hr. Stably transduced cells were obtained after cell sorting for GFP included
in the viral vector (for Alk4, Alk5, Nodal) or using puromycin resistance
(Smad4). For the transduction with the Nanog promoter reporter, we used
a human Nanog-RFP construct with a zeomycin resistance marker for System
Biosciences (SBI; Mountain View, CA).
MRI
Mice were analyzed with a 3-Tesla MRI system (Magnetom Tim Trio, Siemens,
Erlangen, Germany) using a dedicated small animal coil and T2-weighted
scanning.
Statistical Analyses
Results for continuous variables are presented as means ± standard deviation
(SD) unless stated otherwise. Treatment groups were compared with the inde-
pendent samples t test. Pair-wise multiple comparisons were performed with
the one-way ANOVA (two-sided) with Bonferroni adjustment. p < 0.05 was
considered statistically significant. All analyses were performed using SPSS
17.0 (SPSS Inc., Chicago, Illinois).
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Pancreatic cancers contain exclusively tumourigenic cancer stem cells (CSCs), 
which are highly resistant to chemotherapy, resulting in a relative increase in CSC 
numbers during treatment with gemcitabine as standard chemotherapeutic agent. In this 
project we have further consolidated our previous findings that CD133+ pancreatic 
cancer stem cells are highly resistant to chemotherapy, and show that CSCs have an 
increased hedgehog and mammalian Target of Rapamycin (mTOR) pathway activity. 
The separate use of inhibitors of these (stem cell) pathways resulted only in a slight 
reduction of the CD133+ cell fraction. However, the combined use of a hedgehog 
pathway inhibitor (SIBI-C1) and an mTOR inhibitor (Rapamycin) together with the 
cytotoxic agent Gemcitabine (= SIBI+R+Gem) resulted in a virtually complete elimination 
of CSCs in primary human pancreatic cancers.  
Therefore we embarked on further studies evaluating this new therapeutic 
regimen in a clinically most relevant model using mice with pre-established xenografted 
human pancreatic tumours. The resulting triple treatment indeed led to a successful 
depletion of the cancer stem cell pool, and additionally also markedly changed the 
cellular composition of the tumours, depleting the supportive stroma. Overall, this 
resulted in long-term survival of the mice while control animals treated with 
chemotherapy alone died within a few weeks. Since we have previously also performed 
a large-scale pre-clinical safety study, we now firmly establish this (= SIBI+R+Gem) triple 
therapy as a novel therapeutic option for the treatment of advanced pancreatic 
adenocarcinoma.  
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of the manuscript, with input from the rest of the authors and under the supervision of 
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Abstract
Purpose: In spite of intense research efforts, pancreatic ductal adenocarcinoma remains one of the most deadly
malignancies in the world. We and others have previously identified a subpopulation of pancreatic cancer stem cells within
the tumor as a critical therapeutic target and additionally shown that the tumor stroma represents not only a restrictive
barrier for successful drug delivery, but also serves as a paracrine niche for cancer stem cells. Therefore, we embarked on a
large-scale investigation on the effects of combining chemotherapy, hedgehog pathway inhibition, and mTOR inhibition in
a preclinical mouse model of pancreatic cancer.
Experimental Design: Prospective and randomized testing in a set of almost 200 subcutaneous and orthotopic implanted
whole-tissue primary human tumor xenografts.
Results: The combined targeting of highly chemoresistant cancer stem cells as well as their more differentiated progenies,
together with abrogation of the tumor microenvironment by targeting the stroma and enhancing tissue penetration of the
chemotherapeutic agent translated into significantly prolonged survival in preclinical models of human pancreatic cancer.
Most pronounced therapeutic effects were observed in gemcitabine-resistant patient-derived tumors. Intriguingly, the
proposed triple therapy approach could be further enhanced by using a PEGylated formulation of gemcitabine, which
significantly increased its bioavailability and tissue penetration, resulting in a further improved overall outcome.
Conclusions: This multimodal therapeutic strategy should be further explored in the clinical setting as its success may
eventually improve the poor prognosis of patients with pancreatic ductal adenocarcinoma.
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Introduction
Pancreatic ductal adenocarcinoma (hereafter referred to as
‘‘pancreatic cancer’’ or PDAC) is the fourth most frequent cause of
cancer-related death world-wide [1,2,3] and is characterized by a
high rate of metastasis and pronounced resistance to chemother-
apy and radiation. Despite extensive research efforts over the past
decades, little substantial progress has been made towards
improving clinical endpoints [4]. Although the introduction of
the anti-metabolite gemcitabine in 2007 has improved clinical
response by reducing pain and weight loss [5], disease prognosis
has remained extremely poor with a 5 year survival rate of,3–4%
and a median survival period of 4–6 months [1,6]. Indeed, several
studies have consistently shown that gemcitabine treatment mostly
targets differentiated cancer cells resulting in a relative enrichment
of cancer stem cells [7,8,9]. For patients with metastatic disease,
but good performance status, the recent combination therapy
FOLFIRINOX (oxaliplatin, irinotecan, fluorouracil, and leucov-
orin) showed a significant survival advantage but with increased
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toxic side-effects [10]. Alternatively, the regimen of nab-paclitaxel
plus gemcitabine showed substantial anti-tumor activity with more
tolerable adverse effects in a phase I/II trial, warranting phase III
evaluation [11]. However, in all these trials the majority of the
patients ultimately succumbed from disease progression. Thus, the
development of new anti-cancer therapeutics and/or new treat-
ment modalities remains a high healthcare priority.
With increasing evidence supporting the existence of cancer
stem cells, a new horizon is emerging in the development of
therapeutic strategies against pancreatic cancer. Cancer stem cells
represent a subpopulation of cells distinguishable from the bulk of
the tumor based on their exclusive ability to drive tumorigenesis
and metastasis. These cells also play a crucial and driving role in
disease relapse [12,13,14,15,16]; therefore, the elucidation of the
mechanisms underlying pancreatic tumorigenesis and especially
pancreatic cancer stem cells is of crucial relevance for the
development of more efficient clinically-available therapies.
Indeed, we have recently developed novel approaches that both
target cancer stem cells and overcome their mechanisms of chemo-
resistance [9,17,18]. For example, we have shown that the self-
renewal capacity of pancreatic cancer stem cells is dependent on
both Hedgehog and mTOR signaling, and simultaneous targeting of
these two pathways, in combination with Gemcitabine, represents
a novel treatment strategy for epithelial cancers such as pancreatic
cancer [9]. Building on these studies, we here investigate the
applicability, safety, and potential for further optimization of this
combination therapy approach in a large set of primary patient-
derived tumors.
Results
Triple Therapy Markedly Reduces Tumor Size and
Increases Survival
We have shown previously that sphere cultures of pancreatic
cancer cells enrich for cancer stem cells [8,9,17], and that
combined targeting of the Sonic Hedgehog (SHH) and mTOR
pathways may offer a new therapeutic option. Here we verify in
four distinct primary pancreatic cancer cell lines derived from
patient tumors that cancer stem cell-enriched sphere cultures
indeed show marked overexpression of SHH and the Hedgehog
target genes GLI-1 and GLI-2 (Fig. 1A), as well as increased
mTOR pathway activity (Fig. 1B). The subsequent in vivo
evaluation of the combination therapy was performed in clinically
most relevant models of patient-derived pancreatic cancer whole-
tissue xenografts (see Fig. 1C for study design). Pieces of briefly
in vivo expanded primary human pancreatic tumors containing
heterogeneous populations of cancer cells including cancer stem
cells [9] as well as stromal cells [7], pancreatic stellate cells,
inflammatory cells, and extracellular matrix were implanted
subcutaneously and orthotopically into immunocompromised
mice. Tumor take rate was confirmed by tumor growth during
two successive size measurements, and tumor-bearing mice were
randomized for treatment. Subsequently, the tumors were
measured once weekly either by caliper (subcutaneous tumors)
or with a small-animal ultrasound imaging system (orthotopic
tumors). As Gemcitabine (Gem) represents the current standard
treatment for pancreatic cancer, we used Gem-treated mice as the
reference group.
A set of representative tumors was selected based on their
diverse response to Gem treatment [7]. PDAC-265 and 185 were
highly resistant to Gem treatment, showing rapid tumor growth so
that the first mice had to be removed from the study within 3
weeks of the start of the treatment (Fig. 2A–E) due to excessive
tumor growth. In contrast, in tumors PDAC-JH051, 247, and
Pax22, Gem treatment resulted in initial treatment response and
disease stabilization; however, after the removal of chemotherapy,
the tumors reproducibly started to re-grow (Fig. 2C–E). Of all the
tumors investigated, only PDAC-354, which does not carry Kras
mutations [19], showed significant response to Gem treatment
until the end of the observation period (Fig. 2F) and closely
mimicked the treatment response observed in the actual patient
(data not shown).
Importantly, we were able to improve treatment response by
combining chemotherapy with the novel hedgehog pathway
inhibitor SIBI-C1 (SIBI; Siena Biotech) [20]. SIBI strongly inhibits
gene expression of SHH and downstream target genes such as
GLI2 in primary pancreatic cancer cells in vitro (Fig. S1A in File
S1). SIBI was administered for only 3 weeks to reduce potentially
deleterious effects. Gem was given for a total time period of 60
days in accordance with common clinical practice (Fig. 1C). Due
to the strong response to chemotherapy alone, co-treatment of
mice bearing PDAC-354 xenografts with either SIBI did not show
an additional effect at the level of tumor size (Fig. 2F) or survival
(data not shown). For all of the other tumors, however, double
treatment with Gem+SIBI led to a marked reduction in tumor size
(dashed line, Fig. 1 & 2), significant delay in tumor growth, and
thus significantly prolonged survival compared to mice receiving
either no treatment or Gem+Vehicle (Fig. 2G). Importantly,
however, tumors eventually relapsed limiting survival in mice
receiving this double therapy. These data are in line with
improved delivery of gemcitabine following depletion of protective
stromal tissue [21]. As previously shown, inhibition of hedgehog
signaling alone does not completely abrogate the cancer stem cell
population (Fig. 3A & B) [9].
Since we have shown in comprehensive in vitro studies that
cancer stem cells can indeed be eliminated by the addition of an
inhibitor of the mTOR pathways [9], we next investigated the
effect of a treatment regimen comprising Gem, SIBI, and
established mTOR inhibitor rapamycin (Rapa) on our represen-
tative panel of primary pancreatic cancer tissue xenografts.
Interestingly, we observed a very strong response to this triple
therapy, resulting in disease stabilization or even regression in
almost all tumors investigated (dotted line, Fig. 1 & 2). This
translated into a significantly improved cumulative survival as
compared to all other treatment groups (Fig. 2E).
Combination Therapy Depletes Cancer Stem Cell Content
and Alters Tumor Composition
In order to evaluate the in vivo effects of combination therapy on
cancer stem cell populations, we explanted and digested repre-
sentative tumors of each group after completion of the 3 weeks of
triple therapy, and analyzed by flow cytometry the expression of
surface markers previously linked to a cancer stem cell phenotype
[8,9,13]. The percentage of EpCAM+CD133+CD44+ cells in
Gem-treated tumors was regularly 2-3-fold higher as compared to
untreated tumors [data not shown and [8]]. In contrast,
Gem+SIBI already showed a slight decrease in cancer stem cell
numbers as compared to Gem alone (Fig. 3A & B). Importantly,
only the addition of Rapa to the treatment regimen virtually
eliminated cancer stem cells from the tumor. Furthermore, upon
termination of the study period (day 200) we investigated
secondary sphere formation as a functional assay for cancer stem
cell activity in PDAC-Pax22 tumors and observed that sphere
formation capacity was slightly diminished for cultures derived
from tumors treated with Gem+SIBI as compared to Gem alone.
Interestingly, however, it was only after triple treatment that we
could observe complete abrogation of sphere formation activity
Targeting Pancreatic Cancer Stem Cells
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(Fig. 3C), suggesting that triple combination therapy had
effectively depleted the cancer stem cell pool in the tumor.
More detailed histological investigation of the tumors showed
that the different treatment regimens also modified the cellular
composition of the tumor. While the primary tumor-derived
Figure 1. Targeting of sonic hedgehog and mTOR in pancreatic ductal adenocarcinoma. (A) Fold increase mRNA expression levels of SHH,
GLI-1, and GLI-2 of sphere-derived vs. adherent cells. (B) Western blot analysis of mTOR pathway activity via the assessment of S6 kinase expression
(upper panel) and phosphorylation (lower panel) in adherent primary cells versus stem cell-enriched sphere-derived cells. (C) Illustration of
experimental setup. Duration of triple therapy is marked by a dark grey box (day 21 to 48), Gem monotherapy with a light grey box (day 48 to 81).
doi:10.1371/journal.pone.0066371.g001
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xenografts used for this study displayed a reasonably high amount
of stroma (35–70%) in the groups treated with Gem only (Fig. 4A,
left panels), the addition of a hedgehog pathway inhibitor
markedly decreased the stroma content (Fig. 4A, middle
panels), an observation that is well in line with previous
published reports [21]. This effect was slightly more pronounced
after the addition of Rapa (Fig. 4A, right panels), and was
statistically significant as compared to tumors treated with Gem
alone (Fig. 4B). As expected, we observed the same effects after
treatment of Gem-sensitive tumors (Fig. S1B in File S1).
Interestingly, we observed similar effects in orthotopic tumors
(Fig. 4A) as in subcutaneous tumors (Fig. S1B in File S1).
Figure 2. Combination therapy in a representative set of pancreatic ductal adenocarcinoma. (A–F) Tumor growth curves for primary
whole-tissue xenografts PDAC-265, PDAC-185, JH051, 247, Pax22, and 354 implanted subcutaneously and orthotopically. Continuous line depicts
Gem+vehicle, dashed line depicts Gem+SIBI, dotted line depicts Gem+SIBI+Rapa (n$6 per group). (G) Kaplan-Meier Curve depicting cumulative
survival time of all mice pooled by treatment group.
doi:10.1371/journal.pone.0066371.g002
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Figure 3. Effect of combination therapy on cancer stem cell content. (A) Representative flow cytometry plots and (B) quantification of cancer
stem cell (EpCAM+CD133+CD44+) content of tumors in the respective treatment group (cumulative results of cells obtained from different
xenografts). (C) Representative images and quantification of secondary sphere formation of treated PDAC-Pax22 tumors explanted at the end of the
experiment (d200).
doi:10.1371/journal.pone.0066371.g003
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PEGylation of Gemcitabine further Enhances the Effects
of Combination Therapy
Since previous reports have shown that modifying the chemical
structure of Gem by PEGylation leads to significantly increased
circulation time and tissue penetration in vivo and may therefore be
a novel option for the improved treatment of patients with
(pancreatic) cancer [22,23], we decided as a next step to determine
the effects of PolyEthyleneGlycol-bound Gem (PEG-Gem) as the
extended in vivo circulation time and higher tissue penetration of
PEG-Gem may generate superior effects as compared to standard
Gem. First, we evaluated the in vitro effects of PEG-Gem as
compared to Gem on freshly isolated primary human pancreatic
cancer cells. For this purpose, four matching primary cell cultures
generated from in vivo-expanded pancreatic cancer tissues were
treated for 48 hours with either standard Gem or PEG-Gem and
were subsequently analyzed by flow cytometry for the induction of
apoptosis or cell death, as well as for their cancer stem cell content.
Regarding the percentage of apoptotic and dead cells, no
differences could be observed between treatment groups (Fig. 5A
left panel, and data not shown). In addition, we did not
observe differences between standard Gem and PEG-Gem
treatment regarding the content of CD133+ cells in vitro (Fig. 5A
right panel).
Next we treated mice bearing orthotopic or subcutaneous
primary tumor-derived whole-tissue xenografts with PEG-Gem,
analogous to the treatment regimen for standard Gem. We
selected tumors that showed insufficient response with Gem. While
we did not observe a significant difference for median survival
between PEG-Gem and standard Gem for these tumors (Fig. 5B),
it is important to note that the onset of tumor-related death in
mice treated with PEG-Gem was far later than with standard Gem
(Time until progression: PEG-Gem 91d vs. Gem 19d). Encour-
Figure 4. Effect of combination therapy on tumor composition. (A) Representative histological pictures showing stroma content in the
respective treatment groups in gemcitabine resistant orthotopic tumors (PDAC-185, upper panel), (Pax22, lower panel). (B) Quantification of
stroma content throughout the different treated xenografts.
doi:10.1371/journal.pone.0066371.g004
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aged by these promising results, we next replaced standard Gem
treatment with PEG-Gem in the triple therapy approach (PEG-
Gem+SIBI+Rapa) and evaluated the effects on tumor growth and
survival in mice bearing PDAC-185 patient-derived xenografts.
While in our initial in vivo studies Gem+SIBI+Rapa treatment led
to significantly reduced tumor growth and short-term sustained
disease as compared to standard Gem treatment (Fig. 2D), many
tumors eventually relapsed. In response to treatment with PEG-
Gem+SIBI+Rapa, however, we observed virtually complete
regression of the tumors (Fig. 5C), which resulted in 100%
survival until the end of the observation period (day 125) (Fig. 5D).
Combination Therapy Shows no Significant Toxicity
Potential toxicity remains a major concern for combination
therapy approaches. To assess cumulative toxicity of the admin-
istered treatments and their respective combinations, we recorded
body weight for all treated mice on a weekly basis, starting on the
day of randomization until day 100. Excluding cachexia as a
potential treatment-induced side effect, no significant differences
in body weights were observed between the treatment groups
(Fig. 6A), Furthermore, in order to exclude potentially deleterious
effects on the function of normal stem cells (e.g. in the
hematopoietic system), we additionally monitored white blood
cell numbers in the treated mice at the completion of the 3 weeks
of single versus combined therapies. While at this point of the
study the expected cumulative toxicity would be the highest, no
significant reduction in white blood cell counts was observed in
any of the treatment groups as compared to standard Gem
treatment (p = 0.792) (Fig. 6B), suggesting no extensive alterations
of hematopoietic stem cells by the triple combination treatment.
Interestingly, even the increased circulation time and improved
tissue penetration of PEG-Gem did not significantly increase
expected adverse side effects as compared to standard Gem
treatment (Fig. 6A & B).
Discussion
Here we validate the concept of a multimodal therapy for
comprehensively targeting the diverse cell compartments in
pancreatic cancer using a representative set of almost 200
subcutaneous and orthotopic whole-tissue primary tumor xeno-
grafts, making this one of the largest investigations in the cancer
stem cell field. Tumors were selected based on their previously
described diverse response to gemcitabine treatment [7]. Chemo-
therapy and radiation primarily target differentiated cancer cells,
and while these therapies induce apoptosis and cell death in tumor
cells, a population of cancer stem cells is highly resistant
[8,9,18,24], survives the standard therapy, and maintains the
ability to re-populate a tumor in all its heterogeneity. Double
treatment combining Gem and the new Smoothened inhibitor
SIBI consistently prolonged survival in mice transplanted with
tumors. Importantly, however, only in mice treated with triple
therapy cancer stem cells were virtually completely abrogated, and
we observed a long-term disease stabilization or regression, and
subsequent long-term survival. In this combination regimen, the
treatment effect of conventional Gem could be further enhanced
by the use of PEGylated Gem via enhancing its bioavailability.
At the histological level, pancreatic cancer is characterized by
very dense stroma and poor vascularization. Olive et al. showed in
a genetically engineered mouse model of pancreatic cancer that
the stroma is strongly dependent on hedgehog signaling, and
inhibition of the hedgehog pathway with smoothened inhibitors
leads to ‘‘preferential’’ killing of stromal cells and increased vessel
density [21], thus making tumor cells more accessible to
therapeutic intervention. While these observations were obtained
in a mouse model of pancreatic cancer, we have more recently
shown that also in patient-derived whole-tissue xenografts co-
treatment with a smoothened inhibitor significantly increases drug
delivery [17] and markedly reduces tumor-associated stroma
formation. Importantly, we now appreciate that the stroma not
only hampers drug delivery [21], but also provides a supportive
niche for cancer stem cells promoting their self-renewal capacity
and invasiveness [25]. Thus, elimination or abrogation of the
stroma does significantly improve treatment regimens by distinct
mechanism, but is only capable of eliminating cancer stem cells if
combined with Gem.
However, despite the rather modest response of cancer stem
cells to hedgehog pathway inhibition as a single agent, we were
able to demonstrate that smoothened inhibitors are still essential in
order to successfully eliminate chemoresistant pancreatic cancer
stem cells if combined with other stem cell-targeting agents [9,17].
Specifically, we have previously shown for pancreatic cancer that a
combination of chemotherapy and inhibitors of both mTOR and
hedgehog signaling eliminates differentiated cells as well as cancer
stem cells in vitro [9], and that this translates into long-term
survival in vivo. Recently, Wang et al. provided an important
mechanistic link for the combined inhibition of the hedgehog and
mTOR pathway. Specifically, the authors demonstrate that
mTOR/S6K1 signaling results in phosphorylation of Gli and
subsequent expression of downstream targets. Inhibition of both
pathways greatly enhanced the pro-apoptosis effect of inhibition of
either inhibition alone [26]. In the present study, we now saw a
virtually complete elimination of cancer stem cells for this
combination therapy in a large and representative set of primary
xenografts. Whereas flow cytometry using the surface markers
CD133, EpCAM, and CD44 already suggested that the cancer
stem cell content was strongly reduced, functional assays (e.g.
sphere formation assay) validated that the cells isolated from the
explanted tumors indeed were unable to form tumor spheres
in vitro, strongly suggesting that the cancer stem cell population as
the root of the disease, had been effectively targeted by the triple
combination.
Even though the results using Gem-SIBI-Rapa were highly
consistent and encouraging across a panel of patient-derived
tumors, we did observe tumor re-growth in some mice (e.g.
PDAC-185 xenografts) and, subsequently, a decrease in the
survival of these xenograft-bearing animals. As this might be
related to the limited bioavailability of the chemotherapeutic agent
as an essential part of this combination therapy, we further
advanced our treatment strategy by modifying the chemotherapy.
Specifically, Vandana et al. have recently shown that modifying
gemcitabine via PEGylation leads to enhanced bioavailability in
the circulation as compared to native gemcitabine. Although they
Figure 5. Comparison of the in vitro and in vivo effects of Pegylated Gemcitabine. (A) In vitro effects of Gem and PEG-Gem on apoptosis
and cell death as well as CD133 expression (cumulative results of cells obtained from different xenografts). (B) Kaplan-Meier Curve depicting
cumulative survival time of all mice pooled by treatment group. For illustrative purposes, selected survival curves of Fig. 2D are depicted again. (C)
Tumor growth curves for primary whole-tissue xenografts implanted subcutaneously and orthotopically, respectively. Continuous line depicts
Gem+vehicle, dashed line depicts Gem+ SIBI, dotted line depicts Gem+SIBI+Rapa. (D) Kaplan-Meier Curve depicting cumulative survival time of all
mice pooled by treatment group. For illustrative purposes, selected survival curves of Fig. 2D are depicted again.
doi:10.1371/journal.pone.0066371.g005
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have also shown better in vitro response of established pancreatic
cancer cells using PEGylated gemcitabine as compared to the
regular formulation [22], we observed no significant differences
between Gem and PEG-Gem in vitro at the level of cancer stem cell
content or induction of apoptosis or cell death using xenograft-
derived primary cells. While these data are not surprising as drug
delivery and availability is not a critical issue in vitro, the results
clearly emphasize the importance of utilizing primary cancer tissue
for further in vivo evaluation of drug efficacy.
Indeed, we were then able to validate and extend this concept to
the in vivo setting by showing that PEG-Gem treatment signifi-
cantly delayed the time of tumor progression by 72 days. This
enhanced treatment response is certainly impressive as it
represents more than half of the study period. As expected,
however, tumors ultimately progressed resulting in virtually no
difference in median survival of the PEG-Gem treated mice
compared to mice treated with traditional Gem alone. While these
data confirm that PEGylation of Gem does indeed improve drug
availability and delivery, respectively, by enhancing the circulation
time and tissue penetration, as expected, PEG-Gem alone is
clearly not sufficient to overcome the chemoresistance of cancer
stem cells. Therefore, we next investigated the effects of replacing
regular Gem with PEG-Gem in our multimodal approach for
targeting pancreatic tumors, which had originally responded to
Gem+SIBI+Rapa treatment, but eventually relapsed under this
specific treatment regimen. Intriguingly, using the PEG-Gem+SI-
BI+Rapa combination we not only observed virtually complete
tumor regression, but most importantly we obtained 100%
survival throughout the 125d study period in this highly therapy-
resistant tumor. While this observation does not exclude later re-
growth as seen in PDAC-Pax22, these data are very promising and
are consistent with the notion that further improving the
formulation of the combined drugs is mandatory for extending
in vitro findings to the much more complex in vivo setting.
The utilized new smoothened inhibitor SIBI-C1 (Siena Biotech,
Italy) was also highly effective in vivo, as can be seen by reduced
tumor growth in combination with Gem and thus significantly
enhanced survival time. Furthermore, SIBI can be safely
administered in vivo, as we saw no adverse effects on total body
weight or white blood cell counts. Importantly, this is well in line
with previous observations using other smoothened inhibitors
[9,15]. The Gem+SIBI+Rapa combination therapy also showed
no significant toxicity compared to Gem treatment alone during
the course of the experiments. PEG-Gem+SIBI+Rapa combina-
tion treatment, while much more effective in vivo, only slightly, but
non-significantly decreased white blood cell counts and had no
effect on the body weight of the animals as compared to respective
controls. It is important to note, however, that the healthy and
relatively young mice used for this study are likely more capable of
compensating for putative adverse effects on the normal stem cell
Figure 6. Assessment of in vivo biocompatibility/safety. (A) Body weights were recorded for all mice throughout the first 100 days of the
experiment. (B) White blood cell counts of all mice were assessed at the end of the administration period of the triple combination.
doi:10.1371/journal.pone.0066371.g006
Targeting Pancreatic Cancer Stem Cells
PLOS ONE | www.plosone.org 9 June 2013 | Volume 8 | Issue 6 | e66371
compartments during triple therapy treatment. Therefore, it will
be important to further validate the safety of this treatment
regimen in human patients in order to ultimately apply it to the
mostly aged and moribund patients suffering from pancreatic
cancer.
In conclusion, here we provide compelling evidence for the
efficacy of a multimodal therapy targeting differentiated cells as
well as cancer stem cells in pancreatic cancer, resulting in long-
term survival in mice. Thus, these data confirm and expand
previous findings from our laboratory in a very large cohort of
animals with patient-derived pancreatic cancer xenografts
[9,15,17]. In addition, we also offer a new and novel perspective
on how to further improve current therapeutic approaches by
modifying the molecular structure of the mandatory chemother-
apeutic agents using PEGylation. Taken together, these findings
should significantly impact the future development of new anti-
pancreatic cancer therapeutics and/or treatment modalities.
Materials and Methods
Tumor Samples
After patients’ informed consent had been obtained, excess
tissues from resected pancreatic carcinomas was xenografted at
Johns Hopkins Medical Institutions (JHMIRB: 05-04-14-02 ‘‘A
Feasibility Study for Individualized Treatment of Patients with
Advanced Pancreatic Cancer’’) and Hospital de Madrid - Centro
Integral Oncolo´gico Clara Campal (FHM.06.10 "Establishment of
bank for tumors and healthy tissue in patients with cancer’’),
respectively, under the indicated Institutional Review Board-
approved protocols [7]. Briefly, excess tumor tissues not needed for
clinical diagnosis during routine Whipple resections performed by
surgeons that were not involved in the present study were
subsequently implanted into immunocompromised mice. All
patient information was made anonymous by removal of any
information, which identifies, or could lead to the identification of
the patient. None of the patients had undergone neoadjuvant
radiation or chemotherapy prior to resection of the tumor.
Animal Experiments
All animal experiments were conducted in accordance with
institutional guidelines and were approved by the Institutional
Animal Care and Use Committee of the CNIO (Protocol PA34/
2012– ‘‘Xenotransplant model for human pancreatic cancer’’).
Animals were housed and maintained in laminar flow cabinets
under specific pathogen-free conditions. Briefly, 8 mm3 pieces of
primary, in vivo expanded pancreatic cancer tissue pieces were
either orthotopically or subcutaneously implanted into the
pancreas of 6–8 weeks old female nude mice (Harlan Europe) as
described previously [7,9,27]. For each treatment group, $10
tumors were implanted. Tumor size and body weights of all
animals were measured weekly. Size of the subcutaneous tumors
was measured by caliper and calculated as length6width6depth.
Orthotopic tumors were measured with a dedicated small-animal
ultrasound system (Vevo770, Visualsonics, Toronto, Canada), and
size was calculated as (length6width2)/2. Survival was defined as
the time point when tumors reached 1 cm3 and mice had to be
removed from the study. White blood cell counts were performed
with an Abacus Junior Vet hematology analyzer (Diatron, Lenexa,
Kansas).
Allocated Treatments
Gemcitabine was purchased from Lilly (Indianapolis, Indianap-
olis), dissolved in sterile water and administered twice a week
(125 mg/kg i.p.) for 60 days. Rapa (5 mg/kg; Wyeth, Philadel-
phia, Pennsylvania) was orally administered via the drinking water
as described previously [28]. SIBI and Rapa were administered for
21 days. SIBI-C1 (SEN826) was kindly provided by Siena Biotech
S.p.A. (Siena, Italy). The characteristics of the compound are
similar to that of SEN794 and SEN450, some chemical properties
were ameliorated in each of the compounds. SEN450 has
previously been used and characterized extensively in in vitro and
in vivo tumor models of glioblastoma [20]. SIBI-C1 was dissolved
in a 1:1 mixture of NaCl and polyethyleneglycol (Sigma Aldrich,
St. Louis, Minnesota), and administered at 300 mg/kg by daily
oral gavage. At this dose, SIBI-C1 was found to strongly inhibit the
expression of the Hedgehog target genes GLI-1 and PTCH,
comparable to the inhibitory effects of GDC-0449, in a
subcutaneous medulloblastoma model derived from Patch+/2
mice (unpublished data Siena Biotech). For in vitro experiments,
SIBI-C1 was dissolved in DMSO and used at a concentration of
10 mM.
PEGylated gemcitabine was synthesized by Sahoo and col-
leagues as described previously and with modifications [22], and
was administered analogous to regular gemcitabine. The PEGy-
lated gemcitabine was synthesized by conjugating gemcitabine to
HOOC-PEG-COOH in dimethylsulfoxide (DMSO), in the
presence of triethylamine (TEA). Briefly, HOOC-PEG-COOH
(0.1 mM) was dissolved in 2.5 ml of DMSO to which TEA
(0.05 ml) was added. Further, NHS (100 mM) and EDC
(400 mM) were added to the above solution and the reaction
mixture was stirred for 30 min. Later, the synthesized PEG-
(NHS)2 was coupled to gemcitabine. In brief, the gemcitabine
(0.4 mM) was dissolved in 500 ml and added drop wise to the
PEG-(NHS)2 solution in the presence of 2 mM TEA (PEG-NHS/
Gemcitabine/TEA molar ratio = 1:4:20). The reaction mixture
was then kept on constant magnetic stirring overnight at room
temperature. The reaction mixture was later subjected to dialysis
using a dialysis membrane (MWCO: molecular weight cut-
off = 3.5 kDa) against distilled water to remove free and unreacted
gemcitabine. Subsequently, the dialyzed solution was freeze-dried
using a lyophilizer (Labconco, Kansas City, Montana) at a
temperature of 248uC and 0.05 mbar to obtain the powdered
form of the conjugate. The characterization of the PEGylated
gemcitabine was performed as described previously [22].
RNA Preparation and RT-PCR
Total RNAs from human primary pancreatic cancer cells and
spheres were extracted with TRIzol kit (Life Technologies Inc.)
according to the manufacturer’s instructions. One microgram of
total RNA was used for cDNA synthesis with SuperScript II
reverse transcriptase (Life Technologies Inc.) and random
hexamers. Quantitative real-time PCR was performed using
SYBR Green PCR master mix (Qiagen), according to the
manufacturer’s instructions. The list of utilized primers is depicted
in Table S1 in File S2.
Western Blot Analysis
Total protein extracts were obtained using M-PER Mammalian
Protein Extraction Reagent (Thermo Scientific) supplemented
with phosphatase and protease inhibitors. Pellets were incubated
during 1 h in lysis buffer at 4uC, and centrifuged at 13,000 rpm
during 10 min at 4uC. Total protein concentration was measured
with BCA Protein Assay kit (Pierce) and 25–100 mg protein were
separated by SDS/PAGE and transferred to PVDF membranes.
Upon antibody incubation, membranes were visualized by
enhanced chemoluminescence (Amersham). GAPDH was used
as a loading control. A complete list of used antibodies is included
in Table S2 in File S2.
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Flow Cytometry
To characterize pancreatic cancer stem cells, the following
antibodies were used: anti-CD133/1-APC (clone AC133 Miltenyi
Biotech, Bergisch Gladbach, Germany), anti-CD44-PE anti-
EpCAM FITC (both Becton Dickinson, Heidelberg, Germany)
or appropriate isotype-matched control antibodies. Samples were
analyzed by flow cytometry, using a FACSCanto II (BD), and data
were analyzed with FloJo 9.4.4 (Treestar, Ashland, Oregon).
Apoptosis and cell death analyses were performed using DAPI and
an Annexin V fluorescein isothiocyanate (FITC) staining kit (BD).
Histology
Formalin-fixed, paraffin-embedded tumor sections were stained
with a CK19 antibody (1:500, Dako, Carpinteria, CA), and then
visualized with a rabbit anti-mouse and anti-rabbit HRP-
conjugated antibody (both Epitomics). Nuclear counterstaining
was performed using Hematoxylin. The stroma quantification was
performed by two independent investigators, one an experienced
pathologist (E.G.).
Cell Culture
For in vitro studies, tumors were enzymatically digested with
collagenase and pancreatic cancer adherent cell and sphere
cultures were generated and expanded as previously described
[17,18]. Five thousand cells per milliliter were seeded in ultra-low
attachment plates (Corning B.V., Schiphol-Rijk, Netherlands) and
monitored for sphere formation capacity over the course of 14
days. Spheres were defined as 3-dimensional multicellular
structures of approximately 40 mm or larger. For in vitro
treatment, 105 cells per well were seeded in 6-well plates, treated
with either standard gemcitabine or PEG-Gem at a concentration
of 100 ng/mL after 24 h, and analyzed on day 3 by flow
cytometry to detect apoptosis and cancer stem cell content.
Statistical Analysis
Results for continuous variables are expressed as means 6
standard error of the mean (SEM) unless stated otherwise. Overall
comparison of continuous variables was performed with the
Kruskal-Wallis test followed by post hoc pairwise comparison
using the Mann-Whitney U test. Survival was compared using a
Log Rank test. P values ,0.05 were considered statistically
significant. All analyses were performed with SPSS 19 (SPSS Inc.,
Chicago, IL).
Supporting Information
File S1 Figure S1A: Effect of SIBI-C1 on Hedgehog
pathway gene expression. Fold increase mRNA expression
levels of SHH and GLI2 in gemcitabine resistant primary cancer
cells (PDAC-265 left panel, PDAC-354 right panel). Figure S1B:
Effect of combination therapy on tumor composition.
Representative histological pictures showing stroma content in the
respective treatment groups in gemcitabine resistant subcutane-
ously implanted tumors (PDAC-185, upper panel), (354, lower
panel).
(TIF)
File S2 Table S1: Utilized qRT-PCR primers. Table S2:
Utilized antibodies.
(TIF)
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According to the cancer progression model postulated by Fearon and Vogelstein 
in 1990, at least 4-5 genetic events are required for the progression from normal 
epithelium to carcinoma in colorectal cancer (Fearon and Vogelstein, 1990), and a 
similar number of key genetic alterations seem to be necessary for the development of 
pancreatic adenocarcinoma. However, it is currently unclear, in which cell these genetic 
alterations accumulate, leading to the cell’s malignant transformation. Intensive efforts 
are being undertaken to identify this “cell-of-origin” using various genetically engineered 
mouse models encoding the key genetic alterations under different cell-specific 
promoters for pancreatic (Guerra et al., 2007, Hingorani et al., 2005, Kopp et al., 2012) 
and colorectal cancers (Fearon, 2011, Fearon and Vogelstein, 1990). Even though their 
precise origin remains yet to be elucidated, the existence of CSC or tumour-initiating 
cells has now been conclusively proven in most epithelial tumours, and more and more 
evidence is arising that these CSC are indeed clinically relevant due to their pronounced 
resistance to standard therapies (Hermann et al., 2007, Gallmeier et al., 2011, Mueller et 
al., 2009, Todaro et al., 2007, Bao et al., 2006). The resistance of cancer stem cells to 
standard treatment in combination with their capability to recapitulate a tumour in all its 
cellular heterogeneity (one of the defining features of cancer stem cells) provides a 
reasonable explanation for the clinical observation that tumours will relapse after initially 
successful treatment (Figure 5a). Thus, targeting cancer stem cells in addition to 
differentiated tumour cells will be of paramount importance in order to successfully treat 
patients with cancer. Applying this idea clinically would mean specifically targeting CSCs, 
while at the same time maintaining established therapeutic protocols of standard therapy 
such as chemotherapy or radiation (Figure 5b). 
Different approaches are conceivable to successfully target CSCs: either making 
them accessible to standard treatment (e.g. driving normally quiescent CSCs into a 
proliferative state, thus making them more susceptible for chemotherapy), or killing these 
cells directly by interfering with key signaling pathways. Here we provide evidence for 
both approaches, showing three new therapeutic options to treat pancreatic and 
colorectal cancer stem cells. 
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Figure 5: Combination therapy to eliminate cancer stem cells as well as differentiated tumour 
cells. CSCs (red) and their metastatic subclones (green) escape conventional therapy and re-
capitulate tumors and/or metastases, unless anti-CSC therapies are used simultaneously. From: 
(Sergeant et al., 2009)  
 
In the course of this thesis and the projects included therein, we have validated 
the concept of a multimodal therapy for comprehensively targeting the diverse cell 
compartments in pancreatic and colorectal cancer using a large set of more than 200 
subcutaneous and orthotopic whole-tissue primary tumour xenografts, making this one 
of the largest investigations in the cancer stem cell field.  
 
Colorectal Cancer Stem Cells and Inhibition of ATR  !
We demonstrate here that inhibition of ATR function depletes the tumourigenic 
CD133+ fraction of established colon cancer cell lines as well as xenograft-derived 
!! 89!
primary colon cancer cells. This effect translated into a markedly reduced 
tumourigenicity of the remaining cells, as shown by an impaired sphere formation 
capacity in vitro (Ricci-Vitiani et al., 2007, Todaro et al., 2007) as well as a strongly 
reduced capability to form tumours in vivo. Consistent with previous reports describing 
amplified checkpoint activation and increased DNA repair to be distinct features of some 
CSC (Bao et al., 2006, Eyler and Rich, 2008), CD133+ cells displayed a stronger 
activation of the ATR- dependent DDR on treatment with interstrand-crosslinking (ICL) -
agents than did CD133- cells, as evidenced by a more pronounced increase in 
phosphorylation of ATR’s major effector kinase CHK1. Importantly, the depletion of 
CD133+ cells was enhanced on subsequent treatment with ICL-agents, suggesting that 
inhibition of ATR might reverse the chemoresistance of CSC toward ICL-agents in the 
clinical setting and could thus serve as a novel therapeutic strategy for patients suffering 
from colon cancer. 
As the PIK kinases ATM, ATR, MTOR, and DNA-PK all play pivotal roles in cell 
cycle checkpoint functions and all except DNA-PK are effectively inhibited by caffeine 
(Sarkaria et al., 1999), caffeine was used as a screening approach to modulate check- 
point function in colon cancer cells. Caffeine treatment virtually abolished the CD133+ 
cell fraction and was accompanied by a decreased in vitro and in vivo tumourigenicity of 
the remaining cell population, providing functional evidence for a successful targeting of 
the tumour-initiating CSC fraction. Depletion of CD133+ cells was observable as early as 
5 days after caffeine administration and further enhanced after longer exposure, 
indicating that prolonged treatment was required for the complete exhaustion of the 
CD133+ subpopulation, first through the elimination of the rapid cycling cell fraction and 
consecutively through activation of a slow cycling or even quiescent fraction. 
Consistently, caffeine increased the proliferating fraction of CD133+ cells in our 
experiments. 
A panel of small molecule inhibitors was applied to dissect the contributions of 
the different PIK kinases on the caffeine-induced preferential depletion of CD133+ cells. 
As no specific ATR-inhibitors are currently available, several potent, but in comparison 
with the highly specific ATM inhibitors, less-specific inhibitors of CHK1 as the major 
effector kinase of ATR were used as surrogates for ATR inhibition. In contrast to the 
ATM inhibitor KU-55399 and the MTOR inhibitor RAD001, only CHK1 inhibitors 
mimicked the effects of caffeine. As CHK1 activity itself is only marginally suppressed by 
caffeine (Sarkaria et al., 1999), whereas the upstream PIK kinase ATR is potently 
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inhibited, these data suggested that the caffeine- induced depletion of CD133+ cells was 
mediated through direct inhibition of ATR followed by indirect inhibition of its main 
effector kinase CHK1. Importantly, caffeine exerted its detrimental effects on CD133+ 
cells already after short-term treatment, whereas the effects of CHK1 inhibitors were 
observable only after long-term treatment. To exclude different pharmacokinetic 
properties of the used agents as the underlying reason for the observed differences, our 
findings were corroborated by a set of siRNA experiments. Consistently, knockdown of 
CHK1 protein expression over 264 hours did not lead to comparable detrimental effects 
on the CD133+ cell population as did ATR protein depletion. Furthermore, we analyzed 
an isogenic FA knockout model (Gallmeier et al., 2006, Gallmeier and Kern, 2007), as 
ATR had been linked to the FA DNA-repair pathway (Andreassen et al., 2004), but found 
no evidence for an impact of FA pathway abrogation on the depletion of CD133+ colon 
cancer cells. Together, these data suggest that besides CHK1 as the major effector 
kinase of ATR, other ATR-dependent, but FA-independent pathways are operative in 
this setting. 
The complete disruption of the ATR gene is a lethal event in human somatic cells 
(Cortez et al., 2001) and no applicable cellular model presently exists to investigate the 
null state of the ATR gene. However, the hypomorphic ATR-inactivating splicing 
mutation 2101AG, naturally found in Seckel syndrome patients (O'Driscoll et al., 2003), 
causes subtotal depletion of ATR protein without gross effects on cancer cell growth or 
viability (Hurley et al., 2007, Gallmeier and Kern, 2007). Therefore, cancer cells 
homozygously harboring this mutation (ATRs/s cells) were used as a highly specific tool 
to model ATR inhibition in tumours. ATRs/s cells were virtually depleted of CD133+ cells 
as compared with parental ATR+/+ cells. Consistently, ATRs/s cells were impaired in 
sphere formation capacity and unable to form tumours in vivo. ATRs/s cells did not show 
significant differences in proliferation rates as compared with their ATR+/+ counterparts, 
excluding that their loss of tumourigenicity was attributable to a hypothetical cell cycle 
arrest. It should be noted that a limitation of our genetic ATR model is that confounding 
artifacts due to clonal variability cannot definitively be excluded (Gallmeier and Kern, 
2007). Therefore, our data require cautious interpretation, especially when considering 
the CD133 expression status of the originally derived ATRs/s cell clones. As can be 
derived from our initial experiments, tumourigenicity was mainly restricted to the CD133+ 
cell fraction of DLD1 colon cancer cells, which constituted only about 5% of the 
unselected DLD1 cell population. Thus, the engineered ATRs/s cells were more likely 
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originally derived from a CD133- cell clone, which according to our data, would be 
expected not to be capable of regenerating tumourigenic CD133+ cells, at least in our 
short- term experimental setting (14 days). On the other hand, it remains a controversial 
issue whether non-CSC or a subpopulation of them might be able to regenerate CSC in 
the long run, or correspondingly, whether CD133- ATR+/+ cells might at some point 
regenerate CD133+ cells (Chen et al., 2010). Taken together, our data demonstrate that 
ATR-deficient CD133- cancer cells retain a non-tumourigenic phenotype for at least 
several months during cell culture. 
To exclude potential artifacts due to clonal variability, we employed a third model 
of ATR function, using RNA-interference through repetitive application of ATR siRNA, 
which facilitated the continuous depletion of ATR protein in unselected colon cancer cell 
populations. Similar to the results obtained in the genetic model, we observed a time-
dependent decrease of the CD133+ cell fraction in ATR siRNA-treated cells along with a 
concomitant reduction of the in vivo tumourigenicity of the remaining cell population, 
strongly indicative of a successful targeting of the tumour-initiating stem cell fraction. In 
contrast to ATRs/s or caffeine-treated cells, however, ATR siRNA-treated cells did not 
exhibit a complete abrogation of in vivo tumour formation in all animals. This could most 
likely be ascribed to an inevitable methodological shortcoming of experiments applying 
siRNA technology, that is, the incomplete targeting on the cellular level, generally 
leaving a remaining sub- population of not efficiently siRNA-transfectable cells (including 
CD133+ cells), unaffected. Accordingly, traceable amounts of ATR protein were still 
detectable in the ATR siRNA-treated cell population after 384 hours of repetitive siRNA-
application. As a consequence, the decreased, but maybe not absent, tumourigenic cell 
fraction on ATR siRNA treatment would be expected to lead to a significantly decreased, 
but not absent, tumour take rate, as observed in our experiments. Interestingly, in those 
rare instances, in which tumours were generated by ATR siRNA-treated cell populations, 
these tumours were clearly diminutive as compared with those observed in control mice. 
This could be explained by the decreased fraction of tumourigenic CD133+ cells in the 
ATR siRNA-treated population, as a smaller fraction of tumour-initiating cells could 
perceivably also account for a decreased tumour size in those rare instances of 
successful tumour formation. Indeed, a very rare occurrence of CD133+ cells was 
observable in tumours that originated from ATR siRNA-treated cells. Another 
explanation, consistent with the observed sparse proliferation activity of the diminutive 
tumours in vivo, would be that these tumours did not arise from the successfully 
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eliminated tumour-initiating cell fraction but rather from an untargeted subset of short-
lived transient amplifying cells, which only divide a finite number of times until they 
become terminally differentiated and finally undergo senescence (Barker et al., 2009). 
A preferential activation of the DDR, comprising both amplified checkpoint 
activation and increased DNA-repair, has previously been proposed as a likely 
mechanism of CSC drug- resistance (Bao et al., 2006, Eyler and Rich, 2008) and could 
also explain the increased sensitivity of CD133+ colon cancer cells toward ATR 
inhibition; ATR is a central regulator of the replication checkpoint, which blocks cell cycle 
progression on detection of endogenous or exogenously induced SRF. In this process, 
ATR stabilizes SRF via its main effector kinase CHK1 and prevents the inappropriate 
processing of DNA (Paulsen and Cimprich, 2007). Accordingly, cells harboring a 
complete disruption of the ATR gene display increased chromo- some breaks even in 
the absence of exogenous replication stress, most likely induced through SRF occurring 
during nor- mal cellular proliferation, and are not viable over extended periods of time 
(Cortez et al., 2001). The significantly stronger up-regulation of CHK1 phosphorylation in 
the CD133+ as compared with the CD133- cell fraction on treatment with SRF-inducing 
ICL- agents in our experiments thus supports a preferential activation of the ATR-
dependent DDR also in colon CSC. 
Consistently, treatment with SRF-inducing ICL-agents accelerated the depletion 
of CD133+ cells on ATR inhibition, further supporting that the detrimental effects of 
caffeine specifically on CD133+ cells were attributable to the particularly reduced 
capability of these cells to repair, endogenously or exogenously inflicted, SRF when ATR 
function was impaired. It is tempting to speculate that the impaired DNA repair capability 
of CD133+ cells in response to ATR inhibition could be ascribed structurally to 
differences in chromatin compaction between CD133+ and CD133- cells. Overall, 
chromatin accessibility, a dynamic process largely mediated by chromatin compaction, 
represents an innate property of stem cells, which is lost during differentiation (Meshorer 
et al., 2006). The degree of chromatin compaction, on the other hand, determines at 
least in part the extent of DNA damage, the feasibility of DNA repair (Cohn and D'Andrea, 
2008), and the strength of the DDR (Murga et al., 2007) and could thus explain a 
particularly strong dependence of CSC on an intact DDR. 
On confrontation with DNA damage, the DDR mediates whether cells undergo a 
replication arrest to allow DNA repair, bypass the DNA damage and continue to replicate 
DNA, or eventually, undergo apoptosis (Harper and Elledge, 2007). We found that after 
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caffeine treatment, apoptotic cell death did not occur immediately in CD133+ cells, but 
progressively increased with cumulative BrdU incorporation, excluding cytotoxicity as the 
sole source of the caffeine-induced effects. Notably, a small fraction of AnnexinV+ 
CD133+ cells was detectable up to 168 hours after treatment initiation, likely 
representing the CSC fraction progressively recruited to enter an active cell cycle. 
Consistently, after an initial caffeine-induced increase of CD133+ AnnexinV+ cells, their 
amount subsequently declined, paralleling the decline of total CD133+ cell numbers. 
Thus, the caffeine-induced depletion of CD133+ cells was at least in part attributable to 
proliferation-dependent induction of apoptosis. As apoptosis was triggered by caspase 8 
and reinforced by a mitochondrial amplification loop involving the recruitment of caspase 
9, sensitization to extrinsic receptor-mediated apoptosis might provide another tool for 
the specific depletion of the CSC fraction in colon cancer. 
Using three independent model systems, that is, pharmacological ATR inhibition, 
genetic inactivation of the ATR gene, and RNA interference-mediated ATR protein 
depletion, we found that inhibition of ATR function depleted the tumourigenic CD133+ 
cell fraction of established human colon cancer cell lines as well as xenograft-derived 
primary colon cancer cells. This effect was attributable at least in part to apoptosis, 
accelerated on co-treatment with common chemotherapeutics that generate SRF, and 
accompanied by a drastically decreased in vitro and in vivo tumourigenicity of the 
remaining cells. Mechanistically, the preferential depletion of tumourigenic CD133+ cells 
was attributable to the preferential activation of the ATR-dependent DDR in these cells. 
Our study thus illustrates a novel approach to selectively eliminate the tumourigenic cell 
population in colon cancer. As the caffeine blood levels required for inhibiting ATR 
function cannot be achieved in vivo due to the narrow therapeutic window and the 
pronounced cardiovascular side effects of caffeine and its derivatives, our study provides 
a strong rationale for the pharmaceutical development of specific ATR inhibitors as a 
potentially powerful approach to eliminate CSC in colorectal cancer (Nghiem et al., 2001, 
Collis et al., 2003, Wilsker and Bunz, 2007).  
 
Pancreatic Cancer Stem Cells and Inhibition of Nodal / Activin  
 
Patients with pancreatic ductal adenocarcinoma are still suffering from a 
devastating prognosis, which can be at least partially rationalized by the observation that 
the standard chemotherapeutic agent gemcitabine is not capable of eliminating CSCs. 
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Indeed, gemcitabine rather leads to a relative increase in the number of CSCs, indicating 
a preferential targeting of more differentiated and rapidly proliferating cancer cells. The 
restricted elimination of the more differentiated cancer cells, even if associated with 
significant tumour size reduction, will not lead to the eradication of the tumourigenic 
potential of the tumour, as that is restricted to the CSC population, a population that is 
highly resistant (Hermann et al., 2007, Mueller et al., 2009, Gallmeier et al., 2011, Bao et 
al., 2006), survives the standard therapy, and maintains the ability to re-populate a 
tumour in all its heterogeneity. Therefore we evaluated the effects of combination 
therapies targeting both differentiated cancer cells and CSCs on a panel of pancreatic 
tumours, which were selected based on their previously described differential response 
to gemcitabine treatment (Jimeno et al., 2009). Using these tumours, here we 
demonstrate that the Nodal/Activin pathway is essential for the self-renewal capacity and 
stemness properties of pancreatic CSCs. Nodal/Activin is strongly expressed in 
pancreatic CSCs, but is also expressed by pancreatic stellate cells, which are 
abundantly present in the stroma surrounding pancreatic cancer cells and may serve as 
a CSC niche. 
In a large set of primary cells and (fresh) primary patient tissues, we then showed 
that the CSC compartment is severely affected by inhibition of this pathway by making 
use of three different approaches: first, by using a small molecule inhibitor (SB431542) 
targeting the Nodal/Activin receptor Alk4; second, by using recombinant Lefty as the 
specific endogenous Nodal inhibitor; and third, by genetic knockdown of Nodal, Alk4, 
and Smad4 using shRNA technology. Our findings are in line with earlier observations 
that have identified other developmental pathways such as mTOR, hedgehog, Notch, 
and BMP for targeting CSCs (Bar et al., 2007, Li et al., 2007, Mueller et al., 2009, 
Piccirillo et al., 2006), although their targeting may be of limited clinical use for at least 
some of them due to normal stem-cell-related side effects. Intriguingly, an important 
feature of the herein described Nodal/Activin pathway is its complete lack of activity in 
normal pancreas and other adult tissue (Topczewska et al., 2006), spurring the hope for 
little to no side effects because normal stem cells will most likely be spared. 
Nodal and Activin are involved in developmental biology by perpetuating the 
undifferentiated state of ESCs (Vallier et al., 2005, Xiao et al., 2006). While the 
expression of Activin and the Nodal co-receptor Cripto-1 have previously been 
demonstrated in pancreatic cancers (Friess et al., 1994, Kleeff et al., 1998), we here 
provide evidence that Nodal, the second ligand of the Alk4/7 receptor, is expressed in 
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this malignancy, but not in normal pancreas. Most importantly, Nodal is capable of 
strongly propagating the tumourigenic CSC subpopulation as demonstrated by its 
pharmacological inhibition using the extra- cellular Nodal antagonist Lefty and shRNA 
technology, whereas Activin was less drastically enriched in pancreatic CSCs and 
showed limited effects on their self-renewal capacity in some tumours. These data are in 
line with previous reports showing that Nodal is crucial for tumourigenicity in melanoma 
and breast cancer cells, with an embryonic microenvironment reducing tumourigenic 
activity and inducing the expression of epithelial markers by the secretion of Lefty 
(Postovit et al., 2008, Topczewska et al., 2006). 
On the other hand, Activin reportedly contributes to an invasive phenotype in 
esophageal carcinoma, another epithelial malignancy (Yoshinaga et al., 2004, 
Yoshinaga et al., 2008). In a previous report on the dynamic regulation of the invasive 
phenotype of breast cancer cell lines, the interconversion from noninvasive epithelial-like 
CD44+CD24+ cells to invasive mesenchymal CD44+CD24- progeny was also found to 
be Nodal/Activin dependent (Meyer et al., 2009). Consistently, we now provide evidence 
that Activin also promotes invasion of pancreatic CSCs as does Nodal. These data have 
important implications because they indicate that therapeutic strategies should not focus 
on either Nodal or Activin, but rather focus on Alk4/7 as their common receptor. Indeed, 
a comprehensive set of experiments proves that targeting this pathway by blocking the 
Alk4/7 receptor using the small molecule inhibitor SB431542 and shRNA technology has 
a strong impact on both the CD133+ fraction that is enriched for CSCs and sphere 
formation capacity. 
Next, we identified human pancreatic stellate cells (PSCs) as an important 
component of the stroma that also strongly expresses Nodal/Activin. Conditioned 
medium from PSCs promoted self-renewal and invasive- ness of pancreatic CSCs. 
PSCs, which reside in exocrine areas of the pancreas, are myofibroblast-like cells known 
to be activated upon insult. These cells are analogous to hepatic stellate cells, with 
which they share 99% identity at the transcriptome level (Omary et al., 2007). PSCs are 
important mediators in the pancreatic response to injury because they migrate to the 
damaged location and promote cell proliferation, migration, and assembly (Shimizu, 
2008). Therefore, because our data suggest that PSCs may represent an in vivo niche 
for CSCs, targeting these interactions could be of pivotal importance for the 
development of more effective therapies for pancreatic cancer. While targeting Alk4/7 as 
the common receptor for Nodal/Activin should abrogate autocrine and paracrine 
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signaling, directly eliminating this paracrine source for Nodal/Activin may provide 
additional therapeutic benefits. Intriguingly, this can be achieved by targeting the 
hedgehog pathway as a crucial signaling component for PSCs (Bailey et al., 2008, 
Shinozaki et al., 2008) and may account, at least in part, for the striking therapeutic 
effects generated by the addition of a smoothened inhibitor to our armamentarium for 
treating primary pancreatic cancer tissue in our studies (Figure 6).  
 
 
Figure 6: Combination therapy targeting cancer stem cells (CSC). Direct targeting of CSC as well 
as interfering with crucial interactions between cancer stem cells and stromal cells (pancreatic 
stellate cells (PSC) and tumour-associated macrophages (TAM)) by inhibiting the hedgehog 
pathway or the Nodal/Activin pathway via Alk4/7.  
Image courtesy of C. Heeschen   
 
However, translating our findings into the in vivo setting was not only challenged 
by alternative sources for Nodal/Activin, but also by the fact that the Nodal/Activin small 
molecule inhibitor SB431542 as a single therapy was not sufficient to irreversibly 
eliminate the cells’ ability to form tumours in vivo. This lack of in vivo translation of the 
apparently encouraging in vitro effects could be explained by the enhanced plasticity of 
pancreatic cancer cells. Indeed, after withdrawal of SB431542 and continued culture of 
the cells, a drastic rebound of the CD133+ population was also observed in vitro, which 
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retrospectively rationalizes the still-preserved in vivo tumourigenicity of the cells. 
However, the rebound of CD133+ CSCs upon withdrawal was prevented by addition of 
gemcitabine to the treatment regimen. Further mechanistic studies revealed that 
SB431542 alone (reversibly) drives CSCs into a more differentiated state, as evidenced 
by loss of CD133, but cells still retain the ability to revert to the CSC phenotype. 
Intriguingly, although gemcitabine alone led to a relative enrichment of CSCs, the 
combination of SB431542 and gemcitabine resulted in their irreversible and complete 
elimination. Indeed, in vitro combination therapy resulted in complete abrogation of the in 
vivo tumourigenic potential of the remaining cells. 
This chemosensitizing effect of SB431542 should be of great therapeutic value 
for patients with pancreatic cancer and was therefore further evaluated in vivo. However, 
testing this treatment regimen in mouse models of pancreatic cancer came with another 
caveat. Our first in vivo experiments in established pancreatic cancer, which were based 
on the orthotopic implantation of isolated pancreatic cancer cells, confirmed the in vitro 
data by illustrating robust therapeutic efficacy and 100% survival at 100 day follow-up for 
SB431542 plus gemcitabine. Surprisingly, however, when we then moved to a preclinical 
model using xenografted primary human pancreatic cancer tissue, tumour development 
remained virtually unaffected by this combination. It is important to note that xenografted 
pancreatic cancer tissues contain large amounts of stroma whereas implantation of 
cancer cells regularly lacks this important feature. Tumour-associated stroma does not 
only provide an additional source for Nodal/Activin as described above, but is also 
capable of modulating tumour vascularization, which could interfere with drug delivery to 
cancer (stem) cells. Indeed, impaired drug delivery has already been demonstrated for 
pancreatic cancer in a recent landmark study using a genetically engineered mouse 
model (Olive et al., 2009). 
Therefore, breaching the ‘‘stroma fortress’’ of pancreatic cancer represents an 
important challenge for drug delivery in general (Neesse et al., 2010) and CSC-targeted 
therapies in particular because these cells have been proposed to preferably reside in 
hypoxic niches (Borovski et al., 2011, Heddleston et al., 2009). Intriguingly, when we co-
administered the hedgehog pathway inhibitor CUR199691 (Mueller et al., 2009) to 
deplete the stromal compartment together with SB431542, we observed a 10-fold 
increase in drug delivery into the tumour tissue. The addition of gemcitabine then 
translated into rapid disease stabilization, and none of the mice required sacrificing 
during the 100 day study period. Failure to completely eradicate the remaining small 
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tumours can be rationalized by the lack of response of non-proliferating tumour cells to 
gemcitabine. Most importantly, however, these small lesions no longer contain CSCs; 
cells isolated from these remnant tumours did not form spheres anymore. In contrast, all 
mice treated with gemcitabine alone had to be sacrificed within 100 days due to 
excessive tumour growth. Cells isolated from these tumours bear strong sphere forming 
capacity. Therefore, our data demonstrate the successful combination of stroma- and 
CSC-targeting strategies for effectively treating pancreatic cancer in most relevant 
preclinical models. 
 
Canonical downstream signaling of Alk4/7 is mediated by Smad2/3, as well as by 
the co-Smad Smad4, which is shared by all TGF-b family members. Importantly, about 
50% of patients with pancreatic cancer bear inactivating mutations or deletions of the 
Smad4 gene, which could result in dysfunction of the pathway (Schneider and Schmid, 
2003). While non-canonical TGF-b family signaling pathways have been described and 
may account for the enhanced TGF-b1-induced invasiveness of pancreatic CSCs 
(Zhang, 2009), we found that Smad4 knock- down in previously Smad4-competent cells 
resulted in reduced in vivo tumourigenicity, most likely via inhibition of Nodal/Activin 
signaling, because these cells no longer responded to the Alk4/7 inhibitor SB431542. 
Therefore, because Smad4 seems indispensable for the Nodal/Activin signaling cascade, 
tumours carrying functionally relevant Smad4 mutations or deletions may not respond to 
a Nodal/Activin-targeting therapy. Importantly, however, not all Smad4 mutations 
actually result in dysfunctional Smad4; we have identified several tumours bearing 
Smad4 mutations that still demonstrate a functional Smad2/3 cascade, including a 
subsequent translocation of pSmad2 into the nucleus, and that respond to this triple 
therapy. Future studies will have to address the question of which patients will most 
likely respond to this treatment modality and how best to identify them. 
 
Pancreatic Cancer and Inhibition of Hedgehog and mTOR  
 
Based on the observation that pancreatic cancer stem cells are highly resistant to 
standard therapies (Hermann et al., 2007), we demonstrated in 2009 that this resistance 
can be overcome, using a combined inhibition of Sonic Hedgehog (SHH) and the mTOR 
pathway, together with gemcitabine as a chemotherapeutic agent (Mueller et al., 2009). 
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While this study was the first systematic investigation into the effects of combination 
therapy on pancreatic cancer stem cells, only a comparatively small number of patient-
derived tissue xenografts was used for this study. Therefore, in the aforementioned 
study (Hermann et al., 2013) we extend the findings, using a large panel of primary 
pancreatic cancer xenografts with distinct response profiles to gemcitabine (Jimeno et al., 
2009), and different mutational profiles (Jones et al., 2008). Using almost 200 primary 
xenografts, this study is one of the largest investigations of combination therapies in the 
cancer stem cells. Furthermore, we used SIBI-C1 (Siena Biotech, Siena, Italy) as a new 
inhibitor of Smoothened, and thus of the hedgehog pathway.  
At the histological level, pancreatic cancer is characterized by very dense stroma 
and poor vascularization. Olive et al. showed in a genetically engineered mouse model 
of pancreatic cancer that the stroma is strongly dependent on hedgehog signalling, and 
inhibition of the hedgehog pathway with smoothened inhibitors leads to ‘‘preferential’’ 
killing of stromal cells and increased vessel density (Olive et al., 2009), thus making 
tumour cells more accessible to therapeutic intervention. While these observations were 
obtained in a mouse model of pancreatic cancer, we have more recently shown that also 
in patient-derived whole-tissue xenografts co-treatment with a smoothened inhibitor 
significantly increases drug delivery (Lonardo et al., 2011) and markedly reduces 
tumour-associated stroma formation. Importantly, we now appreciate that the stroma not 
only hampers drug delivery (Olive et al., 2009), but also provides a supportive niche for 
cancer stem cells promoting their self-renewal capacity and invasiveness (Lonardo et al., 
2012). Thus, elimination or abrogation of the stroma does significantly improve treatment 
regimens by distinct mechanisms, but is only capable of eliminating cancer stem cells if 
combined with Gem. Interestingly, we have shown previously that interfering with the 
hedgehog pathway via inhibition of Smoothened is not sufficient to deplete cancer stem 
cells (Mueller et al., 2009), but will only lead to CSC eradication in combination with 
mTOR inhibition and gemcitabine chemotherapy. However, these in vitro data have to 
be interpreted carefully, since Lauth and colleagues have shown recently that in the 
context of an activating K-Ras mutation, the Gli family of hedgehog target genes is up-
regulated independently of Smoothened (Lauth et al., 2010). This is particularly 
interesting, considering that mTOR activity, similarly to K-Ras, activates Gli1 
independently of Smoothened (Wang et al., 2012), explaining the need for additional 
mTOR inhibition observed in our studies. Thus, using Gli-inhibitors may not only improve 
stroma depletion, but may also more successfully target cancer stem cells.  
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However, despite the rather modest response of cancer stem cells to hedgehog 
pathway inhibition as a single agent, we were able to demonstrate that smoothened 
inhibitors are still essential in order to successfully eliminate chemoresistant pancreatic 
cancer stem cells if combined with other stem cell-targeting agents (Mueller et al., 2009, 
Lonardo et al., 2011). Specifically, we have previously shown for pancreatic cancer that 
a combination of chemotherapy and inhibitors of both mTOR and hedgehog signaling 
eliminates differentiated cells as well as cancer stem cells in vitro (Mueller et al., 2009), 
and that this translates into long-term survival in vivo. Recently, Wang et al. provided an 
important mechanistic link for the combined inhibition of the hedgehog and mTOR 
pathway. Specifically, the authors demonstrate that mTOR/S6K1 signaling results in 
phosphorylation of Gli and subsequent expression of downstream targets. Inhibition of 
both pathways greatly enhanced the pro-apoptotic effect of inhibition of either inhibition 
alone (Wang et al., 2012). In the presented study, we now saw a virtually complete 
elimination of cancer stem cells for this combination therapy in a large and 
representative set of primary xenografts. Whereas flow cytometry using the surface 
markers CD133, EpCAM, and CD44 already suggested that the cancer stem cell content 
was strongly reduced, functional assays (e.g. sphere formation assay) validated that the 
cells isolated from the explanted tumours indeed were unable to form tumour spheres in 
vitro, strongly suggesting that the cancer stem cell population as the root of the disease, 
had been effectively targeted by the triple combination. 
Even though the results using Gem+SIBI+Rapa were highly consistent and 
encouraging across a panel of patient-derived tumours, we did observe tumour re-
growth in some mice (e.g. PDAC-185 xenografts) and, subsequently, a decrease in the 
survival of these xenograft-bearing animals. As this might be related to the limited 
bioavailability of the chemotherapeutic agent as an essential part of this combination 
therapy, we further advanced our treatment strategy by modifying the chemotherapy. 
Specifically, Vandana et al. have recently shown that modifying gemcitabine via 
PEGylation leads to enhanced bioavailability in the circulation as compared to native 
gemcitabine. Although they have also shown better in vitro response of established 
pancreatic cancer cells using PEGylated gemcitabine as compared to the regular 
formulation (Vandana and Sahoo, 2010), we observed no significant differences 
between Gem and PEG-Gem in vitro at the level of cancer stem cell content or induction 
of apoptosis or cell death using xenograft-derived primary cells. While these data are not 
surprising as drug delivery and availability is not a critical issue in vitro, the results 
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clearly emphasize the importance of utilizing primary cancer tissue for further in vivo 
evaluation of drug efficacy.  
Similar observations have been made recently regarding abraxane, an albumin-
bound paclitaxel used as chemotherapeutic agent (Von Hoff et al., 2011). Pre-clinical 
studies with abraxane have demonstrated that binding paclitaxel to albumin facilitates 
drug delivery in vivo, resulting in a significantly increased intra-tumoural concentration of 
gemcitabine in mice treated with nab-paclitaxel versus those receiving gemcitabine 
alone. Interestingly, abraxane as single agent as well as together with gemcitabine 
depleted the typically dense and almost avascular tumour stroma in PDAC, markedly 
enhancing drug delivery into the tumor. Whereas this treatment resulted in markedly 
increased patient survival in a clinical phase I/II study (Von Hoff et al., 2011), increasing 
survival time from 8.1 to 17.8 months, all patients eventually succumbed to the disease. 
Thus, the results from this study are certainly very promising from a clinical perspective 
and support the idea of modifying chemotherapeutic agents to improve their efficacy. 
However, with all patients eventually dying, it becomes apparent that even stromal 
depletion and improved delivery of chemotherapeutics into the tumour, populations of 
chemoresistant cancer stem cells have survived the chemotherapy and given rise to a 
relapsing tumour, eventually killing the patient. This further supports the notion that 
multimodal therapies will be necessary for successful treatment.  
Indeed, we then validated and extended this concept to the in vivo setting by 
showing that PEG-Gem treatment significantly delayed the time of tumour progression 
by 72 days. This enhanced treatment response is certainly impressive as it represents 
more than half of the study period. As expected, however, tumours ultimately progressed 
resulting in virtually no difference in median survival of the PEG-Gem treated mice 
compared to mice treated with traditional Gem alone. While these data confirm that 
PEGylation of Gem does indeed improve drug availability and delivery, respectively, by 
enhancing the circulation time and tissue penetration, as expected, PEG-Gem alone is 
clearly not sufficient to overcome the chemoresistance of cancer stem cells. Therefore, 
we next investigated the effects of replacing regular Gem with PEG-Gem in our 
multimodal approach for targeting pancreatic tumours, which had originally responded to 
Gem+SIBI+Rapa treatment, but eventually relapsed under this specific treatment 
regimen. Intriguingly, using the PEG-Gem+SIBI+Rapa combination we not only 
observed virtually complete tumour regression, but most importantly we obtained 100% 
survival throughout the 125d study period in this highly therapy-resistant tumour. While 
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this observation does not exclude later re-growth as seen in PDAC-Pax22, these data 
are very promising and are consistent with the notion that further improving the 
formulation of the combined drugs is mandatory for extending in vitro findings to the 
much more complex in vivo setting. 
The utilized new smoothened inhibitor SIBI-C1 was also highly effective in vivo, 
as can be seen by reduced tumour growth in combination with Gem and thus 
significantly enhanced survival time. Furthermore, SIBI can be safely administered in 
vivo, as we saw no adverse effects on total body weight or white blood cell counts. 
Importantly, this is well in line with previous observations using other smoothened 
inhibitors (Mueller et al., 2009, Lonardo et al., 2010). The Gem+SIBI+Rapa combination 
therapy also showed no significant toxicity compared to Gem treatment alone during the 
course of the experiments. PEG-Gem+SIBI+Rapa combination treatment, while much 
more effective in vivo, only slightly, but non-significantly decreased white blood cell 
counts and had no effect on the body weight of the animals as compared to respective 
controls. It is important to note, however, that the healthy and relatively young mice used 
for this study are likely more capable of compensating for putative adverse effects on the 
normal stem cell compartments during triple therapy treatment. Therefore, it will be 
important to further validate the safety of this treatment regimen in human patients in 
order to ultimately apply it to the mostly aged and moribund patients suffering from 
pancreatic cancer.  
 
 
Perspective 
 
The high resistance of cancer stem cells against established standard therapies 
has received more and more attention since being described in solid tumours such as 
glioblastoma (Bao et al., 2006), pancreatic (Hermann et al., 2007), and colorectal cancer 
(Todaro et al., 2007). Since these cells will survive therapy and possibly re-generate the 
entire tumour after primarily successful treatment in a process called tumour relapse, 
finding new and specific ways to target and eliminate these cells will be of paramount 
importance for the long-term success of cancer therapy.  
In the projects performed within the scope of the presented doctoral thesis, we 
have proposed and evaluated three novel therapeutic approaches for the treatment and 
targeted elimination of cancer stem cells in colorectal and pancreatic cancer. We have 
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identified pathways (mTOR, hedgehog, Nodal/Activin), and cellular properties (high 
DNA-damage response mediated by ATR) that are highly typical for (cancer) stem cells. 
Targeting these stem cell features should then either kill cancer stem cells directly by 
inhibition of an essential pathway, or affect them in a way that they are then accessible 
to treatment with chemotherapy. This could happen by either driving CSCs into 
differentiation, or by pushing usually quiescent cancer stem cell populations into an 
active cell cycle, making these proliferating cells an easy target for chemotherapeutic 
agents. In all of the three mentioned strategies, chemotherapy will still play an integral 
part, killing differentiated cancer cells, as well as proliferating CSCs. Thus a multimodal 
therapy including CSC-targeting agents as well as chemotherapy or radiation will be 
necessary for successful therapy. Without a doubt, there will most likely be no “one 
approach fits all” treatment. Considering the vast heterogeneity between different patient 
tumors, it rather very likely that CSCs from different tumors will respond in very distinct 
ways to therapeutic approaches. Therefore, it will be of paramount importance to identify 
further mechanisms that CSCs use for their survival and propagation. This will eventually 
enable us to tailor treatments specifically to the needs and a predicted response profile 
of individual patients. 
Just recently, a combination therapy comprising a hedgehog antagonist (Infinity’s 
IPI-926) and gemcitabine as chemotherapeutic agent has failed and led to the premature 
termination of a phase III clinical study in metastatic pancreatic cancer. Interestingly, IPI-
926 (or Saridegib) is an inhibitor of Smoothened, and not of the downstream effectors of 
the Gli protein family. Since an activating mutation in K-Ras is one of the most frequent 
genetic alterations found in PDAC, and K-Ras activates Gli effector proteins, inhibition of 
upstream smoothened most likely is not sufficient for successful inhibition of the 
hedgehog pathway in cancer stem cells. However, a surprising finding of this trial is that 
the survival of gemcitabine + Saridegib-treated patients was even worse than that of 
patients receiving gemcitabine only. While this is surprising at first sight, a potential 
explanation for this observation is that the addition of the Smoothened inhibitor to 
chemotherapy resulted in at least partially successful elimination of the stroma, leading 
to a “cytokine storm”, i.e. the massed release of pro-inflammatory cytokines from the 
tumor stroma.  
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In summary, there is increasing evidence that multimodal therapies will be 
necessary for the successful treatment of gastrointestinal tumors, and that the 
elimination of cancer stem cells will play an integral part in the success or failure of any 
therapeutic approach. Taking this into account, we identified three different new 
therapeutic approaches, and indeed observed that multimodal therapy resulted in a 
great therapeutic benefit: only in mice treated with the different combination therapies, 
cancer stem cells were completely abrogated, and we could witness a long-term disease 
stabilization or regression, and subsequent long-term survival.  
 
Thus we here provide compelling evidence for the efficacy of multimodal 
therapies targeting CSCs as well as differentiated cells in colorectal and pancreatic 
cancer. Taken together, these findings should significantly impact the future 
development of new therapies for colorectal and pancreatic cancer, and may offer a new 
step on the path towards curing these deadly diseases. 
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CONCLUSIONS 
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1. We have successfully verified the importance of cancer stem cells for the initiation, 
but also for the propagation of tumours in pancreatic and colorectal cancers.  
 
2. With the DNA damage response kinase ATR (Ataxia Telangiectasia- and Rad3-
Related), and the developmental Nodal/Activin signaling pathway we have identified 
two novel targets for the elimination of cancer stem cells, especially when used in 
combination with chemotherapy. 
 
3. We demonstrate that chemical inhibition of ATR or inhibition of its direct downstream 
target Chk1 with small molecule inhibitors or genetic targeting leads to an elimination 
of cancer stem cells in vitro, as evidenced in abrogated sphere formation and 
dramatically reduced expression of CD133.  
 
4. More importantly, we demonstrate that pre-treatment of primary patient-derived 
cancer cells in vitro dramatically decreases in vivo tumourigenicity of these cells, the 
key readout for successful elimination of cancer stem cells. This decreased 
tumourigenicity in vivo translated into significantly enhanced long-term survival of 
mice.  
 
5. Chemical and genetic interference with the Nodal/Activin pathway eliminates CSCs 
as shown by expression levels of stemness-associated genes, reduced CSC 
markers such as CD133 or CD44, virtually completely abrogated sphere formation, 
and, most importantly, dramatically reduced tumourigenicity in vivo. 
This effect is specific for Nodal/Activin, since chemical inhibition of TGF-b shows no 
effects, but gene knockdown for Alk4 had the same functional consequence as 
Nodal/Activin inhibition with small molecule inhibitors.  
 
6. The successful elimination of CSCs in vitro through inhibition of the Nodal/Activin 
pathway was reproducible in a clinically highly relevant in vivo model of pancreatic 
cancer using patient-derived tumour tissue. Combination therapy with pathway 
inhibitors and standard chemotherapy resulted in significantly reduced tumour size, 
but, more importantly, in significantly extended overall survival of mice.  
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7. Co-administration of inhibitors of the sonic hedghehog pathway dramatically 
increased drug delivery to and drug concentration in the tumour tissue. This led to 
long-term stable disease, and subsequently to long-term overall survival in treated 
mice.   
 
8. While Gemcitabine has a limited circulation time and low penetration into tumour 
tissue in vivo, in an attempt to optimize chemotherapy we have shown that applying 
Gemcitabine bound to poly-ethylene glycol (PEG Gem) can significantly enhance 
survival time in combination with cancer stem cell-targeting agents. 
 
9. Finally we have reproduced our previous findings, that cancer stem cells can be 
eliminated using a combination of sonic hedgehog inhibition, mTOR inhibition, and 
chemotherapy.  
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CONCLUSIONES 
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1. Hemos verificado exitosamente la importancia de las células troncales cancerígenas 
en la iniciación, pero también, en la propagación de los tumoures pancreáticos y 
colorectales.  
 
2. Con la respuesta al daño del DNA de la Kinasa (Ataxia Telangiectasia- and Rad3-
Related), y el desarrollo de la ruta de señalización Nodal/Activin , hemos identificado 
dos nuevas dianas para la eliminación de las células troncales cancerígenas, 
especialmente cuando se usan en combinación con quimioterapia.  
 
3. Hemos demostrado que la inhibición química de ATR o la inhibición de su proteína 
diana Chk1 con  una pequeña molécula inhibidora o con una diana genética 
conlleva a la eliminación de las células troncales in vitro, observándose una 
reducción total en la formación de esferas y una reducción dramática de la expresión 
del marcador CD133.  
 
4. Mas importante, hemos demostrado que el pre-tratamiento de las células 
cancerígenas primarias derivadas de paciente in vitro,  dramáticamente reduce la 
tumourigenicidad in vivo de estas células, prueba clave en el éxito de la completa 
eliminación de las células troncales cancerígenas.  Este descenso de 
tumourigenicidad  in vivo se traduce en un significante aumento de la supervivencia 
a largo plazo de los ratones.  
 
5. La interferencia genética y química con la ruta Nodal/Activin elimina las células 
troncales cancerígenas tal y como es mostrado en la expresión de los niveles de los 
genes estaminales  asociados, como la reducción de los marcadores CD133 o CD44, 
la eliminación completa de la formación de esferas y lo mas importante, la dramática 
reducción de la tumourigenicidad in vivo. 
Este efecto es especifico para la ruta Nodal/Activin debido a que la inhibición 
química de TGF-b no muestra efectos, pero la inhibición de la expresión del gen 
Alk4 tuvo la misma consecuencia funcional que la inhibición de Nodal/Activin con 
inhibidores moleculares pequeños.  
 
6. La exitosa eliminación de las células troncales cancerígenas in vitro a través de la 
inhibición de la ruta Nodal/Activin fue reproducible con relevancia clínica en modelos 
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de cáncer de páncreas in vivo utilizando muestras de paciente. La combinación de 
terapias con los inhibidores de ruta y la quimioterapia estándar, resulto en una 
reducción significante del tamaño del tumour, pero, aun mas importante, en el 
aumento significante de la supervivencia global de los ratones.  
 
7. La coadministración  de los inhibidores de la ruta de sonic hedghehog 
dramáticamente aumenta la entrega y  también la concentración en el tejido 
tumoural, conduciendo a una estabilidad a largo plazo de la enfermedad y 
consecuentemente, a un amuento de la supervivencia global en los ratones tratados.   
 
8. El uso de Gemcitabina ha mostrado que la circulación y penetración en el tejido 
tumoural in vivo es limitada, por tanto,  en un intento de optimizar la quimioterapia, 
hemos mostrado que aplicando Gemcitabina ligada a un polyetilenglicol (PEG Gem) 
puede significantemente aumentar el tiempo de supervivencia en combinación con 
terapias diana contra las células troncales cancerígenas.  
 
9. Finalmente, hemos reproducido nuestros  descubrimientos anteriores en que las 
células troncales cancerígenas pueden ser eliminadas usando una combinación de 
inhibidores de sonic hedgehog y mTOR con quimioterapia.  
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